U.S. patent application number 17/526970 was filed with the patent office on 2022-04-07 for proteins for the treatment of epithelial barrier function disorders.
The applicant listed for this patent is Second Genome, Inc.. Invention is credited to Karim Dabbagh, Todd Zachary DeSantis, Andrew W. Goodyear, Tarunmeet Gujral, Andrew Wonhee Han.
Application Number | 20220106365 17/526970 |
Document ID | / |
Family ID | 1000006038771 |
Filed Date | 2022-04-07 |
![](/patent/app/20220106365/US20220106365A1-20220407-D00001.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00002.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00003.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00004.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00005.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00006.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00007.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00008.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00009.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00010.png)
![](/patent/app/20220106365/US20220106365A1-20220407-D00011.png)
View All Diagrams
United States Patent
Application |
20220106365 |
Kind Code |
A1 |
Han; Andrew Wonhee ; et
al. |
April 7, 2022 |
PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION
DISORDERS
Abstract
The disclosure relates to therapeutic proteins and
pharmaceutical compositions comprising said proteins, which have
utility in treating various human diseases. In particular aspects,
the disclosed therapeutic proteins are useful for treating human
gastrointestinal inflammatory diseases and gastrointestinal
conditions associated with decreased epithelial cell barrier
function or integrity. Further, the disclosed therapeutic proteins
are useful for treating human inflammatory bowel disease, including
inter alia, Crohn's disease and ulcerative colitis.
Inventors: |
Han; Andrew Wonhee;
(Brisbane, CA) ; Goodyear; Andrew W.; (Brisbane,
CA) ; Gujral; Tarunmeet; (Brisbane, CA) ;
DeSantis; Todd Zachary; (Brisbane, CA) ; Dabbagh;
Karim; (Brisbane, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Second Genome, Inc. |
Brisbane |
CA |
US |
|
|
Family ID: |
1000006038771 |
Appl. No.: |
17/526970 |
Filed: |
November 15, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16618499 |
Dec 2, 2019 |
11174293 |
|
|
PCT/US2018/035682 |
Jun 1, 2018 |
|
|
|
17526970 |
|
|
|
|
62518138 |
Jun 12, 2017 |
|
|
|
62518137 |
Jun 12, 2017 |
|
|
|
62514165 |
Jun 2, 2017 |
|
|
|
62514148 |
Jun 2, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 15/70 20130101;
C07K 14/195 20130101; C12N 15/85 20130101; C12N 5/06 20130101; A61K
45/06 20130101; A61K 38/164 20130101; A61P 1/04 20180101; C12N 1/20
20130101 |
International
Class: |
C07K 14/195 20060101
C07K014/195; A61P 1/04 20060101 A61P001/04; A61K 38/16 20060101
A61K038/16; A61K 45/06 20060101 A61K045/06; C12N 1/20 20060101
C12N001/20; C12N 5/07 20060101 C12N005/07; C12N 15/70 20060101
C12N015/70; C12N 15/85 20060101 C12N015/85 |
Claims
1-77. (canceled)
78. A pharmaceutical composition, comprising a protein comprising
an amino acid sequence having at least about 90% sequence identity
to the sequence set forth in SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:13
or SEQ ID NO:19, and a pharmaceutically acceptable carrier.
79. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises an amino acid sequence having at
least about 95% sequence identity to the sequence set forth in SEQ
ID NO: 1 SEQ ID NO:9, SEQ ID NO: 13 or SEQ ID NO: 19.
80. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises an amino acid sequence having at
least about 97% sequence identity to the sequence set forth in SEQ
ID NO: 1 SEQ ID NO:9, SEQ ID NO: 13 or SEQ ID NO: 19.
81. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises an amino acid sequence having at
least about 98% sequence identity to the sequence set forth in SEQ
ID NO: 1, SEQ ID NO:9, SEQ ID NO: 13 or SEQ ID NO: 19.
82. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises an amino acid sequence having at
least about 99% sequence identity to the sequence set forth in SEQ
ID NO: 1, SEQ ID NO:9, SEQ ID NO: 13 or SEQ ID NO: 19.
83. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises an amino acid sequence selected from
the group consisting of: SEQ ID NO: 1, SEQ 1D NO:9, SEQ ID NO: 13
and SEQ ID NO: 19.
84. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises the amino acid sequence of SEQ ID NO:
1.
85. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises the amino acid sequence of SEQ ID
NO:9.
86. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises the amino acid sequence of SEQ ID NO:
13.
87. The pharmaceutical composition of claim 78, wherein the
therapeutic protein comprises the amino acid sequence of SEQ ID NO:
19.
88. The pharmaceutical composition of claim 78, formulated for
rectal, parenteral, intravenous, topical, oral, dermal,
transdermal, or subcutaneous administration.
89. The pharmaceutical composition of claim 78, formulated such
that the therapeutic protein has activity in the gastrointestinal
lumen and/or intestines of the patient.
90. The pharmaceutical composition of claim 78, wherein the amino
acid sequence comprises at least one modification.
91. The pharmaceutical composition of claim 90, wherein the
modification is at least one amino acid substitution.
92. The pharmaceutical composition of claim 90, wherein the
modification is a post translational modification.
93. The pharmaceutical composition of claim 92, wherein the post
transcriptional modification is pegylation.
94. The pharmaceutical composition of claim 92, wherein the post
transcriptional modification is glycosylation, ubiquitination,
nitrosylation, methylation, acetylation, or lipidation.
95. The pharmaceutical composition of claim 92, wherein the post
transcriptional modification is phosphorylation, glycosylation,
ubiquitination, nitrosylaton, methylation, acetylation, lipidation,
or proteolysis.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a National Stage Application under 35
U.S.C. .sctn. 371 and claims the benefit of International
Application No. PCT/US2018/035682, filed on Jun. 1, 2018, which
claims the benefit of priority to U.S. Provisional Application No.
62/514,165, filed on Jun. 2, 2017, U.S. Provisional Application No.
62/514,148, filed on Jun. 2, 2017, U.S. Provisional Application No.
62/518,137, filed on Jun. 12, 2017, and U.S. Provisional
Application No. 62/518,138, filed on Jun. 12, 2017. Each of these
applications is incorporated herein by reference in its
entirety.
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
[0002] The contents of the text file submitted electronically
herewith are incorporated herein by reference in their entirety: A
computer readable format copy of the Sequence Listing filename:
SEGE 012_01WO_SeqList_ST25.txt, date created, May 31, 2018, file
size 53.1 kilobytes.
FIELD
[0003] The present disclosure relates to novel proteins and
pharmaceutical compositions comprising said proteins that have
application, inter alia, in the treatment of gastrointestinal
inflammatory diseases and epithelial barrier function disorders. In
some embodiments, the proteins and pharmaceutical compositions
described herein have particular application in the treatment or
prevention of disease states associated with abnormally permeable
epithelial barriers as well as inflammatory bowel diseases or
disorders.
BACKGROUND
[0004] Inflammatory bowel disease (IBD) is a heterogeneous disease
of unknown etiology resulting in frequent and bloody bowel
movements accompanied with histopathological damage to the
gastrointestinal mucosa (Zhang et al., 2017, Front Immunol, 8:942).
While specific triggers of disease remain poorly defined, one
proposal of disease progression suggests a breakdown of intestinal
barrier function allows bacteria or bacterial components to
translocate into mucosal tissue (Coskun, 2014, Front Med
(Lausanne), 1:24; Martini et al., 2017, Cell Mol Gastroenterol
Hepatol, 4:33-46). Bacterial translocation results in activation of
inflammatory signaling which triggers additional barrier
disruption, resulting in a cyclic amplification loop of barrier
disruption, bacterial translocation and inflammation. While many
current therapies target inflammation, the lack of therapies
promoting mucosal healing provides an opportunity for novel
therapies promoting epithelial repair and intestinal barrier
integrity.
[0005] Expanding upon the hypothesis that bacterial translocation
can trigger IBD, more recent studies have demonstrated detrimental
changes in intestinal microbiota, or dysbiosis, may promote
development of IBD.
[0006] Currently, many IBD therapeutics available in the market
merely aim to target and suppress the discussed inflammatory
response associated with IBD. While helpful, this narrow
therapeutic mode of action disregards the important contribution
that epithelial barrier integrity plays in the etiology of the
disease.
[0007] Thus, there is a great need in the art for the development
of a therapeutic, which not only suppresses the immune system's
inflammatory response, but that also acts in concert to restore the
epithelial barrier function in an individual. Also, there is a need
for the production of a protein therapeutic such as that described
herein which is stable through the manufacturing and/or processing
of the protein therapeutic as well as under long term storage
conditions.
SUMMARY OF THE DISCLOSURE
[0008] The present disclosure addresses the important need in the
medical community for a therapeutic which can effectively treat a
subject suffering from a gastrointestinal disorder such as an
inflammatory bowel disease (IBD). In one aspect, novel protein
therapeutics are provided which can facilitate or enhance the
maintenance of epithelial barrier integrity and/or improve
epithelial barrier repair. In some embodiments, the epithelial
barrier is intestinal epithelial barrier. These protein
therapeutics can also reduce inflammation of the intestine of the
subject and/or decrease symptoms associated with inflammation of
the intestine.
[0009] The protein therapeutics provided herein are useful in
treating the numerous diseases and/or symptoms that may be
associated with decreased gastrointestinal epithelial cell barrier
function or integrity.
[0010] Provided herein is a therapeutic protein encoded by the
genome of Eubacterium eligens, the protein designated herein as
"SG-15." In some embodiments, the SG-15 protein comprises the amino
acid sequence of SEQ ID NO:1, as well as fragments or variants
thereof.
[0011] In some embodiments, the SG-15 protein comprises an amino
acid sequence which is at least about 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to SEQ ID NO:1, SEQ ID NO:3, SEQ
ID NO:5, or SEQ ID NO:7 wherein the amino acid sequence has at
least 1, 2, 3 or 4 amino acid substitutions relative to SEQ ID
NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7, respectively. In
other embodiments, the amino acid sequence has at least 2 and less
than 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions. In still
other embodiments, the SG-15 protein comprises an amino acid
sequence which is not naturally occurring.
[0012] In some embodiments, the SG-15 protein comprises SEQ ID
NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
[0013] In some embodiments, the SG-15 protein is about 350 to 450
amino acids, 375 to 425 amino acids, 380 to 420 amino acids, 390 to
410 amino acids, or 395 to 405 amino acids in length. In other
embodiments, the SG-15 protein is 390, 391, 392, 393, 394, 395,
396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408,
409, or 410 amino acids in length.
[0014] In some embodiments, a polynucleotide is provided which
encodes the amino acid sequence of SG-15 (SEQ ID NO:1) or fragment
or variant thereof. In other embodiments, the polynucleotide
encodes a protein which is at least about 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to SEQ ID NO:1, SEQ ID NO:3, SEQ
ID NO:5, or SEQ ID NO:7. In still other embodiments, the
polynucleotide comprises a nucleotide sequence which is at least
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
100% identical to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID
NO:8.
[0015] Provided herein is a therapeutic protein encoded by the
genome of Eubacterium eligens, the protein designated herein as
"SG-16." In some embodiments, the SG-16 protein comprises the amino
acid sequence of SEQ ID NO:9, as well as fragments or variants
thereof.
[0016] In some embodiments, the SG-16 protein comprises an amino
acid sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%,
99.8%, or 99.9% identical to SEQ ID NO:9 or SEQ ID NO:11, wherein
the amino acid sequence has at least 1, 2, 3 or 4 amino acid
substitutions relative to SEQ ID NO:9 or SEQ ID NO:11,
respectively. In other embodiments, the amino acid sequence has at
least 2 and less than 3, 4, 5, 6, 7, 8, 9, or 10 amino acid
substitutions. In still other embodiments, the SG-16 protein
comprises an amino acid sequence which is not naturally
occurring.
[0017] In some embodiments, the SG-16 protein comprises SEQ ID NO:9
or SEQ ID NO:11.
[0018] In some embodiments, the SG-16 protein is about 95 to 150
amino acids, 100 to 135 amino acids, 105 to 130 amino acids, or 110
to 125 amino acids in length. In other embodiments, the SG-16
protein is 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120,
121, 122, 123, 124, 125, 126, 127, 128, 129, or 130 amino acids in
length.
[0019] In some embodiments, a polynucleotide is provided which
encodes the amino acid sequence of SG-16 (SEQ ID NO:9) or fragment
or variant thereof. In other embodiments, the polynucleotide
encodes a protein which is at least about 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to SEQ ID NO:9 or SEQ ID NO:11. In
still other embodiments, the polynucleotide comprises a nucleotide
sequence which is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:10 or SEQ ID
NO:12.
[0020] Provided herein is a therapeutic protein encoded by the
genome of Eubacterium eligens, the protein designated herein as
"SG-17." In some embodiments, the SG-17 protein comprises the amino
acid sequence of SEQ ID NO:13, as well as fragments or variants
thereof.
[0021] In some embodiments, the SG-17 protein comprises an amino
acid sequence which is at least about 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to SEQ ID NO:13, SEQ ID NO:15 or
SEQ ID NO:17 wherein the amino acid sequence has at least 1, 2, 3
or 4 amino acid substitutions relative to SEQ ID NO:13, SEQ ID
NO:15, or SEQ ID NO:17, respectively. In other embodiments, the
amino acid sequence has at least 2 and less than 3, 4, 5, 6, 7, 8,
9, or 10 amino acid substitutions. In still other embodiments, the
SG-17 protein comprises an amino acid sequence which is not
naturally occurring.
[0022] In some embodiments, the SG-17 protein comprises SEQ ID
NO:13, SEQ ID NO:15, or SEQ ID NO:17.
[0023] In some embodiments, the SG-17 protein is about 300 to 475
amino acids, 310 to 450 amino acids, 315 to 335 amino acids, or 320
to 330 amino acids in length. In other embodiments, the SG-17
protein is 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325,
326, 327, 328, 329, 330, 331, 332, 333, 334, or 335 amino acids in
length.
[0024] In some embodiments, a polynucleotide is provided which
encodes the amino acid sequence of SG-17 (SEQ ID NO:13) or fragment
or variant thereof. In other embodiments, the polynucleotide
encodes a protein which is at least about 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to SEQ ID NO:13, SEQ ID NO:15, or
SEQ ID NO:17. In still other embodiments, the polynucleotide
comprises a nucleotide sequence which is at least 75%, 80%, 85%,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical
to SEQ ID NO:14, SEQ ID NO:16 or SEQ ID NO:18.
[0025] Provided herein is a therapeutic protein encoded by the
genome of Clostridium bartlettii sp. nov., the protein designated
herein as "SG-18." In some embodiments, the SG-18 protein comprises
the amino acid sequence of SEQ ID NO:19, as well as fragments or
variants thereof.
[0026] In some embodiments, the SG-18 protein comprises an amino
acid sequence which is at least about 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to SEQ ID NO:19, SEQ ID NO:21, SEQ
ID NO:23 or SEQ ID NO:25 wherein the amino acid sequence has at
least 1, 2, 3 or 4 amino acid substitutions relative to SEQ ID
NO:19, SEQ ID NO:21, SEQ ID NO:23 or SEQ ID NO:25, respectively. In
other embodiments, the amino acid sequence has at least 2 and less
than 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions. In still
other embodiments, the t SG-18 protein comprises an amino acid
sequence which is not naturally occurring.
[0027] In some embodiments, the SG-18 protein comprises to SEQ ID
NO:19, SEQ ID NO:21, SEQ ID NO:23 or SEQ ID NO:25.
[0028] In some embodiments, the SG-18 protein is about 240 to 290
amino acids, 250 to 275 amino acids, 255 to 280 amino acids, or 260
to 275 amino acids in length. In other embodiments, the SG-18
protein is 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265,
266, 267, 268, 269, 270, 271, 272, 273, 274, or 275 amino acids in
length.
[0029] In some embodiments, a polynucleotide is provided which
encodes the amino acid sequence of SG-18 (SEQ ID NO:19) or fragment
or variant thereof. In other embodiments, the polynucleotide
encodes a protein which is at least about 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9% identical to SEQ ID NO:19, SEQ ID NO:21, SEQ
ID NO: 23 or SEQ ID NO:25. In still other embodiments, the
polynucleotide comprises a nucleotide sequence which is at least
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
100% identical to SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ
ID NO:26.
Additional Embodiments
[0030] In some embodiments, the SG protein is chemically modified
at the N-terminus and/or the C-terminus. In other embodiments, the
N-terminus of the SG protein is chemically modified by acetylation.
In still other embodiments, the C-terminus is chemically modified
by amidation.
[0031] In some embodiments, the SG protein is pegylated.
[0032] In some embodiments, the SG protein is substantially
purified and which is modified by glycosylation, ubiquitination,
nitrosylation, methylation, acetylation, or lipidation.
[0033] In some embodiments, the SG protein is fused to second
protein. In other embodiments, the second protein is an
immunoglobulin Fc domain or a human serum albumin protein
domain.
[0034] In some embodiments, the disclosure teaches an antibody or
fragment thereof which specifically binds the SG protein.
[0035] In some embodiments, the SG protein increases the barrier
function of an epithelial cell layer in an in vitro assay, wherein
the increase is relative to the barrier function in the assay in
the absence of the protein. In other embodiments, the in vitro
assay is a transepithelial electrical resistance (TEER) assay. In
still other embodiments, the increase in barrier function is an
increase in electrical resistance of at least 5%, 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, or 90% greater than the electrical
resistance in the assay in the absence of the SG protein. In some
embodiments, the epithelial cell layer is an intestinal epithelial
cell layer. In still other embodiments, the intestinal epithelial
cell layer is a cell layer which comprises enterocytes and goblet
cells.
[0036] In some embodiments, the SG protein decreases the secretion
of a pro-inflammatory cytokine from a cell in an in vitro assay. In
other embodiments, the in vitro assay comprises incubation of
monocytic cells with heat killed E. coli in the presence and
absence of the SG protein. In still other embodiments, the at least
one pro-inflammatory cytokine is selected from the group consisting
of TNF-.alpha., IL-17, IL-1.beta., IL-2, IFN-.gamma., IL-6, IL-12,
IL-25, IL-33, IL-8, MCP-1, MIP-3a, CXCL1, and IL-23.
[0037] In some embodiments, the SG protein increases secretion of
an anti-inflammatory cytokine from a cell in an in vitro assay. In
other embodiments, the in vitro assay comprises incubation of a
monocyte with heat killed E. coli in the presence and absence of
the SG protein. In still embodiments, the at least one
anti-inflammatory cytokine is selected from the group consisting of
IL-4, IL-10, IL-13, IFN-.alpha., and TGF-.beta..
[0038] In some embodiments, the SG protein reduces intestinal
tissue pathology in a subject administered the SG protein. In some
embodiments, the subject was induced to have intestinal tissue
damage by treatment with a chemical. In other embodiments, the
subject was treated with the chemical dextran sodium sulfate (DSS)
to induce intestinal tissue damage. In still other embodiments, the
subject is a mammal. In yet other embodiments, the animal is a
rodent. In other embodiments, the subject is a non human
primate.
[0039] In some embodiments, the SG protein reduces gastrointestinal
inflammation in a subject administered the SG protein. In other
embodiments, the SG protein reduces intestinal mucosa inflammation
in the subject. In still other embodiments, the SG protein improves
intestinal epithelial cell barrier function or integrity in the
subject.
[0040] In some embodiments, the SG protein increases the amount of
mucin in intestinal tissue in a subject administered the SG
protein.
[0041] In some embodiments, the SG protein increases intestinal
epithelial cell wound healing in a subject administered the SG
protein. In other embodiments, the SG protein increases intestinal
epithelial cell wound healing in an in vitro assay.
[0042] In some embodiments, the SG protein prevents or reduces
colon shortening in a subject administered the SG protein.
[0043] In some embodiments, the SG protein modulates (i.e.
increases or decreases) a cytokine in the blood, plasma, serum,
tissue and/or mucosa of a subject administered the SG protein.
[0044] In some embodiments, the SG protein decreases the levels of
at least one pro-inflammatory cytokine in the blood, plasma, serum,
tissue and/or mucosa of the subject. In other embodiments, the at
least one pro-inflammatory cytokine is selected from the group
consisting of TNF-.alpha., IL-17, IL-1.beta., IL-2, IFN-.gamma.,
IL-6, IL-12, IL-25, IL-33, IL-8, MCP-1, MIP-3.alpha., CXCL1, and
IL-23.
[0045] In some embodiments, the SG protein increases the levels of
at least one anti-inflammatory cytokine in the blood, plasma,
serum, tissue and/or mucosa of the subject. In other embodiments,
the at least one anti-inflammatory cytokine is selected from the
group consisting of IL-4, IL-10, IL-13, IFN-.alpha., and
TGF-.beta..
[0046] In some embodiments, the SG protein decreases the level of
at least one anti-inflammatory cytokine in the blood, plasma,
serum, tissue and/or mucosa of the subject. In other embodiments,
the at least one anti-inflammatory cytokine is selected from the
group consisting of IL-4, IL-10, IL-13, IFN-.alpha., and
TGF-.beta..
[0047] In some embodiments, the disclosure teaches a polynucleotide
encoding an SG protein and methods of expressing the polypeptide in
a host cell. In a particular embodiment, the polynucleotide
comprises a sequence which encodes an SG protein that is at least
about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,
99.7%, 99.8%, or 99.9%, or 100% identical to SEQ ID NO:1, SEQ ID
NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID
NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ
ID NO:23, or SEQ ID NO:25. In further embodiments, the
polynucleotide comprises a sequence which encodes an SG protein
that is less than 100% identical to SEQ ID NO:1, SEQ ID NO:3, SEQ
ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ
ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23,
or SEQ ID NO:25, respectively. In still other embodiments, the
polynucleotide is codon-optimized for expression in a recombinant
host cell. In yet other embodiments, the polynucleotide is
codon-optimized for expression in E. coli.
[0048] In some embodiments, the disclosure teaches a nucleic acid
which comprises a sequence that is at least 70%, 75%, 80%, 85%,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical
to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID
NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ
ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ ID NO:26. In further
embodiments, the nucleic acid comprises a sequence which is less
than 100% identical to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ
ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16,
SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ ID
NO:26, respectively.
[0049] In some aspects, an expression vector is provided,
comprising an exogenous polynucleotide that encodes an SG protein
comprising an amino acid sequence having at least 70%, 75%, 80%,
85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ
ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17,
SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. In
further embodiments, the polynucleotide encodes a protein which is
less than 100% identical to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5,
SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15,
SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID
NO:25, respectively.
[0050] In some aspects, an expression system is provided,
comprising a host cell and the expression vector comprising the
aforementioned exogenous polynucleotide.
[0051] In some embodiments, the host cell is prokaryotic or
eukaryotic. In other embodiments, the host cell is mammalian cell,
a yeast cell or a bacterial cell. In still other embodiments, the
bacterial cell is Escherichia coli. In yet other embodiments, the
mammalian cell is a CHO cell.
[0052] In some aspects, a method of producing the SG protein is
provided.
[0053] In some embodiments, the method for producing the SG protein
comprises transforming or transfecting the aforementioned host cell
with the aforementioned expression vector, culturing the
transformed or transfected host cell under conditions sufficient
for the expression of the SG protein encoded by the aforementioned
exogenous polynucleotide. In other embodiments, the method further
comprises purifying the protein from the transformed or transfected
host cell and culture media.
[0054] In some aspects, the disclosure provides a pharmaceutical
composition for treating an inflammatory bowel disease, comprising:
an SG protein comprising an amino acid sequence having at least
70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%,
99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%
or 100% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5,
SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15,
SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID
NO:25 and a pharmaceutically acceptable carrier. In some
embodiments, the SG protein is purified or substantially purified.
In some embodiments, the SG protein comprises the amino acid
sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ
ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17,
SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25 or a
variant thereof wherein the variant is at least 70%, 75%, 80%, 85%,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%,
99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to but
less than 100% identical to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5,
SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15,
SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID
NO:25, respectively.
[0055] In some embodiments, the pharmaceutical composition is
formulated for rectal, parenteral, intravenous, topical, oral,
dermal, transdermal, or subcutaneous administration. In other
embodiments, the pharmaceutical composition is a liquid, a gel, or
a cream. In still other embodiments, the pharmaceutical composition
is a solid composition comprising an enteric coating.
[0056] In some embodiments, the pharmaceutical composition is a
cream, a capsule, a liquid, a gel, or an emulsion.
[0057] In some embodiments, the pharmaceutical composition is
formulated to provide delayed release of the SG protein. In other
embodiments, the delayed release is release of the SG protein into
the gastrointestinal tract. In yet other embodiments, the delayed
release of the SG protein is into the mouth, the small intestine,
the large intestine and/or the rectum.
[0058] In some embodiments, the pharmaceutical composition is
formulated to provide sustained release of the SG protein. In other
embodiments, the sustained release of the SG protein is release
into the gastrointestinal tract. In yet other embodiments, the
sustained release of the SG protein is into the mouth, the small
intestine, the large intestine and/or the rectum. In still other
embodiments, the sustained release composition releases the SG
protein over a time period of about 1 to 20 hours, 1 to 10 hours, 1
to 8 hours, 4 to 12 hours or 5 to 15 hours.
[0059] In some embodiments, the pharmaceutical composition further
comprises a second therapeutic agent. In other embodiments, the
second therapeutic agent is selected from the group consisting of
an anti-diarrheal, a 5-aminosalicylic acid compound, an
anti-inflammatory agent, an antibiotic, an anti-cytokine agent, an
anti-inflammatory cytokine agent, a steroid, a corticosteroid, an
immunosuppressant, a JAK inhibitor, an anti-integrin biologic, an
anti-IL12/23R biologic, and a vitamin.
[0060] In some embodiments, the pharmaceutical composition further
comprises a protease inhibitor. In still other embodiments, the
protease inhibitor inhibits degradation of the SG protein in the
presence of fecal matter and/or in the presence of blood.
[0061] As aforementioned, these novel protein therapeutics are able
to promote epithelial barrier function and integrity in a subject.
In some embodiments, the epithelial barrier function is intestinal
epithelial barrier function. Additionally, the therapeutic effect
of the SG protein includes suppression of an inflammatory immune
response in an IBD individual. Thus, the disclosure provides
detailed guidance for methods of utilizing the taught therapeutic
proteins to treat a host of gastrointestinal inflammatory
conditions, and disease states involving compromised
gastrointestinal epithelial barrier integrity. Accordingly, in some
aspects, methods of treating a disease--such as an intestinal
epithelium barrier function associated disease--are provided, which
utilize any sequence disclosed in the current application and
sequence listing.
[0062] In some embodiments, a method for treating an inflammatory
bowel disease or disorder in a patient in thereof is provided,
comprising: administering to the patient a pharmaceutical
composition, comprising: i) an SG protein as described herein; and
ii) a pharmaceutically acceptable carrier.
[0063] In some embodiments, the patient has been diagnosed with
intestinal inflammation. In other embodiments, the intestinal
inflammation is in the small intestine and/or the large intestine.
In still other embodiments, the intestinal inflammation is in the
rectum. In still other embodiments, the patient has been diagnosed
with pouchitis.
[0064] In some embodiments, the patient has been diagnosed with
intestinal ulcers. In other embodiments, the patient has been
diagnosed with draining enterocutaneous and/or rectovaginal
fistulas.
[0065] In some embodiments, the patient has been diagnosed with
Crohn's disease (CD). In other embodiments, the CD is mildly active
CD. In still other embodiments, the CD is moderately to severely
active CD. In yet other embodiments, the patient has been diagnosed
with pediatric CD.
[0066] In some embodiments, the patient has been diagnosed with
short bowel syndrome or irritable bowel syndrome.
[0067] In some embodiments, the patient has been diagnosed with
mucositis. In other embodiments, the mucositis is oral mucositis.
In still other embodiments, the mucositis is chemotherapy-induced
mucositis, radiation therapy-induced mucositis,
chemotherapy-induced oral mucositis, or radiation therapy-induced
oral mucositis. In yet other embodiments, the mucositis is
gastrointestinal mucositis. In still other embodiments, the
gastrointestinal mucositis is mucositis of the small intestine, the
large intestine, or the rectum.
[0068] In some embodiments, the administering to a patient
diagnosed with CD resulted in a reduced number of draining
enterocutaneous and/or rectovaginal fistulas. In other embodiments,
the administering maintains fistula closure in adult patients with
fistulizing disease.
[0069] In other embodiments, the patient has been diagnosed with
ulcerative colitis (UC). In other embodiments, the UC is mildly
active UC. In still other embodiments, the UC is moderately to
severely active UC. In still other embodiments, the patient has
been diagnosed with pediatric UC.
[0070] In some embodiments, the patient is in clinical remission
from an IBD. In other embodiments, the patient is in clinical
remission from UC, pediatric UC, CD or pediatric CD.
[0071] In some embodiments, the patient has an inflammatory bowel
disease or disorder other than Crohn's disease or ulcerative
colitis. In other embodiments, the patient has at least one symptom
associated with inflammatory bowel disease.
[0072] In some embodiments, the administering reduces
gastrointestinal inflammation and/or reduces intestinal mucosa
inflammation associated with inflammatory bowel disease in the
patient. In other embodiments, the administering improves
intestinal epithelial cell barrier function or integrity in the
patient.
[0073] In some embodiments, after the administering the patient
experiences a reduction in at least one symptom associated with an
inflammatory bowel disease or disorder. In other embodiments, the
at least one symptom is selected from the group consisting of
abdominal pain, blood in stool, pus in stool, fever, weight loss,
frequent diarrhea, fatigue, reduced appetite, nausea, cramps,
anemia, tenesmus, and rectal bleeding. In still other embodiments,
after the administering the patient experiences reduced frequency
of diarrhea, reduced blood in stool and/or reduced rectal
bleeding.
[0074] In some embodiments, the patient has experienced inadequate
response to conventional therapy. In other embodiments, the
conventional therapy is treatment with an aminosalicylate, a
corticosteroid, a thiopurine, methotrexate, a JAK inhibitor, a
sphingosine 1-phosphate (S1P) receptor inhibitor, an anti-integrin
biologic, an anti-IL12/23R or anti-IL23/p10 biologic, and/or an
anti-tumor necrosis factor agent or biologic.
[0075] In some embodiments, the administering modulates (i.e.
increases or decreases) levels of a cytokine in the blood, plasma,
serum, mucosa or tissue of the patient.
[0076] In some embodiments, the administering suppresses the levels
of at least one pro-inflammatory cytokine in the blood, plasma,
serum, mucosa or tissue of the patient. In other embodiments, the
at least one pro-inflammatory cytokine is selected from the group
consisting of TNF-.alpha., IL-17, IL-1.beta., IL-2, IFN-.gamma.,
IL-6, IL-12, IL-25, IL-33, IL-8, MCP-1, MIP-3.alpha., CXCL1, and
IL-23.
[0077] In some embodiments, the administering increases the levels
of at least one anti-inflammatory cytokine in the blood, plasma,
serum, mucosa or tissue of the patient. In other embodiments, the
at least one anti-inflammatory cytokine is selected from the group
consisting of IL-4, IL-10, IL-13, IFN-.alpha., and TGF-.beta..
[0078] In some embodiments, the administering decreases the level
of at least one anti-inflammatory cytokine in the blood, plasma,
serum, mucosa or tissue of the patient. In other embodiments, the
at least one anti-inflammatory cytokine is selected from the group
consisting of IL-4, IL-10, IL-13, IFN-.alpha., and TGF-.beta..
[0079] In some embodiments, the administering increases the amount
of mucin in intestinal lumen of the patient.
[0080] In some embodiments, the administering increases intestinal
epithelial cell wound healing in the patient.
[0081] In some embodiments, the administering prevents or reduces
colon shortening in the patient.
[0082] In some embodiments, the administering comprises rectal,
intravenous, parenteral, oral, topical, dermal, transdermal or
subcutaneous administering of the pharmaceutical composition to the
patient. In other embodiments, the administering is to the
gastrointestinal lumen.
[0083] In some embodiments, the patient is also administered at
least one second therapeutic agent. In other embodiments, the at
least one second therapeutic agent is selected from the group
consisting of an anti-diarrheal, an anti-inflammatory agent, an
antibody, an antibiotic, or an immunosuppressant. In still other
embodiments, the at least one second therapeutic agent is an
aminosalicylate, a steroid, or a corticosteroid. In other
embodiments, the at least one second therapeutic agent is selected
from the group consisting of adalimumab, pegol, golimumab,
infliximab, vedolizumab, ustekinumab, tofacitinib, and certolizumab
or certolizumab pegol.
BRIEF DESCRIPTION OF THE DRAWINGS
[0084] FIG. 1A and FIG. 1B show restoration, by SG-15, of
epithelial barrier integrity following inflammation induced
disruption, as described in Example 1B.
[0085] FIG. 2A shows effects of SG-15 administration on TNF-.alpha.
production induced by heat killed Escherichia coli (HK E. coli), as
described in Example 1C.
[0086] FIG. 2B shows effects of SG-15 administration on IL-23
production induced by HK E. coli, as described in Example 1C.
[0087] FIG. 2C shows effects of SG-15 administration on IL-10
production induced by HK E. coli, as described in Example 1C.
[0088] FIG. 3 shows effects of SG-15 administration on epithelial
cell wound healing, as described in Example 1D.
[0089] FIG. 4 shows effects of SG-15 administration on epithelial
centric barrier function readouts in a DSS model of inflammatory
bowel disease, as described in Example 1E.
[0090] FIG. 5 shows effects of SG-15 administration on inflammatory
readouts responsive to impaired barrier function in a DSS model of
inflammatory bowel disease, as described in Example 1F.
[0091] FIG. 6 shows effects of SG-15 administration on body weight
in a DSS model of inflammatory bowel disease, as described in
Example 1G.
[0092] FIG. 7 shows effects of SG-15 administration on gross
pathology in a DSS model of inflammatory bowel disease, as
described in Example 1H.
[0093] FIG. 8 shows effects of SG-15 administration on colon length
in a DSS model of inflammatory bowel disease, as described in
Example H.
[0094] FIG. 9 shows effects of SG-15 administration on colon weight
to length ratio in a DSS model of inflammatory bowel disease, as
described in Example 1J.
[0095] FIG. 10A and FIG. 10B show restoration, by SG-16, of
epithelial barrier integrity following inflammation induced
disruption, as described in Example 2B.
[0096] FIG. 11A shows effects of SG-16 administration on
TNF-.alpha. production induced by heat killed Escherichia coli (HK
E. coli), as described in Example 2C.
[0097] FIG. 11B shows effects of SG-16 administration on IL-23
production induced by HK E. coli, as described in Example 2C.
[0098] FIG. 11C shows effects of SG-16 administration on IL-10
production induced by HK E. coli, as described in Example 2C.
[0099] FIG. 12 shows effects of SG-16 administration on mucin
expression following stimulation with HK E. coli, as described in
Example 2D.
[0100] FIG. 13 shows effects of SG-16 administration on epithelial
cell wound healing, as described in Example 2E.
[0101] FIG. 14 shows effects of SG-16 administration on epithelial
centric barrier function readouts in a DSS model of inflammatory
bowel disease, as described in Example 2F.
[0102] FIG. 15 shows effects of SG-16 administration on
inflammatory readouts responsive to impaired barrier function in a
DSS model of inflammatory bowel disease, as described in Example
2G.
[0103] FIG. 16 shows effects of SG-16 administration on body weight
in a DSS model of inflammatory bowel disease, as described in
Example 2H.
[0104] FIG. 17 shows effects of SG-16 administration on gross
pathology in a DSS model of inflammatory bowel disease, as
described in Example 21.
[0105] FIG. 18 shows effects of SG-16 administration on colon
length in a DSS model of inflammatory bowel disease, as described
in Example 2J.
[0106] FIG. 19 shows effects of SG-16 administration on colon
weight to length ratio in a DSS model of inflammatory bowel
disease, as described in Example 2K.
[0107] FIG. 20A and FIG. 20B show restoration, by SG-17, of
epithelial barrier integrity following inflammation induced
disruption, as described in Example 3B.
[0108] FIG. 21A shows effects of SG-17 administration on
TNF-.alpha. production induced by heat killed Escherichia coli (HK
E. coli), as described in Example 3C.
[0109] FIG. 21B shows effects of SG-17 administration on IL-23
production induced by HK E. coli, as described in Example 3C.
[0110] FIG. 21C shows effects of SG-17 administration on IL-10
production induced by HK E. coli, as described in Example 3C.
[0111] FIG. 22 shows effects of SG-17 administration on mucin
expression following stimulation with HK E. coli, as described in
Example 3D.
[0112] FIG. 23 shows effects of SG-17 administration on epithelial
cell wound healing, as described in Example 3E.
[0113] FIG. 24 shows effects of SG-17 administration on epithelial
centric barrier function readouts in a DSS model of inflammatory
bowel disease, as described in Example 3F.
[0114] FIG. 25 shows effects of SG-17 administration on
inflammatory readouts responsive to impaired barrier function in a
DSS model of inflammatory bowel disease, as described in Example
3G.
[0115] FIG. 26 shows effects of SG-17 administration on body weight
in a DSS model of inflammatory bowel disease, as described in
Example 3H.
[0116] FIG. 27 shows effects of SG-17 administration on gross
pathology in a DSS model of inflammatory bowel disease, as
described in Example 31.
[0117] FIG. 28 shows effects of SG-17 administration on colon
length in a DSS model of inflammatory bowel disease, as described
in Example 3J.
[0118] FIG. 29 shows effects of SG-17 administration on colon
weight to length ratio in a DSS model of inflammatory bowel
disease, as described in Example 3K.
[0119] FIG. 30A and FIG. 30B show restoration, by SG-18, of
epithelial barrier integrity following inflammation induced
disruption, as described in Example 4B.
[0120] FIG. 31A shows effects of SG-18 administration on
TNF-.alpha. production induced by heat killed Escherichia coli (HK
E. coli), as described in Example 4C.
[0121] FIG. 31B shows effects of SG-18 administration on IL-23
production induced by HK E. coli, as described in Example 4C.
[0122] FIG. 31C shows effects of SG-18 administration on IL-10
production induced by HK E. coli, as described in Example 4C.
[0123] FIG. 32 shows effects of SG-18 administration on epithelial
cell wound healing, as described in Example 4D.
[0124] FIG. 33 shows effects of SG-18 administration on epithelial
centric barrier function readouts in a DSS model of inflammatory
bowel disease, as described in Example 4E.
[0125] FIG. 34 shows effects of SG-18 administration on
inflammatory readouts responsive to impaired barrier function in a
DSS model of inflammatory bowel disease, as described in Example
4F.
[0126] FIG. 35 shows effects of SG-18 administration on body weight
in a DSS model of inflammatory bowel disease, as described in
Example 4G.
[0127] FIG. 36 shows effects of SG-18 administration on gross
pathology in a DSS model of inflammatory bowel disease, as
described in Example 4H.
[0128] FIG. 37 shows effects of SG-18 administration on colon
length in a DSS model of inflammatory bowel disease, as described
in Example 41.
[0129] FIG. 38 shows effects of SG-18 administration on colon
weight to length ratio in a DSS model of inflammatory bowel
disease, as described in Example 4J.
DETAILED DESCRIPTION
[0130] The present disclosure provides novel protein therapeutics
that are useful in the treatment of subjects suffering from
symptoms associated with gastrointestinal disorders. For example,
an SG protein described herein can promote or enhance epithelial
barrier function and/or integrity. The SG protein may also suppress
the inflammatory immune response in an IBD individual. The protein
therapeutic provided herein is useful in treating the numerous
diseases that are associated with decreased gastrointestinal
epithelial cell barrier function or integrity and inflammation of
the intestine.
[0131] In the present disclosure, provided are also SG protein
variants that have therapeutic activity comparable to or superior
to the original protein, but the SG protein variants have enhanced
stability through the manufacturing and processing of the protein
therapeutic products as well as under long-term storage
conditions.
Definitions
[0132] Unless otherwise defined herein, scientific and technical
terms used in this application shall have the meanings that are
commonly understood by those of ordinary skill in the art.
Generally, nomenclature used in connection with, and techniques of,
chemistry, molecular biology, cell and cancer biology, immunology,
microbiology, pharmacology, and protein and nucleic acid chemistry,
described herein, are those well-known and commonly used in the
art. Thus, while the following terms are believed to be well
understood by one of ordinary skill in the art, the following
definitions are set forth to facilitate explanation of the
presently disclosed subject matter.
[0133] Throughout this specification, the word "comprise" or
variations such as "comprises" or "comprising" will be understood
to imply the inclusion of a stated component, or group of
components, but not the exclusion of any other components, or group
of components.
[0134] The term "a" or "an" refers to one or more of that entity,
i.e. can refer to a plural referents. As such, the terms "a" or
"an," "one or more," and "at least one" are used interchangeably
herein. In addition, reference to "an element" by the indefinite
article "a" or "an" does not exclude the possibility that more than
one of the elements is present, unless the context clearly requires
that there is one and only one of the elements.
[0135] The term "including" is used to mean "including but not
limited to." "Including" and "including but not limited to" are
used interchangeably.
[0136] The terms "SG protein" and "SG" as used herein and when
immediately followed by a numerical designation refer to various
proteins, wherein the complete designation (i.e., SG/number) refers
to specific protein sequences as described herein. The terms
"SG/number protein" and "SG/number" wherein the term "number" is
provided as an actual numerical designation as used herein
encompass SG protein sequence variants and/or fragments (which are
further defined herein).
[0137] The terms "gastrointestinal" or "gastrointestinal tract,"
"alimentary canal," and "intestine," as used herein, may be used
interchangeably to refer to the series of hollow organs extending
from the mouth to the anus and including the mouth, esophagus,
stomach, small intestine, large intestine, rectum and anus. The
terms "gastrointestinal" or "gastrointestinal tract," "alimentary
canal," and "intestine" are not always intended to be limited to a
particular portion of the alimentary canal.
[0138] The term "SG-15" as used herein refers to a protein
comprising the amino acid sequence of SEQ ID NO:1 and also to
variants thereof having the same or similar functional activity as
described herein. Accordingly, SG-15 can refer herein to proteins
comprising or consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5
or SEQ ID NO:7, or variants or fragments thereof. In U.S.
provisional patent application (62/514,165, filed Jun. 2, 2017, to
which the present specification claims priority and which is
incorporated herein by reference in its entirety) the term
"Experimental Protein 4" and variants thereof was used and is
synonymous with SG-15 as used herein or variants thereof.
[0139] The term "SG-16" as used herein refers to a protein
comprising the amino acid sequence of SEQ ID NO:9 and also to
variants thereof having the same or similar functional activity as
described herein. Accordingly, SG-16 can refer herein to proteins
comprising or consisting of SEQ ID NO:9 or SEQ ID NO:11, or
variants or fragments thereof. In U.S. provisional patent
application (62/514,148, filed Jun. 2, 2017, to which the present
specification claims priority and which is incorporated herein by
reference in its entirety) the term "Experimental Protein 6" and
variants thereof was used and is synonymous with SG-16 as used
herein or variants thereof.
[0140] The term "SG-17" as used herein refers to a protein
comprising the amino acid sequence of SEQ ID NO:13 and also to
variants thereof having the same or similar functional activity as
described herein. Accordingly, SG-17 can refer herein to proteins
comprising or consisting of SEQ ID NO:13, SEQ ID NO:15 or SEQ ID
NO:17, or variants or fragments thereof. In U.S. provisional patent
application (62/518,137, filed Jun. 12, 2017, to which the present
specification claims priority and which is incorporated herein by
reference in its entirety) the term "Experimental Protein 7" and
variants thereof was used and is synonymous with SG-17 as used
herein or variants thereof.
[0141] The term "SG-18" as used herein refers to a protein
comprising the amino acid sequence of SEQ ID NO:19 and also to
variants thereof having the same or similar functional activity as
described herein. Accordingly, SG-18 can refer herein to proteins
comprising or consisting of SEQ ID NO:19, SEQ ID NO:21, SEQ ID
NO:23 or SEQ ID NO:25, or variants or fragments thereof. In U.S.
provisional patent application (62/518,138, filed Jun. 12, 2017, to
which the present specification claims priority and which is
incorporated herein by reference in its entirety) the term
"Experimental Protein 5" and variants thereof was used and is
synonymous with SG-18 as used herein or variants thereof.
[0142] A "signal sequence" (also termed "presequence," "signal
peptide," "leader sequence," or "leader peptide") refers to a
sequence of amino acids located at the N-terminus of a nascent
protein, and which can facilitate the secretion of the protein from
the cell. The resultant mature form of the extracellular protein
lacks the signal sequence, which is cleaved off during the
secretion process.
[0143] The recitations "sequence identity," "percent identity,"
"percent homology," or for example, comprising a "sequence 50%
identical to," as used herein, refer to the extent that sequences
are identical on a nucleotide-by-nucleotide or amino acid-by-amino
acid basis, over a window of comparison. Thus, a "percentage of
sequence identity" may be calculated by comparing two optimally
aligned sequences over the window of comparison, determining the
number of positions at which the identical nucleic acid base (e.g.,
A, T, C, G, I) or the identical amino acid residue (e.g., Ala, Pro,
Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp,
Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the
number of matched positions, dividing the number of matched
positions by the total number of positions in the window of
comparison (i.e., the window size), and multiplying the result by
100 to yield the percentage of sequence identity.
[0144] Calculations of sequence similarity or sequence identity
between sequences (the terms are used interchangeably herein) can
be performed as follows. To determine the percent identity of two
amino acid sequences, or of two nucleic acid sequences, the
sequences can be aligned for optimal comparison purposes (e.g.,
gaps can be introduced in one or both of a first and a second amino
acid or nucleic acid sequence for optimal alignment and
non-homologous sequences can be disregarded for comparison
purposes). In certain embodiments, the length of a reference
sequence aligned for comparison purposes is at least 30%,
preferably at least 40%, more preferably at least 50%, 60%, and
even more preferably at least 70%, 80%, 90%, or 100% of the length
of the reference sequence. The amino acid residues or nucleotides
at corresponding amino acid positions or nucleotide positions are
then compared. When a position in the first sequence is occupied by
the same amino acid residue or nucleotide as the corresponding
position in the second sequence, then the molecules are identical
at that position. The percent identity between the two sequences is
a function of the number of identical positions shared by the
sequences, taking into account the number of gaps, and the length
of each gap, which need to be introduced for optimal alignment of
the two sequences.
[0145] The phrases "substantially similar" and "substantially
identical" in the context of at least two nucleic acids or
polypeptides typically means that a polynucleotide or polypeptide
comprises a sequence that has at least about 70%, 75%, 80%, 85%,
86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, 99.5%, 99.6%, 99.7% or even 99.8% sequence identity, in
comparison with a reference polynucleotide or polypeptide. In some
embodiments, substantially identical polypeptides differ only by
one or more conservative amino acid substitutions. In some
embodiments, substantially identical polypeptides are
immunologically cross-reactive. In some embodiments, substantially
identical nucleic acid molecules hybridize to each other under
stringent conditions (e.g., within a range of medium to high
stringency).
[0146] As used herein, the term "nucleotide change" refers to,
e.g., nucleotide substitution, deletion, and/or insertion, as is
well understood in the art. For example, mutations contain
alterations that produce silent substitutions, additions, or
deletions, but do not alter the properties or activities of the
encoded protein or how the proteins are made.
[0147] Related (and derivative) proteins encompass "variant"
proteins. Variant proteins can differ from another (i.e., parental)
protein and/or from one another by a small number of amino acid
residues. A variant may include one or more amino acid mutations
(e.g., amino acid deletion, insertion or substitution) as compared
to the parental protein from which it is derived.
[0148] "Conservatively modified variants" applies to both amino
acid and nucleic acid sequences. With respect to particular nucleic
acid sequences, a conservatively modified variant refers to nucleic
acids encoding identical amino acid sequences, or amino acid
sequences that have one or more "conservative substitutions." An
example of a conservative substitution is the exchange of an amino
acid in one of the following groups for another amino acid of the
same group (see U.S. Pat. No. 5,767,063; Kyte and Doolittle (1982)
J Mol. Biol. 157:105-132). (1) Hydrophobic: Norleucine, Ile, Val,
Leu, Phe, Cys, Met; (2) Neutral hydrophilic: Cys, Ser, Thr; (3)
Acidic: Asp, Glu; (4) Basic: Asn, Gln, His, Lys, Arg; (5) Residues
that influence chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr,
Phe; and (7) Small amino acids: Gly, Ala, Ser. Thus, the term
"conservative substitution" with respect to an amino acid denotes
that one or more amino acids are replaced by another, chemically
similar residue, wherein said substitution does not generally
affect the functional properties of the protein. Examples include
substitution of amino acid residues with similar characteristics,
e.g., small amino acids, acidic amino acids, polar amino acids,
basic amino acids, hydrophobic amino acids and aromatic amino
acids. In some embodiments, the disclosure provides for proteins
that have at least one non-naturally occurring, conservative amino
acid substitution relative to the amino acid sequence identified in
SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9,
SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID
NO:19, SEQ ID NO:21, SEQ ID NO:23 or SEQ ID NO:25. Some common
exemplary examples of conservative amino acid substitutions are
found below.
[0149] The term "amino acid" or "any amino acid" refers to any and
all amino acids, including naturally occurring amino acids (e.g.,
.alpha.-amino acids), unnatural amino acids, modified amino acids,
and unnatural or non-natural amino acids. It includes both D- and
L-amino acids. Natural amino acids include those found in nature,
such as, e.g., the 23 amino acids that combine into peptide chains
to form the building-blocks of a vast array of proteins. These are
primarily L stereoisomers, although a few D-amino acids occur,
e.g., in bacterial envelopes and some antibiotics. The 20
"standard," natural amino acids are listed in the above tables. The
"non-standard," natural amino acids are pyrrolysine (found in
methanogenic organisms and other eukaryotes), selenocysteine
(present in many noneukaryotes as well as most eukaryotes), and
N-formylmethionine (encoded by the start codon AUG in bacteria,
mitochondria and chloroplasts). "Unnatural" or "non-natural" amino
acids are non-proteinogenic amino acids (i.e., those not naturally
encoded or found in the genetic code) that either occur naturally
or are chemically synthesized. Over 140 unnatural amino acids are
known and thousands of more combinations are possible. "Modified"
amino acids include amino acids (e.g., natural amino acids) that
have been chemically modified to include a group, groups, or
chemical moiety not naturally present on the amino acid.
[0150] As used herein, a "synthetic nucleotide sequence" or
"synthetic polynucleotide sequence" is a nucleotide sequence that
is not known to occur in nature, or that is not naturally
occurring. Generally, such a synthetic nucleotide sequence will
comprise at least one nucleotide difference when compared to any
other naturally occurring nucleotide sequence. As used herein, a
"synthetic amino acid sequence" or "synthetic peptide sequence" or
"synthetic polypeptide sequence" or "synthetic protein sequence" is
an amino acid sequence that is not known to occur in nature, or
that is not naturally occurring. Generally, such a synthetic amino
acid sequence will comprise at least one amino acid difference when
compared to any other naturally occurring amino acid sequence.
[0151] As used herein, a "synthetic protein" or "synthetic
therapeutic protein" means a protein that comprises an amino acid
sequence that contains one or more amino acids substituted with
different amino acids relative to a naturally occurring amino acid
sequence. That is, a "synthetic protein" comprises an amino acid
sequence that has been altered to contain at least one
non-naturally occurring substitution modification at a given amino
acid position(s) relative to a naturally occurring amino acid
sequence.
[0152] The term "about" as used herein with respect to % sequence
identity, or % sequence homology, of a nucleic acid sequence, or
amino acid sequence, means up to and including .+-.1.0% in 0.1%
increments. For example, "about 90%" sequence identity includes
89.0%, 89.1%, 89.2%, 89.3%, 89.4%, 89.5%, 89.6%, 89.7%, 89.8%,
89.9%, 90%, 90.1%, 90.2%, 90.3%, 90.4%, 90.5%, 90.6%, 90.7%, 90.8%,
90.9%, and 91%. If not used in the context of % sequence identity,
then "about" means.+-.1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%,
depending upon context of the value in question.
[0153] For the most part, the names of natural and non-natural
aminoacyl residues used herein follow the naming conventions
suggested by the IUPAC Commission on the Nomenclature of Organic
Chemistry and the IUPAC-IUB Commission on Biochemical Nomenclature
as set out in "Nomenclature of .alpha.-Amino Acids
(Recommendations, 1974)" Biochemistry, 14(2), (1975). To the extent
that the names and abbreviations of amino acids and aminoacyl
residues employed in this specification and appended claims differ
from those suggestions, they will be made clear to the reader.
[0154] Throughout the present specification, unless natural amino
acids are referred to by their full name (e.g., alanine, arginine,
etc.), they are designated by their conventional three-letter or
single-letter abbreviations (e.g., Ala or A for alanine, Arg or R
for arginine, etc.). Unless otherwise indicated, three-letter and
single-letter abbreviations of amino acids refer to the L-isomeric
form of the amino acid. The term "L-amino acid," as used herein,
refers to the "L" isomeric form of a peptide, and conversely the
term "D-amino acid" refers to the "D" isomeric form of a peptide
(e.g., Dasp, (D)Asp or D-Asp; Dphe, (D)Phe or D-Phe). Amino acid
residues in the D isomeric form can be substituted for any L-amino
acid residue, as long as the desired function is retained by the
peptide. D-amino acids may be indicated as customary in lower case
when referred to using single-letter abbreviations.
[0155] In the case of less common or non-natural amino acids,
unless they are referred to by their full name (e.g., sarcosine,
ornithine, etc.), three- or four-character codes are frequently
employed for residues thereof, including, Sar or Sarc (sarcosine,
i.e. N-methylglycine), Aib (.alpha.-aminoisobutyric acid), Dab
(2,4-diaminobutanoic acid), Dapa (2,3-diaminopropanoic acid),
.gamma.-Glu (.gamma.-glutamic acid), Gaba (.gamma.-aminobutanoic
acid), .beta.-Pro (pyrrolidine-3-carboxylic acid), and 8Ado
(8-amino-3,6-dioxaoctanoic acid), Abu (2-amino butyric acid),
.beta.hPro (.beta.-homoproline), .beta.hPhe
(.beta.-homophenylalanine) and Bip (.beta.,.beta. diphenylalanine),
and Ida (Iminodiacetic acid).
[0156] Among sequences disclosed herein are sequences incorporating
a "Hy-" moiety at the amino terminus (N-terminus) of the sequence,
and either an "--OH" moiety or an "--NH.sub.2" moiety at the
carboxy terminus (C-terminus) of the sequence. In such cases, and
unless otherwise indicated, a "Hy-" moiety at the N-terminus of the
sequence in question indicates a hydrogen atom, corresponding to
the presence of a free primary or secondary amino group at the
N-terminus, while an "--OH" or an "--NH.sub.2" moiety at the
C-terminus of the sequence indicates a hydroxy group or an amino
group, corresponding to the presence of an amido (CONH.sub.2) group
at the C-terminus, respectively. In each sequence of the
disclosure, a C-terminal "--OH" moiety may be substituted for a
C-terminal "--NH.sub.2" moiety, and vice-versa.
[0157] The term "Ac," as used herein, refers to acetyl protection
through acylation of the C- or N-terminus of a polypeptide. In
certain peptides shown herein, the NH.sub.2 locates at the
C-terminus of the peptide indicates an amino group. The term
"carboxy," as used herein, refers to --CO.sub.2H.
[0158] The term "pharmaceutically acceptable salt," as used herein,
represents salts or zwitterionic forms of the peptides, proteins,
or compounds of the present disclosure, which are water or
oil-soluble or dispersible, which are suitable for treatment of
diseases without undue toxicity, irritation, and allergic response;
which are commensurate with a reasonable benefit/risk ratio, and
which are effective for their intended use. The salts can be
prepared during the final isolation and purification of the
compounds or separately by reacting an amino group with a suitable
acid. Representative acid addition salts include acetate, adipate,
alginate, citrate, aspartate, benzoate, benzenesulfonate,
bisulfate, butyrate, camphorate, camphorsulfonate, digluconate,
glycerophosphate, hemisulfate, heptanoate, hexanoate, formate,
fumarate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxyethansulfonate (isethionate), lactate, maleate,
mesitylenesulfonate, methanesulfonate, naphthylenesulfonate,
nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate,
persulfate, 3-phenylproprionate, picrate, pivalate, propionate,
succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate,
glutamate, bicarbonate, para-toluenesulfonate, and undecanoate.
Also, amino groups in the compounds of the present disclosure can
be quaternized with methyl, ethyl, propyl, and butyl chlorides,
bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl
sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides,
and iodides; and benzyl and phenethyl bromides. Examples of acids
which can be employed to form therapeutically acceptable addition
salts include inorganic acids such as hydrochloric, hydrobromic,
sulfuric, and phosphoric, and organic acids such as oxalic, maleic,
succinic, and citric. A pharmaceutically acceptable salt may
suitably be a salt chosen, e.g., among acid addition salts and
basic salts. Examples of acid addition salts include chloride
salts, citrate salts and acetate salts. Examples of basic salts
include salts where the cation is selected among alkali metal
cations, such as sodium or potassium ions, alkaline earth metal
cations, such as calcium or magnesium ions, as well as substituted
ammonium ions. Other examples of pharmaceutically acceptable salts
are described in "Remington's Pharmaceutical Sciences", 17th
edition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton,
Pa., USA, 1985 (and more recent editions thereof), in the
"Encyclopaedia of Pharmaceutical Technology", 3rd edition, James
Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY, USA, 2007, and
in J. Pharm. Sci. 66: 2 (1977). Also, for a review on suitable
salts, see Handbook of Pharmaceutical Salts: Properties, Selection,
and Use by Stahl and Wermuth (Wiley-VCH, 2002).
[0159] As used herein, the term "at least a portion" or "fragment"
of a nucleic acid or polypeptide means a portion having the minimal
size characteristics of such sequences, or any larger fragment of
the full length molecule, up to and including the full length
molecule.
[0160] The term "primer" as used herein refers to an
oligonucleotide which is capable of annealing to a target
polynucleotide.
[0161] As used herein, the phrases "recombinant construct,"
"expression construct," "chimeric construct," "construct," and
"recombinant DNA construct" are used interchangeably herein and are
well-known to the ordinarily skilled artisan.
[0162] As used herein, the term "host cell" refers to a cell or
cell line into which a recombinant expression vector for production
of a polypeptide may be introduced for expression of the
polypeptide.
[0163] The terms "isolated," "purified," "separated," and
"recovered" as used herein refer to a material (e.g., a protein,
nucleic acid, or cell) that is removed from at least one component
with which it is naturally associated, for example, at a
concentration of at least 90% by weight, or at least 95% by weight,
or at least 98% by weight of the sample in which it is contained.
For example, these terms may refer to a material which is
substantially or essentially free from components which normally
accompany it as found in its native state, such as, for example, an
intact biological system.
[0164] The terms "patient," "subject," and "individual" may be used
interchangeably and refer to either a human or a non-human animal.
These terms include mammals such as humans, non-human primates,
livestock animals (e.g., bovines, porcines), companion animals
(e.g., canines, felines) and rodents (e.g., mice and rats). In
certain embodiments, the terms refer to a human patient. In
exemplary embodiments, the terms refer to a human patient that
suffers from a gastrointestinal inflammatory condition.
[0165] As used herein, "improved" should be taken broadly to
encompass improvement in an identified characteristic of a disease
state, said characteristic being regarded by one of skill in the
art to generally correlate, or be indicative of, the disease in
question, as compared to a control, or as compared to a known
average quantity associated with the characteristic in question.
For example, "improved" epithelial barrier function associated with
application of a protein of the disclosure can be demonstrated by
comparing the epithelial barrier integrity of a human treated with
a protein of the disclosure, as compared to the epithelial barrier
integrity of a human not treated. Alternatively, one could compare
the epithelial barrier integrity of a human treated with a protein
of the disclosure to the average epithelial barrier integrity of a
human, as represented in scientific or medical publications known
to those of skill in the art. In the present disclosure, "improved"
does not necessarily demand that the data be statistically
significant (i.e. p<0.05); rather, any quantifiable difference
demonstrating that one value (e.g. the average treatment value) is
different from another (e.g. the average control value) can rise to
the level of "improved."
[0166] As used herein, "inhibiting and suppressing" and like terms
should not be construed to require complete inhibition or
suppression, although this may be desired in some embodiments.
Thus, an "inhibited immune response" or the "inhibition of
inflammatory cytokines" does not require absolute inhibition.
[0167] Thus, as used herein, the terms "increase," "suppress" or
"reduce," or grammatical equivalents thereof, indicate values that
are relative to a reference (e.g., baseline) measurement, such as a
measurement taken under comparable conditions (e.g., in the same
individual prior to initiation of treatment described herein, or a
measurement in a control individual (or multiple control
individuals) in the absence of treatment) described herein. In some
embodiments, a suitable control is a baseline measurement, such as
a measurement in the same individual prior to initiation of the
treatment described herein, or a measurement in a control
individual (or multiple control individuals) in the absence of the
treatment described herein.
[0168] As used herein, the term "IBD" or "inflammatory bowel
disease" refers to conditions in which individuals have chronic or
recurring immune response and inflammation of the gastrointestinal
(GI) tract. The two most common inflammatory bowel diseases are
ulcerative colitis (UC) and Crohn's disease (CD).
[0169] As used herein, the term "therapeutically effective amount"
refers to an amount of a therapeutic agent (e.g., a peptide,
polypeptide, or protein of the disclosure), which confers a
therapeutic effect on the treated subject, at a reasonable
benefit/risk ratio applicable to any medical treatment. Such a
therapeutic effect may be objective (i.e., measurable by some test
or marker) or subjective (i.e., subject gives an indication of, or
feels an effect). In some embodiments, "therapeutically effective
amount" refers to an amount of a therapeutic agent or composition
effective to treat, ameliorate, or prevent (e.g., delay onset of) a
relevant disease or condition, and/or to exhibit a detectable
therapeutic or preventative effect, such as by ameliorating
symptoms associated with the disease, preventing or delaying onset
of the disease, and/or also lessening severity or frequency of
symptoms of the disease. A therapeutically effective amount is
commonly administered in a dosing regimen that may comprise
multiple unit doses. For any particular therapeutic agent, a
therapeutically effective amount (and/or an appropriate unit dose
within an effective dosing regimen) may vary, for example,
depending on route of administration, or on combination with other
therapeutic agents. Alternatively or additionally, a specific
therapeutically effective amount (and/or unit dose) for any
particular patient may depend upon a variety of factors including
the particular form of disease being treated; the severity of the
condition or pre-condition; the activity of the specific
therapeutic agent employed; the specific composition employed; the
age, body weight, general health, sex and diet of the patient; the
time of administration, route of administration, and/or rate of
excretion or metabolism of the specific therapeutic agent employed;
the duration of the treatment; and like factors as is well known in
the medical arts. The current disclosure utilizes therapeutically
effective amounts of novel proteins, and compositions comprising
same, to treat a variety of diseases, such as: gastrointestinal
inflammatory diseases or diseases involving gastrointestinal
epithelial barrier malfunction. The therapeutically effective
amounts of the administered protein, or compositions comprising
same, will in some embodiments reduce inflammation associated with
IBD or repair gastrointestinal epithelial barrier integrity and/or
function.
[0170] As used herein, the term "treatment" (also "treat" or
"treating") refers to any administration of a therapeutic agent
(e.g., a peptide, polypeptide, or protein of the disclosure),
according to a therapeutic regimen that achieves a desired effect
in that it partially or completely alleviates, ameliorates,
relieves, inhibits, delays onset of, reduces severity of and/or
reduces incidence of one or more symptoms or features of a
particular disease, disorder, and/or condition (e.g., chronic or
recurring immune response and inflammation of the gastrointestinal
(GI) tract); in some embodiments, administration of the therapeutic
agent according to the therapeutic regimen is correlated with
achievement of the desired effect. Such treatment may be of a
subject who does not exhibit signs of the relevant disease,
disorder and/or condition and/or of a subject who exhibits only
early signs of the disease, disorder, and/or condition.
Alternatively or additionally, such treatment may be of a subject
who exhibits one or more established signs of the relevant disease,
disorder and/or condition. In some embodiments, treatment may be of
a subject who has been diagnosed as suffering from the relevant
disease, disorder, and/or condition. In some embodiments, treatment
may be of a subject known to have one or more susceptibility
factors that are statistically correlated with increased risk of
development of the relevant disease, disorder, and/or
condition.
[0171] "Pharmaceutical" implies that a composition, reagent,
method, and the like, are capable of a pharmaceutical effect, and
also that the composition is capable of being administered to a
subject safely. "Pharmaceutical effect," without limitation, can
imply that the composition, reagent, or method, is capable of
stimulating a desired biochemical, genetic, cellular,
physiological, or clinical effect, in at least one individual, such
as a mammalian subject, for example, a human, in at least 5% of a
population of subjects, in at least 10%, in at least 20%, in at
least 30%, in at least 50% of subjects, and the like.
"Pharmaceutically acceptable" means approved by a regulatory agency
of the Federal or a state government or listed in the U.S.
Pharmacopoeia or other generally recognized pharmacopoeia for safe
use in animals, and more particularly safe use in humans.
"Pharmaceutically acceptable vehicle" or "pharmaceutically
acceptable excipient" refers to a diluent, adjuvant, excipient or
carrier with which a protein as described herein is
administered.
[0172] "Preventing" or "prevention" refers to a reduction in risk
of acquiring a disease or disorder (i.e., causing at least one of
the clinical symptoms of the disease not to develop in a subject
that may be exposed to or predisposed to the disease but does not
yet experience or display symptoms of the disease, or causing the
symptom to develop with less severity than in absence of the
treatment). "Prevention" or "prophylaxis" may refer to delaying the
onset of the disease or disorder.
[0173] The therapeutic pharmaceutical compositions taught herein
may comprise one or more natural products. However, in certain
embodiments, the therapeutic pharmaceutical compositions themselves
do not occur in nature. Further, in certain embodiments, the
therapeutic pharmaceutical compositions possess markedly different
characteristics, as compared to any individual naturally occurring
counterpart, or composition component, which may exist in nature.
That is, in certain embodiments, the pharmaceutical compositions
taught herein--which comprise a therapeutically effective amount of
a purified protein--possess at least one structural and/or
functional property that impart markedly different characteristics
to the composition as a whole, as compared to any single individual
component of the composition as it may exist naturally. The courts
have determined that compositions comprising natural products,
which possess markedly different characteristics as compared to any
individual component as it may exist naturally, are statutory
subject matter. Thus, the taught therapeutic pharmaceutical
compositions as a whole possess markedly different characteristics.
These characteristics are illustrated in the data and examples
taught herein.
[0174] Details of the disclosure are set forth herein. Although
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
disclosure, illustrative methods and materials are now described.
Other features, objects, and advantages of the disclosure will be
apparent from the description and from the claims.
Therapeutic Proteins Derived from the Microbiome--Overview of the
Disclosure
[0175] Numerous diseases and disorders are associated with
decreased gastrointestinal epithelial cell barrier function or
integrity. These diseases and disorders are multifaceted and
present diagnostically in a myriad of ways. One such disease is
inflammatory bowel disease (IBD), the incidence and prevalence of
which is increasing with time and in different regions around the
world, indicating its emergence as a global disease. (Molodecky et
al., Gastroenterol 142:46-54, 2012). IBD is a collective term that
describes conditions with chronic or recurring immune response and
inflammation of the gastrointestinal (GI) tract. The two most
common inflammatory bowel diseases are ulcerative colitis (UC) and
Crohn's disease (CD). Both are marked by an abnormal response of
the GI immune system. Normally, immune cells protect the body from
infection. In people with IBD, however, this immune system mistakes
food, bacteria, and other materials in the intestine for pathogens
and an inflammatory response is launched into the lining of the
intestines, creating chronic inflammation. When this happens, the
patient experiences the symptoms of IBD.
[0176] IBD involves chronic inflammation of all, or part, of the
digestive tract. Both UC and CD usually involve, for example,
severe diarrhea, abdominal pain, fatigue, and weight loss. IBD and
associated disorders can be debilitating and sometimes lead to
life-threatening complications.
[0177] With respect to intestinal barrier integrity, loss of
integrity of the intestinal epithelium plays a key pathogenic role
in IBD. Maloy, Kevin J.; Powrie, Fiona, "intestinal homeostasis and
its breakdown in inflammatory bowel disease," (2011) Nature. 474
(7351): 298-306. It is hypothesized that detrimental changes in the
intestinal microbiota induce an inappropriate or uncontrolled
immune response that results in damage to the intestinal
epithelium. Breaches in this critical intestinal epithelium barrier
allow further infiltration of microbiota that, in turn, elicit
further immune responses. Thus, IBD is a multifactorial disease
that is driven in part by an exaggerated immune response to gut
microbiota that can cause defects in epithelial barrier
function.
[0178] Microbiome profiling of IBD patients has revealed distinct
profiles such as increased Proteobacteria, including
adherent-invasive E. coli, often at the expense of potentially
beneficial microbes such as Roseburia spp (Machiels et al., 2014,
Cut, 63:1275-1283; Patterson et al., 2017, Front Immunol, 8:1166;
Shawki and McCole, 2017, Cell Mol Gastroenterol Hepatol, 3:41-50).
Moreover, a decrease in Roseburia hominis was linked with dysbiosis
in patients with ulcerative colitis. IBD affected individuals have
been found to have 30-50 percent reduced biodiversity of commensal
bacteria, such as decreases in Firmicutes (namely Lachnospiraceae)
and Bacteroidetes. Further evidence of the role of gut flora in the
cause of inflammatory bowel disease is that IBD affected
individuals are more likely to have been prescribed antibiotics in
the 2-5 year period before their diagnosis than unaffected
individuals. See, Aroniadis OC, Brandt L J, "Fecal microbiota
transplantation: past, present and future," (2013) Curr. Opin.
Gastroenterol. 29 (1) (2013): 79-84.
[0179] Protective bacterial communities, probiotics and bacterially
derived metabolites have been demonstrated to improve disease in
various clinical and pre-clinical studies. For example, fecal
microbial transfer (FMT) experiments have shown some success in IBD
patients, although challenges still exist with FMT (Moayyedi et
al., 2015, Gastroenterology, 149:102-109 e106; Qazi et al., 2017,
Gut Microbes, 8:574-588; Narula et al., 2017, Inflamm Bowel Dis,
23:1702-1709). In other studies treatment with probiotics including
VSL #3, Lactobacillus spp. and Bifidobacterium spp. have also shown
to have beneficial effects in humans and animal models (Srutkova et
al., 2015, PLoS One, 10:e0134050; Pan et al., 2014, Benef Microbes,
5:315-322; Huynh et al., 2009, Inflamm Bowel Dis, 15:760-768;
Bibiloni et al., 2005, Am J Gastroenterol, 100:1539-1546).
Furthermore, bacterial products such as p40 from L. rhamnosus GG
and Amuc-1100 from A. mucimphila have been shown to promote barrier
function and protect in animal models of IBD and metabolic disease,
receptively (Yan et al., 2011, J Clin Invest, 121:2242-2253;
Plovier et al., Nat Med, 23:107-113).
[0180] While uses of live microbial populations to treat diseases
is increasingly common, such methods rely on the ability of the
administered bacteria to survive in the host or patient and to
interact with the host tissues in a beneficial and therapeutic way.
An alternative approach, provided here, is to identify
microbially-encoded proteins and variants thereof which can affect
cellular functions in the host and provide therapeutic benefit.
Such proteins can be administered, for example, as pharmaceutical
compositions comprising a substantially isolated or purified
therapeutic, bacterially-derived protein or as a live
biotherapeutic (bacterium) engineered to express the therapeutic
protein as an exogenous protein. Moreover, methods of treatment
comprising administration of the therapeutic protein are not
limited to the gut (small intestine, large intestine, rectum) but
may also include treatment of other disorders within the alimentary
canal such as oral mucositis.
[0181] To identify microbially-derived proteins which may have
therapeutic application in gastrointestinal inflammatory disorders,
mucosal biopsies from humans who were healthy or who were diagnosed
with IBD (UC) were analyzed to determine the microbial compositions
of these mucosal biopsies. A comparison of the bacterial profiles
from healthy vs. diseased subjects identified bacteria that were
either likely to be beneficial (greater numbers in healthy vs.
diseased) or detrimental (lower numbers in healthy vs. diseased).
Among the bacterial species identified as beneficial was
Eubacterium eligens and Clostridium bartlettii. Extensive
bioinformatics analysis was then performed to predict proteins
encoded by the bacterium and then to identify those proteins which
are likely to be secreted by the bacterium. Proteins which were
predicted to be secreted proteins were then characterized using a
series of in vitro assays to study the effect of each protein on
epithelial barrier integrity, cytokine production and/or release,
and wound healing. Proteins identified as having activity which may
facilitate maintenance or repair of epithelial barrier integrity
were then assessed in an in vivo mouse model for colitis. These
proteins, identified herein as "SG-15," "SG-16," SG-17" and SG-18,"
demonstrated in vitro and/or in vivo activity indicative of its
ability to provide therapeutic benefit for improving epithelial
barrier integrity and for treating diseases and disorders
associated with epithelial barrier integrity as well as treating
inflammatory gastrointestinal diseases such as IBDs, as described
in more detail below.
The SG-15 Protein
[0182] A protein referred to herein as SG-15 is 400 amino acid
residues in length (SEQ ID NO:1) and is encoded by a nucleotide
sequence (provided as SEQ ID NO:2) present in the genome of
Eubacterium eligens. A complete genomic sequence for an E. eligens
strain can be found at GenBank accession number CP001104 (the
sequence incorporated herein by reference in its entirety). A 16S
rRNA gene sequence for the E. eligens strain can be found at
GenBank accession number NR_074613. A predicted full-length protein
(including a predicted signal sequence) encoded by the E. eligens
genomic sequence is 494 amino acids in length (SEQ ID NO:5),
encoded by SEQ ID NO:6. An alternate predicted full-length protein
is 475 amino acids in length (SEQ ID NO:7), encoded by SEQ ID NO:8.
Recombinant SG-15 can be expressed with an N-terminal methionine
(encoded by the codon ATG). For example, recombinantly expressed
SG-15 can be 401 amino acids in length (SEQ ID NO:3), encoded by
SEQ ID NO:4 (1203 bp). SG-15 refers to the above proteins and
variants thereof as taught herein.
The SG-16 Protein
[0183] A protein referred to herein as SG-16 is 119 amino acid
residues in length (SEQ ID NO:9) and is encoded by a nucleotide
sequence (provided as SEQ ID NO:10) present in the genome of
Eubacterium eligens (e.g., GenBank accession number CP001104). A
predicted full-length protein (including a predicted signal
sequence) encoded by the E. eligens genomic sequence is 143 amino
acids in length (SEQ ID NO:11), encoded by SEQ ID NO:12. SG-16
refers to the above proteins and variants thereof as taught
herein.
The SG-17 Protein
[0184] A protein referred to herein as SG-17 is 327 amino acid
residues in length (SEQ ID NO:13) and is encoded by a nucleotide
sequence (provided as SEQ ID NO:14) present in the genome of
Eubacterium eligens (e.g., GenBank accession number CP001104). A
predicted full-length protein (including a predicted signal
sequence) encoded by the E. eligens genomic sequence is 345 amino
acids in length (SEQ ID NO:17), encoded by SEQ ID NO:18.
Recombinant SG-17 can be expressed with an N-terminal methionine
(encoded by the codon ATG). For example, recombinantly expressed
SG-17 can be 328 amino acids in length (SEQ ID NO:15), encoded by
SEQ ID NO:16. SG-17 refers to the above proteins and variants
thereof as taught herein.
The SG-18 Protein
[0185] A protein referred to herein as SG-18 is 267 amino acid
residues in length (SEQ ID NO:19) and is encoded by a nucleotide
sequence (provided as SEQ ID NO:20) present in the genome of
Clostridium bartlettii sp. nov. A genomic sequence for a C.
bartlettii strain can be found at GenBank accession number
FUXV01000001 (the sequence incorporated herein by reference in its
entirety). A predicted full-length protein (including a predicted
signal sequence) encoded by the C. bartlettii genomic sequence is
290 amino acids in length (SEQ ID NO:23), encoded by SEQ ID NO:24.
An alternate predicted full-length protein is 279 amino acids in
length (SEQ ID NO:25), encoded by SEQ ID NO:26. Recombinant SG-18
can be expressed with an N-terminal methionine (encoded by the
codon ATG). For example, recombinantly expressed SG-18 can be 268
amino acids in length (SEQ ID NO:21), encoded by SEQ ID NO:22.
SG-18 refers to the above proteins and variants thereof as taught
herein.
[0186] The SG-15, SG-16, SG-17 and SG-18 proteins can be
recombinantly expressed in commercially available and routinely
used expression vectors and host cells. For example, these SG
proteins used in the Examples below were expressed using a pGEX
expression vector which expresses the protein of interest with a
GST tag and protease site which is cleaved after expression and
purification. This expression system can result in a protein, after
cleavage with a protease, with an N-terminus which differs with
respect to a few amino acid residues relative to the wildtype
protein. Moreover, a few exogenous amino acid residues may be
present at the C-terminus of the protein. Alternative expression
systems include but are not limited to a pET-28 expression vector
which adds an N-terminal FLAG tag, and a pD451 expression vector
which can be used to express an SG protein having no exogenous
N-terminal or C-terminal amino acids. Experiments performed and
repeated with these proteins can show that the minor N-terminal
and/or C-terminal variations resulting from the use of the
different protein expression systems and DNA constructs retain
equivalent functional activity in in vivo and in vitro assays. It
is understood that unless otherwise indicated, for each of SG-15,
SG-16, SG-17 and SG-18, the term "SG-number" refers herein to the
amino acid sequence depicted herein as SEQ ID NO:1, SEQ ID NO:9,
SEQ ID NO:13, or SEQ ID NO:19 respectively, and such variants of
the specified SG protein comprising an amino acid sequence as
taught herein. For example, SG protein variants can include
variations in amino acid residues (substitution, insertion,
deletion) as well as modifications such as fusion constructs and
post-translational modifications (phosphorylation, glycosylation,
etc.). Some exemplary embodiments of the SG proteins and encoding
nucleic acids are provided in Table 1 below.
TABLE-US-00001 TABLE 1 Amino Acid Sequence Encoding Nucleic Acid
Sequence SEQ ID NO: 1 (SG-15) SEQ ID NO: 2 (SG-15)
EYTEIRTASELVEAAKS GAATACACAGAAATCCGAACAGCGTCAGAACTTGTGGA
ASGNYKLMTDIDMTGV AGCAGCTAAGAGTGCGTCAGGAAATTATAAACTGATGA
EWTPWDFSGTFDGNGH CAGATATAGATATGACAGGAGTTGAGTGGACGCCATGG
SILNLSVKTVSKKTMKT GATTTTTCGGGAACATTTGACGGTAACGGACACAGCAT
YDGNRKEYKTYGAGFF ACTTAACCTGTCAGTAAAGACAGTAAGCAAGAAGACAA
GVLTGAKVTGLDIYGA TGAAGACCTATGACGGCAACAGAAAAGAGTACAAAAC
RIEITTTEPCFAAPIAGLA ATACGGCGCAGGCTTCTTTGGGGTGCTTACAGGTGCGA
DDSDISDCIIKDTYVSLT AAGTAACAGGACTGGATATATATGGAGCAAGAATTGAG
DSAKMWGTGGIAGFGS ATTACTACAACGGAACCATGTTTTGCGGCACCAATAGC
GNLDNITTDVTLVCVDT AGGGCTTGCAGACGACAGCGACATATCAGACTGTATAA
DAAVRDEQFMGGAYA TTAAGGATACATATGTGTCACTCACAGATTCAGCTAAA
AGFLNIRNCSITIDGYDS ATGTGGGGAACAGGCGGAATCGCTGGATTTGGAAGCGG
DHGYVHDGGLVGMYM CAATCTTGATAATATTACTACAGATGTGACACTTGTATG
VYPLELSKTYQGEVLNN TGTAGATACAGACGCAGCGGTCAGGGACGAGCAGTTCA
KVKGMITFFEDNTDRRA TGGGAGGCGCGTATGCAGCAGGTTTCCTTAATATAAGG
YCQANMGEVMNWTYA AATTGTTCTATAACAATAGATGGATATGATTCAGACCA
YSGFTSDFKRNETYDYS CGGATATGTGCATGATGGCGGACTTGTCGGCATGTATA
VTLLPEMCSNPSYTDVV TGGTATATCCATTGGAACTGTCAAAGACATATCAGGGC
TEATASDFGYTTHTCST GAAGTGCTTAACAACAAAGTTAAGGGAATGATAACATT
CGYTYSDTYTIHEHKVD TTTCGAAGACAATACAGACCGCCGTGCATACTGTCAGG
SYSVVKEAASTDKKDGI CAAATATGGGTGAGGTCATGAACTGGACATATGCATAT
EAGTCSLCNQTVYREY TCAGGCTTCACATCAGATTTTAAGAGAAATGAGACATA
AANVVTDDNTQATDNK TGATTATTCAGTGACACTGCTTCCGGAAATGTGCAGCA
ASGTAVKKGMKESTAV ATCCTTCATACACAGATGTAGTGACAGAAGCAACAGCA FA
TCAGACTTTGGATACACAACACACACCTGCAGTACATG
TGGCTACACATATTCAGACACTTACACAATACATGAGC
ATAAGGTCGACAGTTACAGCGTGGTAAAGGAAGCAGCC
AGCACAGACAAGAAAGACGGAATAGAGGCAGGAACAT
GCAGCCTGTGCAATCAGACAGTTTACAGGGAATATGCT
GCAAATGTAGTAACAGACGATAATACACAGGCAACAG
ACAATAAAGCATCAGGCACGGCTGTCAAAAAAGGAAT GAAAGAAAGTACAGCAGTATTTGCA SEQ
ID NO: 9 (SG-16) SEQ ID NO: 10 (SG-16) MTGCSGSKEPDNKTSV
ATGACAGGGTGTTCTGGCAGCAAAGAGCCAGATAATAA DYTVVENADLPEELKKL
GACCAGTGTTGATTATACAGTGGTTGAAAATGCAGACC IESKKDKVMRLTYTTKD
TGCCGGAAGAGCTTAAGAAGCTTATTGAAAGCAAAAAA YTYVVAGYGTRETSGY
GATAAAGTGATGAGGCTTACATACACGACTAAGGATTA SIKVNDVYTGDNALYID
TACATATGTTGTGGCCGGTTATGGAACAAGGGAAACAA LNLIGPAAGEAVNEVET
GTGGATATTCAATTAAGGTAAATGATGTATACACAGGA YPVIVLKMERREESVVF
GATAATGCACTATACATTGATCTTAATCTGATAGGTCCG KM
GCAGCGGGGGAAGCTGTAAATGAGGTTGAGACATATCC
GGTAATAGTGCTTAAGATGGAAAGACGTGAAGAAAGC GTTGTTTTTAAAATG SEQ ID NO: 13
(SG-17) SEQ ID NO: 14 (SG-17) CNSKIDVKYDYNVEDY
TGTAATAGTAAGATTGATGTTAAGTATGATTATAATGTT VQLGQYENISVQVDKTS
GAAGATTATGTTCAGCTTGGACAGTATGAAAACATATC IENELIESKIKQDVEDNT
AGTCCAGGTAGATAAAACTTCAATAGAGAATGAACTTA TYTEVDRGAIASDQILV
TAGAGAGTAAAATTAAACAGGATGTAGAAGATAATACT TYTATSSGASLSGLTNT
ACTTATACAGAAGTTGACAGAGGTGCGATAGCTTCTGA DGKTMILGTDTLGLELD
TCAGATTCTTGTTACATATACTGCTACATCTTCAGGCGC ELDQALYGMTPGQTKIL
ATCTCTTAGCGGACTTACTAATACAGATGGTAAAACAA IVDIPEDYSSDLYKGTRV
TGATTCTTGGAACGGATACTCTCGGACTTGAACTTGATG VFELTMQTVAQANVPM
AGTTAGATCAGGCTTTATATGGTATGACCCCAGGTCAG ITNAYVKEAFGYDTVEE
ACAAAGATACTTATTGTTGATATACCTGAGGATTATAGT YRQSIKESLETDINSKVE
TCGGATTTATATAAGGGCACGAGGGTTGTATTTGAACTT NKIQEDVLSSLQDTFKIS
ACAATGCAGACAGTTGCACAGGCAAATGTTCCAATGAT SYPDSLMEETRSRLETSI
AACTAATGCATATGTTAAGGAAGCGTTTGGATATGATA GFYADFSNLSKDEYCQK
CCGTTGAAGAATATAGACAGTCAATAAAGGAATCTCTT QYGLSFDDFVKKSVVQ
GAAACTGATATTAATTCAAAGGTTGAGAACAAGATACA QLIMEAIVKDRNMTMR
GGAAGATGTATTATCTTCTTTACAGGATACATTCAAGAT EYDYKGSLDDFAADNG
AAGCAGTTATCCTGATTCACTTATGGAAGAAACAAGAT YSNADTFVEKFGKDKIV
CCAGACTTGAAACATCTATTGGTTTCTATGCGGATTTTT KAMLVQKAQDYVIEHA
CAAATCTTTCAAAGGATGAATACTGTCAGAAGCAGTAT NISYK
GGACTTTCTTTTGATGACTTTGTTAAGAAATCTGTTGTA
CAGCAGCTTATCATGGAGGCTATAGTTAAAGACCGCAA
TATGACAATGAGAGAATACGATTATAAAGGTTCTCTTG
ATGATTTTGCGGCAGATAATGGATATTCTAATGCGGAT
ACATTTGTTGAAAAATTCGGAAAAGATAAGATTGTAAA
GGCTATGCTTGTGCAGAAGGCACAGGATTATGTTATTG AGCATGCCAATATTTCTTATAAG SEQ
ID NO: 19 (SG-18) SEQ ID NO: 20 (SG-18) EVDSSKEQATSKDEKQV
GAGGTAGATAGTTCTAAAGAACAAGCTACATCAAAAGA VVATSVAITEILDRLGVE
TGAAAAACAAGTAGTAGTAGCTACATCAGTTGCAATTA VSGVPQTSYELPESAKG
CTGAAATATTAGATAGGTTAGGTGTAGAAGTTAGTGGT ATEIGSPMNPDMEIIKSL
GTACCACAAACTAGCTATGAACTTCCAGAAAGTGCAAA NPTDVICVDTLGSDFEK
AGGTGCTACGGAAATTGGAAGTCCAATGAATCCAGATA QFEENNINADFYNLSNV
TGGAAATAATAAAATCACTAAATCCAACAGACGTAATA DGLKETIAALGEKFNKQ
TGTGTTGATACTTTAGGAAGTGATTTTGAAAAACAATTT DKANEILDEIKEVENKV
GAAGAAAACAATATAAATGCTGATTTTTATAATCTAAG NSNKKSDDKILVLFGAP
CAATGTAGACGGATTAAAAGAAACAATAGCTGCTTTAG GSVMVATDKSYIGNLV
GAGAAAAATTCAATAAACAAGATAAAGCAAATGAAAT ELAGGNNIFSNATSSFTQ
ATTAGATGAAATAAAAGAAGTAGAAAATAAAGTTAATT INLEEIIKLNPDKILVMT
CTAATAAAAAATCTGATGATAAGATCTTAGTATTATTTG HAVPEAAKKSVEEELSK
GAGCACCAGGAAGTGTAATGGTAGCTACGGACAAAAGT DLWKNVNAVKNNDITY
TATATAGGAAACTTAGTCGAGTTAGCTGGAGGAAATAA LENGYFGMSANLQIVEA
TATATTCTCAAATGCAACTAGCTCATTTACTCAAATAAA VEKLGDILYE
CTTAGAAGAAATAATAAAGTTAAATCCAGATAAAATAT
TAGTTATGACTCATGCCGTTCCAGAGGCTGCAAAAAAA
TCTGTAGAAGAAGAATTAAGTAAAGACCTTTGGAAAAA
TGTAAATGCAGTTAAAAATAACGATATAACTTATTTAG
AAAATGGTTATTTCGGAATGAGTGCAAACTTACAAATA
GTTGAGGCAGTAGAAAAATTAGGAGATATATTATATGA G
Epithelial Barrier Function in Disease
[0187] Studies in recent years have identified a major role of both
genetic and environmental factors in the pathogenesis of IBD.
Markus Neurath, "Cytokines in Inflammatory Bowel Disease," Nature
Reviews Immunology, Vol. 14., 329-342 (2014). A combination of
these IBD risk factors seems to initiate detrimental changes in
epithelial barrier function, thereby allowing the translocation of
luminal antigens (for example, bacterial antigens from the
commensal microbiota) into the bowel wall. Id. Subsequently,
aberrant and excessive responses, such as increased
pro-inflammatory cytokine release, to such environmental triggers
cause subclinical or acute mucosal inflammation in a genetically
susceptible host. Id. Thus, the importance of proper epithelial
barrier function in IBD is apparent, for in subjects that fail to
resolve acute intestinal inflammation, chronic intestinal
inflammation develops that is induced by the uncontrolled
activation of the mucosal immune system. In particular, mucosal
immune cells, such as macrophages, T cells, and the subsets of
innate lymphoid cells (ILCs), seem to respond to microbial products
or antigens from the commensal microbiota by, e.g., producing
cytokines that can promote chronic inflammation of the
gastrointestinal tract. Consequently, restoring proper epithelial
barrier function to patients may be critical in resolving IBD.
[0188] The therapeutic activity of the SG proteins was assessed in
part by its effects on epithelial barrier function both in vitro
and in vivo. As shown in Examples 1B, 2B, 3B and 4B, SG protein
activity was evaluated for effects on epithelial barrier integrity
as shown by an in vitro trans-epithelial electrical resistance
(TEER) assay. TEER assays are well-known methods for measuring
effects on the structural and functional integrity of an epithelial
cell layer (Srinivasan et al., 2015, J Lab Autom, 20:107-126;
Beduneau et al., 2014, Eur J Pharm Biopharm, 87:290-298;
Zolotarevsky et al., 2002, Gastroenterology, 123:163-172; Dewi, et
al. (2004) J. Virol. Methods. 121:171-180, and in Mandic, et al.
(2004) Clin. Exp. Metast. 21:699-704). The assay performed and
described herein consists of an epithelial monolayer made up of
enterocyte and goblets cells to more accurately model the
structural and functional components of the intestinal epithelium.
The cells are cultured until tight junction formation occurs and
barrier function capacity is assessed by a measurement of
trans-epithelial electrical resistance. Upon addition of an insult,
such as heat killed E. coli, there is a decrease in electrical
resistance across the epithelial layer. Control reagents useful in
the TEER assay include staurosporine and a myosin light chain
kinase inhibitor. Staurosporine is a broad spectrum kinase
inhibitor, originating from Streptomyces staurosporeus, which
induces apoptosis. This reagent disrupts about 98% of the gap
junctions leading to a decrease in electrical resistance in a TEER
assay. Myosin light chain kinase (MLCK) is the terminal effector in
a signaling cascade induced by pro-inflammatory cytokines, which
results in contraction of the perijunctional actomyosin ring,
resulting in separation of the gap junctions. By inhibiting MLCK,
disruption of tight junctions is prevented. MLCK inhibitor in a
TEER assay should reduce or prevent the reduction of electrical
resistance in a TEER assay.
[0189] In some embodiments, the SG protein or variant or fragment
thereof as described herein can be characterized by its ability to
increase epithelial barrier function integrity as assessed by an in
vitro TEER assay. The SG protein or variant or fragment thereof may
increase electrical resistance in a TEER assay by at least about
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% as compared to the
TEER assay performed in the absence of the protein.
[0190] In addition, Examples 1D, 2E, 3E and 4D assess effects of an
SG protein on epithelial wound healing, an activity that can play a
role in the maintenance or repair of and epithelial barrier such as
an intestinal or mucosal epithelial barrier.
[0191] SG proteins were also characterized in an in vivo assay,
specifically, the proteins were analyzed for their effects on
pathological markers in a rodent model of IBD. Specifically,
experiments were performed using a DSS (dextran sodium sulfate)
animal model, a model well accepted for the study of agents on IBDs
(Chassaign et al., 2014, Curr Protoc Imunol, 104:Unit-15.25;
Kiesler et al., 2015, Cell Mol Gastroenterol Hepatol). DSS is a
sulfated polysaccharide that is directly toxic to colonic
epithelium and causes epithelial cell injury leading to loss of
barrier function due to disrupted gap junctions. In these
experiments, animals were treated with SG proteins prior to
induction of colitis in the mouse. As a positive control, the mice
were also treated with Gly2-GLP2, a stable analog of glucagon-like
peptide 2 (GLP2). Gly2-GLP2 is known to promote epithelial cell
growth and reduce colonic injury in experiment mouse colitis
models. Results of the DSS studies show that the SG proteins
affected markers such as epithelial barrier permeability, plasma
levels of LPS binding protein, total body weight, and gross
pathology.
Variants of SG Proteins
[0192] In another example, certain amino acids of the taught
proteins may be substituted for other amino acids in a protein
structure without appreciable loss of interactive binding capacity
with structures such as, for example, binding sites on substrate
molecules, receptors, antigen-binding regions of antibodies, and
the like. Thus, these proteins would be biologically functional
equivalents of the disclosed proteins (e.g. comprising SEQ ID NO:1,
SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:19, or variants thereof).
So-called "conservative" changes do not disrupt the biological
activity of the protein, as the structural change is not one that
impinges on the protein's ability to carry out its designed
function. It is thus contemplated by the inventors that various
changes may be made in the sequence of genes and proteins disclosed
herein, while still fulfilling the goals of the present
disclosure.
[0193] In some embodiments, a modified or variant protein is
provided which contains at least one non-naturally occurring amino
acid substitution relative to the SG protein amino acid sequence
(i.e., SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:19). In
other embodiments, the variant protein comprises 1, 2, 3, 4, 5, 6,
7, 8, 9 or 10 amino acid substitutions relative to SEQ ID NO:1, SEQ
ID NO:9, SEQ ID NO:13 or SEQ ID NO:19.
[0194] In some embodiments, the taught proteins have markedly
different structural and/or functional characteristics, as compared
to a protein comprising or consisting of SEQ ID NO:1, SEQ ID NO:9,
SEQ ID NO:13 or SEQ ID NO:19.
[0195] The term "SG variant" as used herein can include SG proteins
that are, e.g., not identical to a protein comprising the sequence
of SEQ ID NO:1 (SG-15), SEQ ID NO:9 (SG-16), SEQ ID NO:13 (SG-17)
or SEQ ID NO:19 (SG-18) and which are further modified such as by a
PTM or fusion or linkage to a second agent, e.g., a protein or
peptide.
[0196] Protein PTMs occur in vivo and can increase the functional
diversity of the proteome by the covalent addition of functional
groups or proteins, proteolytic cleavage of regulatory subunits or
degradation of entire proteins. Isolated SG proteins prepared
according to the present disclosure can undergo 1 or more PTMs in
vivo or in vitro. The type of modification(s) depends on host cell
in which the protein is expressed and includes but is not limited
to phosphorylation, glycosylation, ubiquitination, nitrosylation
(e.g., S-nitrosylation), methylation, acetylation (e.g.,
N-acetylation), lipidation (myristoylation, N-myristoylation,
S-palmitoylation, farnesylation, S-prenylation, S-palmitoylation)
and proteolysis may influence almost all aspects of normal cell
biology and pathogenesis. The isolated and/or purified SG proteins
or variants or fragments thereof as disclosed herein may comprise
one or more the above recited post-translational modifications.
[0197] The SG protein or variant or fragment thereof may be a
fusion protein in which the N- and/or C-terminal domain of the SG
protein is fused to a second protein via a peptide bond. Commonly
used fusion partners well known to the ordinarily skilled artisan
include but are not limited to human serum albumin and the
crystallizable fragment, or constant domain of IgG, Fc. In some
embodiments, the SG protein or variant or fragment thereof is
linked to a second protein or peptide via a disulfide bond, wherein
the second protein or peptide comprises a cysteine residue.
[0198] As aforementioned, modifications and/or changes (e.g.,
substitutions, insertions, deletions) may be made in the structure
of proteins disclosed herein. Thus, the present disclosure
contemplates variation in sequence of these proteins, and nucleic
acids coding therefore, where they are nonetheless able to retain
substantial activity with respect to the functional activities
assessed in various in vitro and in vivo assays as well as in
therapeutic aspects of the present disclosure. In terms of
functional equivalents, it is well understood by the skilled
artisan that, inherent in the definition of a "biologically
functional equivalent" protein and/or polynucleotide, is the
concept that there is a limit to the number of changes that may be
made within a defined portion of the molecule while retaining a
molecule with an acceptable level of equivalent biological
activity.
[0199] It is also contemplated that the SG protein or variant or
fragment thereof is one which, when administered to a subject, can
reduce disease-associated weight loss, improve the clinical
pathology score, and/or minimize colon shortening in the subject.
In some embodiments, the subject is a mammal which has genetically
or clinically induced inflammatory disorder or dysfunctional
epithelial barrier function. Alternatively, the animal has an
idiopathic gastrointestinal disorder involving a decrease in
epithelial barrier function or intestinal inflammatory disorder. In
other embodiments, the mammal is a human, non-human primate, or a
rodent. The rodent may be a mouse or rat.
[0200] In some embodiments, the SG protein or variant or fragment
thereof according to the present disclosure is one which can
modulate production of and/or secretion of a cytokine in an in
vitro assay or in an subject administered the protein. In some
embodiments, secretion of cytokines is reduced in vitro. Levels of
cytokines produced and/or secreted in an in vitro assay or subject
administered the protein are likely to be measured in the blood,
serum, and/or plasma of the subject. Administration of the SG
protein may result in a decrease in the serum levels of a
pro-inflammatory cytokine such as one or more of TNF-.alpha.,
IL-17, IL-1.beta., IL-2, IFN-.gamma., IL-6, IL-12, IL-25, IL-33,
IL-8, MCP-1, MIP-3.alpha., CXCL1, and IL-23. Alternatively, the
cytokine may be an anti-inflammatory cytokine, in which case
administration of the SG protein results in an increase in serum
levels of an anti-inflammatory cytokine such as IL-4, IL-10, IL-13,
IFN-.alpha., and TGF-.beta..
[0201] In some embodiments, the SG protein or variant or fragment
thereof has the functional ability to reduce gastrointestinal
inflammation when administered to a subject such as a mammal (e.g.,
rodent, non human primate, or human). In other embodiments, the SG
protein has the functional ability to reduce inflammatory (i.e.
pro-inflammatory) cytokines, when administered to the subject. In
yet other embodiments, the SG protein is able to reduce TNF-.alpha.
and/or IL-23, when administered to the subject. In still other
embodiments, the SG protein has the functional ability to increase
anti-inflammatory cytokines, when administered to the subject. In
some aspects, an SG protein of the disclosure is able to increase
IL-10, when administered to the subject.
[0202] An SG protein or variant or fragment thereof according to
the present disclosure is one which, when administered to a subject
(e.g., rodent, non human primate, or human), can improve
gastrointestinal epithelial cell barrier function, reduce
disease-associated weight loss, improve clinical scores, improve
colon length and/or colon weight-to-length readouts, induce or
increase mucin gene expression (e.g., muc2 expression), increase
the structural integrity and/or functionality of a gastrointestinal
mucous barrier (e.g., in the small intestine, large intestine,
mouth and/or esophagus), and/or reduce inflammation in the
gastrointestinal tract.
[0203] In some embodiments, the SG protein or variant or fragment
thereof resulting from such a substitution, insertion and/or
deletion of amino acids relative to SEQ ID NO:1 (SG-15), SEQ ID
NO:9 (SG-16), SEQ ID NO:13 (SG-17) or SEQ ID NO:19 (SG-18),
maintains a level of functional activity which is substantially the
same as that of the SG protein without the variation (e.g., is able
to decrease epithelial barrier permeability in a DSS mouse model).
The variant SG protein may be useful as a therapeutic for treatment
or prevention of a variety of conditions, including, but not
limited to inflammatory conditions and/or barrier function
disorders, including, but not limited to, inflammation of the
gastrointestinal (including oral, esophageal, and intestinal)
mucosa, impaired intestinal epithelial cell gap junction integrity.
In some embodiments, the modified SG protein has one or more of the
following effects when administered to an individual suffering
from, or predisposed to, an inflammatory condition and/or barrier
function disorder: improvement of epithelial barrier integrity,
e.g., following inflammation induced disruption; suppression of
production of at least one pro-inflammatory cytokine (e.g.,
TNF-.alpha. and/or IL-23) by one or more immune cell(s); induction
of mucin production in epithelial cells; and/or improvement of
epithelial wound healing. Moreover, the modified or variant SG
protein may be used for treatment or prevention of a disorder or
condition such as, but not limited to, inflammatory bowel disease,
ulcerative colitis, Crohn's disease, short bowel syndrome, GI
mucositis, oral mucositis, chemotherapy-induced mucositis,
radiation-induced mucositis, necrotizing enterocolitis, pouchitis,
a metabolic disease, celiac disease, inflammatory bowel syndrome,
or chemotherapy associated steatohepatitis (CASH).
[0204] As demonstrated in the Examples, in some embodiments, the SG
protein can enhance epithelial wound healing. Accordingly, provided
herein is a therapeutic SG protein comprising the amino acid
sequence of SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:19,
or a variant or fragment thereof, wherein the SG protein can
increase wound healing in an in vitro assay.
Methods of Treatment
[0205] The SG proteins described herein including variants (e.g.,
amino acid substitutions, deletions, insertions), modifications
(e.g., glycosylation, acetylation), SG fragments and fusions
thereof are contemplated for use in treating a subject diagnosed
with or suffering from a disorder related to inflammation within
the gastrointestinal tract and/or malfunction of epithelial barrier
function within the gastrointestinal tract.
[0206] Provided herein are methods for treating a subject in need
thereof comprising administering to the subject a pharmaceutical
composition comprising an SG protein or fragment or variant thereof
as described in the present disclosure. The subject can be one who
has been diagnosed with inflammatory bowel disease, ulcerative
colitis, pediatric UC, Crohn's disease, pediatric Crohn's disease,
short bowel syndrome, mucositis GI mucositis, oral mucositis,
mucositis of the esophagus, stomach, small intestine (duodenum,
jejunum, ileum), large intestine (colon), and/or rectum,
chemotherapy-induced mucositis, radiation-induced mucositis,
necrotizing enterocolitis, pouchitis, a metabolic disease, celiac
disease, irritable bowel syndrome, or chemotherapy associated
steatohepatitis (CASH) Administration of the pharmaceutical
compositions comprising an SG protein or fragment or variant
thereof as described herein may also be useful for wound healing
applications.
Inflammatory Bowel Disease
[0207] Inflammatory bowel disease (IBD) classically includes
ulcerative colitis (UC) and Crohn's disease (CD). The pathogenesis
of inflammatory bowel disease is not known. A genetic
predisposition has been suggested, and a host of environmental
factors, including bacterial, viral and, perhaps, dietary antigens,
can trigger an ongoing enteric inflammatory cascade. Id. IBD can
cause severe diarrhea, pain, fatigue, and weight loss. IBD can be
debilitating and sometimes leads to life-threatening complications.
Accordingly, in some embodiments, the method of treatment as
described herein is effective to reduce, prevent or eliminate any
one or more of the symptoms described above wherein the method
comprises administering to a patient in need thereof a
therapeutically effective amount of a pharmaceutical composition
comprising the SG protein or variant or fragment thereof. In some
embodiments, the method of treatment results in remission.
Ulcerative Colitis
[0208] Ulcerative colitis is an inflammatory bowel disease that
causes long-lasting inflammation and sores (ulcers), in the
innermost lining of your large intestine (colon) and rectum.
[0209] Ulcerative colitis typically presents with shallow,
continuous inflammation extending from the rectum proximally to
include, in many patients, the entire colon. Fistulas, fissures,
abscesses and small-bowel involvement are absent. Patients with
limited disease (e.g., proctitis) typically have mild but
frequently recurrent symptoms, while patients with pancolitis more
commonly have severe symptoms, often requiring hospitalization.
Botoman et al., "Management of Inflammatory Bowel Disease," Am.
Fam. Physician, Vol. 57(1):57-68 (Jan. 1, 1998) (internal citations
omitted). Thus, ulcerative colitis is an IBD that causes
long-lasting inflammation and sores (ulcers) in the innermost
lining of your large intestine (colon) and rectum.
Crohn's Disease
[0210] Unlike ulcerative colitis, Crohn's disease can involve the
entire intestinal tract, from the mouth to the anus, with
discontinuous focal ulceration, fistula formation and perianal
involvement. The terminal ileum is most commonly affected, usually
with variable degrees of colonic involvement. Subsets of patients
have perianal disease with fissures and fistula formation. Only 2
to 3 percent of patients with Crohn's disease have clinically
significant involvement of the upper gastrointestinal tract.
Botoman et al., "Management of Inflammatory Bowel Disease," Am.
Fam. Physician, Vol. 57(1):57-68 (Jan. 1, 1998) (internal citations
omitted). Thus, Crohn's disease is an IBD that causes inflammation
of the lining of your digestive tract. In Crohn's disease,
inflammation often spreads deep into affected tissues. The
inflammation can involve different areas of the digestive tract,
i.e. the large intestine, small intestine, or both. Collagenous
colitis and lymphocytic colitis also are considered inflammatory
bowel diseases, but are usually regarded separately from classic
inflammatory bowel disease.
Clinical Parameters of Inflammatory Bowel Disease
[0211] As previously discussed, inflammatory bowel disease
encompasses ulcerative colitis and Crohn's disease. There are
numerous scores and clinical markers known to one of skill in the
art that can be utilized to access the efficacy of the administered
proteins described herein in treating these conditions.
[0212] There are two general approaches to evaluating patients with
IBD. The first involves the visual examination of the mucosa and
relies on the observation of signs of damage to the mucosa, in view
of the fact that IBD is manifested by the appearance of
inflammation and ulcers in the GI tract. Any procedure that allows
an assessment of the mucosa can be used. Examples include barium
enemas, x-rays, and endoscopy. An endoscopy may be of the
esophagus, stomach and duodenum (esophagogastroduodenoscopy), small
intestine (enteroscopy), or large intestine/colon (colonoscopy,
sigmoidoscopy). These techniques are used to identify areas of
inflammation, ulcers and abnormal growths such as polyps.
[0213] Scoring systems based on this visual examination of the GI
tract exist to determine the status and severity of IBD, and these
scoring systems are intended to ensure that uniform assessment of
different patients occurs, despite the fact that patients may be
assessed by different medical professionals, in diagnosis and
monitoring of these diseases as well as in clinical research
evaluations. Examples of evaluations based on visual examination of
UC are discussed and compared in Daperno M et al (J Crohns Colitis.
2011 5:484-98).
[0214] Clinical scoring systems also exist, with the same purpose.
The findings on endoscopy or other examination of the mucosa can be
incorporated into these clinical scoring systems, but these scoring
systems also incorporate data based on symptoms such as stool
frequency, rectal bleeding and physician's global assessment. IBD
has a variety of symptoms that affect quality of life, so certain
of these scoring systems also take into account a quantitative
assessment of the effect on quality of life as well as the
quantification of symptoms.
[0215] One example of a scoring system for UC is the Mayo scoring
system (Schroeder et al., N Eng J Med, 1987, 317:1625-1629), but
others exist that have less commonly been used and include the
Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score
(Travis et al, 2012, Gut, 61:535-542), Baron Score (Baron et al.,
1964, BMJ, 1:89), Ulcerative Colitis Colonoscopic Index of Severity
(UCCIS) (Thia et al., 2011, Inflamm Bowel Dis, 17:1757-1764),
Rachmilewitz Endoscopic Index (Rachmilewitz, 1989, BMJ, 298:82-86),
Sutherland Index (also known as the UC Disease Activity Index
(UCDAI) scoring system; Sutherland et al., 1987, Gastroenterology,
92:1994-1998), Matts Score (Matts, 1961, QJM, 30:393-407), and
Blackstone Index (Blackstone, 1984, Inflammatory bowel disease. In:
Blackstone MO (ed.) Endoscopic interpretation: normal and
pathologic appearances of the gastrointestinal tract, 1984, pp.
464-494). For a review, see Paine, 2014, Gastroenterol Rep
2:161-168. Accordingly, also contemplated herein is a method for
treating a subject diagnosed with and suffering from UC, wherein
the treatment comprises administering an SG protein or variant or
fragment thereof as described herein and wherein the treatment
results in a decrease in the UC pathology as determined by
measurement of the UCEIS score, the Baron score, the UCCIS score,
the Rachmilewitz Endoscopic Index, the Sutherland Index, and/or the
Blackstone Index.
[0216] An example of a scoring system for CD is the Crohn's Disease
Activity Index (CDAI) (Sands B et al 2004, N Engl J Med 350 (9):
876-85); most major studies use the CDAI in order to define
response or remission of disease. Calculation of the CDAI score
includes scoring of the number of liquid stools over 7 days,
instances and severity of abdominal pain over 7 days, general
well-being over 7 days, extraintestinal complications (e.g.,
arthritis/arthralgia, iritis/uveitis, erythema nodosum, pyoderma
gangrenosum, aphtous stomatitis, anal fissure/fistula/abscess,
and/or fever >37.8.degree. C.), use of antidiarrheal drugs over
7 days, present of abdominal mass, hematocrit, and body weight as a
ratio of ideal/observed or percentage deviation from standard
weight. Based on the CDAI score, the CD is classified as either
asymptomatic remission (0 to 149 points), mildly to moderately
active CD (150 to 220 points), moderately to severely active CD
(221 to 450 points), or severely active fulminant disease (451 to
1000 points). In some embodiments, the method of treatment
comprising administering to a patient diagnosed with CD a
therapeutically effective amount of an SG protein or variant or
fragment thereof results in a decrease in a diagnostic score of CD.
For example, the score may change the diagnosis from severely
active to mildly or moderately active or to asymptomatic
remission.
[0217] The Harvey-Bradshaw index is a simpler version of the CDAI
which consists of only clinical parameters (Harvey et al., 1980,
Lancet 1(8178):1134-1135). The impact on quality of life is also
addressed by the Inflammatory Bowel Disease Questionnaire (IBDQ)
(Irvine et al., 1994, Gastroenterology 106: 287-296). Alternative
methods further include CDEIS and SES CD (see, e.g., Levesque, et
al. (2015) Gastroentrol. 148:37 57).
[0218] In some embodiments, a method of treating an IBD, e.g., UC,
is provided wherein the treatment is effective in reducing the Mayo
Score. The Mayo Score is a combined endoscopic and clinical scale
used to assess the severity of UC and has a scale of 1-12 The Mayo
Score is a composite of subscores for stool frequency, rectal
bleeding, findings of flexible proctosigmoidoscopy or colonoscopy,
and physician's global assessment (Paine, 2014, Gastroenterol Rep
2:161-168). With respect to rectal bleeding, blood streaks seen in
the stool less than half the time is assigned 1 point, blood in
most stools is assigned 2 points and pure blood passed is assigned
3 points. Regarding stool frequency, a normal number of daily
stools is assigned 0 points, 1 or 2 more stools than normal is
assigned 1 point, 3 or 4 more stools than normal is assigned 2
points, and 5 or more stools than usual is assigned 3 points. With
respect to the endoscopy component, a score of 0 indicates normal
mucosa or inactive UC, a score of 1 is given for mild disease with
evidence of mild friability, reduced vascular pattern, and mucosal
erythema, a score of 2 is given for moderate disease with
friability, erosions, complete loss of vascular pattern, and
significant erythema, and a score of 3 is given for ulceration and
spontaneous bleeding (Schroeder et al., 1987, N Engl J Med,
317:1625-1629). Global assessment by a physician assigns 0 points
for a finding of normal, 1 point for mild colitis, 2 points for
moderate colitis and 3 points for severe colitis. Accordingly, in
some embodiments, a patient treated with an SG therapeutic protein
or variant or fragment thereof is successfully treated when the
patient experiences a reduction in the Mayo Score by at least 1, 2
or 3 points in at least one of: rectal bleeding, blood streaks seen
in the stool, endoscopy subscore and physician's global assessment.
In some embodiments, the method of treatment comprising
administering to a patient diagnosed with UC a therapeutically
effective amount of an SG protein or variant or fragment thereof
results in a decrease in a diagnostic score of UC. For example, the
score may change a diagnostic score, e.g., Mayo Score, by at least
1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 points.
Pouchitis
[0219] Additionally or alternatively, the compositions comprising
an SG therapeutic protein or variant and methods of administration
as described herein can be used to treat pouchitis. Pouchitis is an
inflammation of the lining of a pouch that is surgically created in
the treatment of UC. Specifically, subjects having serious UC may
have their diseased colon removed and the bowel reconnected by a
procedure called ileoanal anastomosis (IPAA) or J-pouch surgery.
Pouchitis cases can recur in many patients, manifesting either as
acute relapsing pouchitis or chronic, unremitting pouchitis.
Accordingly, provided herein are methods for treating pouchitis,
acute pouchitis or recurrent pouchitis.
[0220] Pouchitis activity can be classified as remission (no active
pouchitis), mild to moderately active (increased stool frequency,
urgency, and/or infrequent incontinence), or severely active
(frequent incontinence and/or the patient is hospitalized for
dehydration). The duration of pouchitis can be defined as acute
(less than or equal to four weeks) or chronic (four weeks or more)
and the pattern classified as infrequent (1-2 acute episodes),
relapsing (three or fewer episodes) or continuous. The response to
medical treatment can be labeled as treatment responsive or
treatment refractory, with the medication for either case being
specified. Accordingly, in some embodiments, a method for treating
a subject diagnosed with pouchitis is provided wherein treatment
with a pharmaceutical composition comprising an SG protein or
variant or fragment thereof results in a decrease in the severity
of the pouchitis and/or results in remission.
Mucositis and Mucosal Barriers
[0221] The mucosa of the gastrointestinal (GI) tract is a complex
microenvironment involving an epithelial barrier, immune cells, and
microbes. A delicate balance is maintained in the healthy colon.
Luminal microbes are physically separated from the host immune
system by a barrier consisting of epithelium and mucus. The
pathogenesis of IBD, although not fully elucidated, may involve an
inappropriate host response to an altered commensal flora with a
dysfunctional mucous barrier. See, Boltin et al., "Mucin Function
in Inflammatory Bowel Disease an Update," J. Clin. Gastroenterol.,
Vol. 47(2):106-111 (February 2013).
[0222] Mucositis occurs when cancer treatments (particularly
chemotherapy and radiation) break down the rapidly divided
epithelial cells lining the intestinal tract (which goes from the
mouth to the anus), leaving the mucosal tissue open to ulceration
and infection. Mucosal tissue, also known as mucosa or the mucous
membrane, lines all body passages that communicate with the air,
such as the respiratory and alimentary tracts, and have cells and
associated glands that secrete mucus. The part of this lining that
covers the mouth, called the oral mucosa, is one of the most
sensitive parts of the body and is particularly vulnerable to
chemotherapy and radiation. The oral cavity is the most common
location for mucositis. While the oral mucosa is the most frequent
site of mucosal toxicity and resultant mucositis, it is understood
that mucositis can also occur along the entire alimentary tract
including the esophagus, stomach, small intestine (duodenum,
jejunum, ileum), large intestine (colon), and rectum. In some
embodiments, a pharmaceutical composition comprising an SG protein
or a variant or fragment thereof is therapeutically effective to
treat mucositis of the mouth, esophagus, stomach, small intestine
(duodenum, jejunum, ileum), large intestine (colon), and/or
rectum
[0223] Oral mucositis can lead to several problems, including pain,
nutritional problems as a result of inability to eat, and increased
risk of infection due to open sores in the mucosa. It has a
significant effect on the patient's quality of life and can be
dose-limiting (i.e., requiring a reduction in subsequent
chemotherapy doses). The World Health Organization has an oral
toxicity scale for diagnosis of oral mucositis: Grade 1: soreness
.+-.erythema, Grade 2: erythema, ulcers; patient can swallow solid
food; Grade 3: ulcers with extensive erythema; patient cannot
swallow solid food; Grade 4: mucositis to the extent that
alimentation is not possible. Grade 3 and Grade 4 oral mucositis is
considered severe mucositis. Accordingly, provided herein is a
method for treating a subject diagnosed with oral mucositis,
wherein administration of a pharmaceutical composition comprising
an SG protein or a variant or fragment thereof reduces the grade of
oral toxicity by at least 1 point of the grade scale of 1 to 4.
Colon Shortening
[0224] Ulcerative colitis is an idiopathic inflammatory bowel
disease that affects the colonic mucosa and is clinically
characterized by diarrhea, abdominal pain and hematochezia. The
extent of disease is variable and may involve only the rectum
(ulcerative proctitis), the left side of the colon to the splenic
flexure, or the entire colon (pancolitis). The severity of the
disease may also be quite variable histologically, ranging from
minimal to florid ulceration and dysplasia. Carcinoma may develop.
The typical histological (microscopic) lesion of ulcerative colitis
is the crypt abscess, in which the epithelium of the crypt breaks
down and the lumen fills with polymorphonuclear cells. The lamina
propria is infiltrated with leukocytes. As the crypts are
destroyed, normal mucosal architecture is lost and resultant
scarring shortens and can narrow the colon. Thus, colon shortening
can be a consequence of colitis disease and is often used
diagnostically. For example, non-invasive plain abdominal x-rays
can demonstrate the gaseous outline of the transverse colon in the
acutely ill patient. Shortening of the colon and loss of haustral
markings can also be demonstrated by plain films, as well as a
double-contrast barium enema. Indications of ulcerative disease
include loss of mucosal detail, cobblestone filling defects, and
segmental areas of involvement. See, "Ulcerative Colitis:
Introduction--Johns Hopkins Medicine," found at:
www.hopkinsmedicine.org/gastroenterology_hepatology/_pdfs/small_large_int-
estine/ulcerative_colitis.pdf.
[0225] Further, art recognized in vivo models of colitis will
utilize shortening of colon length in scoring the severity of
colitis in the model. See, Kim et al., "Investigating Intestinal
Inflammation in DSS-induced Model of IBD," Journal of Visualized
Experiments, Vol. 60, pages 2-6 (February 2012).
Epithelial Barrier Function in Non-IBD Disease
[0226] An improperly functioning epithelial barrier is increasingly
implicated in, e.g., IBDs and mucositis. Moreover, there are
numerous other diseases that studies have shown are also caused,
linked, correlated, and/or exacerbated by, an improperly
functioning epithelial barrier. These diseases include: (1)
metabolic diseases, including--obesity, type 2 diabetes,
non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver
disease (NAFLD), liver disorders, and alcoholic steatohepatitis
(ASH); (2) celiac disease; (3) necrotizing enterocolitis; (4)
irritable bowel syndrome (IBS); (5) enteric infections (e.g.
Clostridium difficile); (6) other gastro intestinal disorders in
general; (7) interstitial cystitis; (8) neurological disorders or
cognitive disorders (e.g. Alzheimer's, Parkinson's, multiple
sclerosis, and autism); (9) chemotherapy associated steatohepatitis
(CASH); and (10) pediatric versions of the aforementioned diseases.
See, e.g.: Everard et al., "Responses of Gut Microbiota and Glucose
and Lipid Metabolism to Prebiotics in Genetic Obese and
Diet-Induced Leptin-Resistant Mice," Diabetes, Vol. 60, (November
2011), pgs. 2775-2786; Everard et al., "Cross-talk between
Akkermansia muciniphila and intestinal epithelium controls
diet-induced obesity," PNAS, Vol. 110, No. 22, (May 2013), pgs.
9066-9071; Cani et al., "Changes in Gut Microbiota Control
Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced
Obesity and Diabetes in Mice," Diabetes, Vol. 57, (June 2008), pgs.
1470-1481; Delzenne et al., "Targeting gut microbiota in obesity:
effects of prebiotics and probiotics," Nature Reviews, Vol. 7,
(November 2011), pgs. 639-646. Consequently, restoring proper
epithelial barrier function to patients may be critical in
resolving the aforementioned disease states.
[0227] A properly functioning epithelial barrier in the lumen of
the alimentary canal, including the mouth, esophagus, stomach,
small intestine, large intestine, and rectum, is critical in
controlling and maintaining the microbiome within the
gastrointestinal tract and alimentary canal. The ecosystem for the
microbiome includes the environment, barriers, tissues, mucus,
mucin, enzymes, nutrients, food, and communities of microorganism,
that reside in the gastrointestinal tract and alimentary canal. The
integrity and permeability of the intestinal mucosal barrier
impacts health in many critical ways.
[0228] A loss of integrity of the mucosal barrier in
gastro-intestinal disorders due to changes in mucin secretion may
be related to host immune changes, luminal microbial factors, or
directly acting genetic or environmental determinants. Thus, the
disequilibrium of the mucous barrier may be central to the
pathogenesis of IBD. Boltin et al., "Mucin Function in Inflammatory
Bowel Disease an Update," J. Clin. Gastroenterol., Vol.
47(2):106-111 (February 2013).
[0229] Mucins are the primary constituent of the mucous layer
lining the GI tract. There are at least 21 mucin (MUC) genes known
in the human genome, encoding either secreted or membrane-bound
mucins. The predominant mucins in the normal colorectum are MUC1,
MUC2, MUC3A, MUC3B, MUC4, MUC13, and MUC17.1 MUC2 is the primary
secretory, gel-forming component of intestinal mucus, produced in
goblet cells. See, Boltin et al., "Mucin Function in Inflammatory
Bowel Disease an Update," J. Clin. Gastroenterol., Vol.
47(2):106-111 (February 2013). Along with additional secreted
mucins such as MUC1, 3A, 3B, 4, 13 and 17.1, goblet cell secretion
of MUC2 forms a protective barrier on colonic epithelial cells
reducing exposure to intestinal contents which may damage
epithelial cells or prime immune responses.
Inflammatory Mechanisms in IBDs
[0230] There is significant evidence showing that certain cytokines
are involved with IBD. Recent studies have demonstrated that
cytokines play a crucial role in the pathogenesis of inflammatory
bowel diseases (IBDs), such as Crohn's disease and ulcerative
colitis, where they control multiple aspects of the inflammatory
response. Markus Neurath, "Cytokines in Inflammatory Bowel
Disease," Nature Reviews Immunology, Vol. 14., 329-342 (2014). In
particular, the imbalance between pro-inflammatory and
anti-inflammatory cytokines that occurs in IBD impedes the
resolution of inflammation and instead leads to disease
perpetuation and tissue destruction. Id. Recent studies suggest the
existence of a network of regulatory cytokines that has important
implications for disease progression. Id. Accordingly, experiments
were performed to study the effects of an SG protein on production
and/or secretion of pro-inflammatory and anti-inflammatory
cytokines.
Pro-Inflammatory Cytokines
[0231] Briefly, pro-inflammatory cytokines are cytokines that are
important in cell signaling and promote systemic inflammation. They
are produced predominantly by activated macrophages and are
involved in the upregulation of inflammatory reactions.
Pro-inflammatory cytokines arise from genes that code for the
translation of small mediator molecules that induce a response
after upregulation. Interleukin-1 (IL-1), IL6, IL-12, IL-18, IL-23,
CD40L, tumor necrosis factor (TNF) such as TNF-.alpha.,
gamma-interferon (IFN-gamma), granulocyte-macrophage colony
stimulating factor, and MCP-1 are well characterized as
pro-inflammatory cytokines. Inflammation is characterized by an
interplay between pro- and anti-inflammatory cytokines.
[0232] Reducing the biological activities of pro-inflammatory
cytokines can be useful for the treatment of some diseases. For
instance, blocking IL-1 or TNF-.alpha. has been successful in
helping patients with rheumatoid arthritis, inflammatory bowel
disease, or graft-vs-host disease. See, Strober W, Fuss I J (May
2011). "Proinflammatory cytokines in the pathogenesis of
inflammatory bowel diseases," Gastroenterology, Vol. 140 (6):
1756-67.
Anti-Inflammatory Cytokines
[0233] Briefly, anti-inflammatory cytokines are a series of
immunoregulatory molecules that regulate the proinflammatory
cytokine response. These molecules thus modulate and help to
decrease inflammatory responses triggered by pro-inflammatory
cytokines. Anti-inflammatory cytokines include, e.g., IL4, IL-10,
IL-13, IFN-.alpha., and transforming growth factor-beta
(TGF-.beta.) are recognized as anti-inflammatory cytokines.
[0234] In some embodiments of the methods taught herein,
administration of the pharmaceutical composition comprising an SG
protein or variant or fragment thereof is able to bring about
reduced production of at least one pro-inflammatory cytokine (e.g.,
TNF-.alpha. and/or IL-23) by an immune cell in a patient
administered the composition. In some embodiments, the
administration is able to bring about an increase in the production
of at least one anti-inflammatory cytokine (e.g., IL-10) by an
immune cell in the patient. In some embodiments, the administration
is able to bring about a decrease in the production of at least one
anti-inflammatory cytokine (e.g., IL-10) by an immune cell in the
patient. In some embodiments, the administration is able to bring
about an improvement of mucin production in epithelial cells and/or
epithelial wound healing in the patient.
[0235] The dosing regimen used for treatment depends upon the
desired therapeutic effect, on the route of administration, and on
the duration of the treatment. The dose will vary from patient to
patient, depending upon the nature and severity of disease, the
patient's weight, special diets then being followed by a patient,
concurrent medication, and other factors which those skilled in the
art will recognize.
[0236] Generally, dosage levels of a therapeutic (e.g., SG) protein
between 0.0001 to 10 mg/kg of body weight daily are administered to
the patient, e.g., patients suffering from inflammatory bowel
disease. The dosage range will generally be about 0.5 mg to 100.0 g
per patient per day, which may be administered in single or
multiple doses.
[0237] In some aspects, the dosage range will be about 0.5 mg to 10
g per patient per day, or 0.5 mg to 9 g per patient per day, or 0.5
mg to 8 g per patient per day, or 0.5 mg to 7 g per patient per
day, or 0.5 mg to 6 g per patient per day, or 0.5 mg to 5 g per
patient per day, or 0.5 mg to 4 g per patient per day, or 0.5 mg to
3 g per patient per day, or 0.5 mg to 2 g per patient per day, or
0.5 mg to 1 g per patient per day.
[0238] In some aspects, the dosage range will be about 0.5 mg to
900 mg per patient per day, or 0.5 mg to 800 mg per patient per
day, or 0.5 mg to 700 mg per patient per day, or 0.5 mg to 600 mg
per patient per day, or 0.5 mg to 500 mg per patient per day, or
0.5 mg to 400 mg per patient per day, or 0.5 mg to 300 mg per
patient per day, or 0.5 mg to 200 mg per patient per day, or 0.5 mg
to 100 mg per patient per day, or 0.5 mg to 50 mg per patient per
day, or 0.5 mg to 40 mg per patient per day, or 0.5 mg to 30 mg per
patient per day, or 0.5 mg to 20 mg per patient per day, or 0.5 mg
to 10 mg per patient per day, or 0.5 mg to 1 mg per patient per
day.
Combination Therapies Comprising Therapeutic Proteins
[0239] The pharmaceutical compositions taught herein comprising an
SG protein may be combined with other treatment therapies and/or
pharmaceutical compositions. For example, a patient suffering from
an inflammatory bowel disease, may already be taking a
pharmaceutical prescribed by their doctor to treat the condition.
In embodiments, the pharmaceutical compositions taught herein, are
able to be administered in conjunction with the patient's existing
medicines.
[0240] For example, the SG proteins taught herein may be combined
with one or more of: an anti-diarrheal, a 5-aminosalicylic acid
compound, an anti-inflammatory agent, an antibiotic, an antibody
(e.g., antibodies targeting an inflammatory cytokine, e.g.,
antibodies targeting an anti-cytokine agent such as
anti-TNF-.alpha., (e.g., adalimumab, certolizumab pegol, golimumab,
infliximab, V565) or anti-IL-12/IL-23 (e.g., ustekinumab,
risankizumab, brazikumab, ustekinumab), a JAK inhibitor (e.g.,
tofacitinib, PF06700841, PF06651600, filgotinib, upadacitinib), an
anti-integrin agent (e.g., vedolizumab, etrolizumab), a SW
inhibitor (e.g., etrasimod, ozanimod, amiselimod), a recombinant
cell-based agent (e.g., Cx601), a steroid, a corticosteroid, an
immunosuppressant (e.g., azathioprine and mercaptopurine),
vitamins, and/or specialized diet.
[0241] Cancer patients undergoing chemotherapy or radiation therapy
and suffering from or at risk of developing mucositis, e.g., oral
mucositis, may be administered a pharmaceutical composition
according to the present disclosure in combination with an agent
used to treat mucositis such as oral mucositis. In some
embodiments, a method of treatment comprises administering to a
patient suffering from mucositis a combination of a pharmaceutical
composition comprising an SG protein or a variant or fragment
thereof and one or more second therapeutic agents selected from the
group consisting of amifostine, benzocaine, benzydamine,
ranitidine, omeprazole, capsaicin, glutamine, prostaglandin E2,
Vitamin E, sucralfate, and allopurinol.
[0242] In some embodiments of the methods herein, the second
therapeutic agent is administered in conjunction with an SG protein
described herein, either simultaneously or sequentially. In some
embodiments, the protein and the second agent act synergistically
for treatment or prevention of the disease, or condition, or
symptom. In other embodiments, the protein and the second agent act
additively for treatment or prevention of the disease, or
condition, or symptom.
Pharmaceutical Compositions Comprising a Therapeutic SG Protein
[0243] Pharmaceutical compositions are provided herein which
comprise an SG protein, variant or fragment thereof according to
the present disclosure or pharmaceutically acceptable salt thereof
and a pharmaceutically acceptable excipient. In some embodiments,
the pharmaceutical composition is formulated for administration to
the gastrointestinal lumen, including the mouth, esophagus, small
intestine, large intestine, rectum and/or anus.
[0244] In some embodiments, the composition comprises one or more
other substances which are associated with the source of the SG
protein, for example, cellular components from a host cell, or
substance associated with chemical synthesis of the protein. In
other embodiments, the pharmaceutical composition is formulated to
include one or more second active agents as described herein.
Moreover, the composition may comprise ingredients that preserve
the structural and/or functional activity of the active agent(s) or
of the composition itself. Such ingredients include but are not
limited to antioxidants and various antibacterial and antifungal
agents, including but not limited to parabens (e.g.,
methylparabens, propylparabens), chlorobutanol, phenol, sorbic
acid, thimerosal or combinations thereof.
[0245] The terms "pharmaceutical" or pharmaceutically acceptable"
refers compositions that do not or preferably do not produce an
adverse, allergic, or other untoward reaction when administered to
an animal, such as, for example, a human, as appropriate. The
preparation of a pharmaceutical composition or additional active
ingredient will be known to those of skill in the art in light of
the present disclosure, as exemplified by Remington's
Pharmaceutical Sciences, 18.sup.th Ed. Mack Printing Company, 1990,
incorporated herein by reference. Moreover, for animal (e.g.,
human) administration, it will be understood that preparations
should meet sterility, pyrogenicity, general safety and purity
standards as required by the FDA Office of Biological
Standards.
[0246] The pharmaceutical compositions of the disclosure are
formulated according to the intended route of administration and
whether it is to be administered, e.g., in solid, liquid or aerosol
form. In a preferred embodiment, the composition can be
administered rectally, but may also be administered topically, by
injection, by infusion, orally, intrathecally, intranasally,
subcutaneously, mucosally, localized perfusion bathing target cells
directly, via a catheter, via a lavage, or by other method or any
combination of the foregoing as would be known to one of ordinary
skill in the art. Liquid formulations comprising a therapeutically
effective amount of the SG protein can be administered rectally by
enema, catheter, use of a bulb syringe. A suppository is an example
of a solid dosage form formulated for rectal delivery. In general,
for suppositories, traditional carriers may include, for example,
polyalkylene glycols, triglycerides or combinations thereof. In
certain embodiments, suppositories may be formed from mixtures
containing, for example, the active ingredient in the range of
about 0.5% to about 10%, and or about 1% to about 2%. Injectable
liquid compositions are typically based upon injectable sterile
saline or phosphate-buffered saline or other injectable carriers
known in the art. Other liquid compositions include suspensions and
emulsions. Solid compositions such as for oral administration may
be in the form of tablets, pills, capsules (e.g., hard or
soft-shelled gelatin capsules), buccal compositions, troches,
elixirs, suspensions, syrups, wafers, or combinations thereof. The
active agent in such liquid and solid compositions, i.e., a protein
as described herein, is typically a component, being about 0.05% to
10% by weight, with the remainder being the injectable carrier and
the like.
[0247] The pharmaceutical composition may be formulated as a
controlled or sustained release composition which provide release
of the active agent(s) including the therapeutic protein of the
present disclosure over an extended period of time, e.g., over
30-60 minutes, or over 1-10 hours, 2-8 hours, 8-24 hours, etc.
Alternatively or additionally, the composition is formulated for
release to a specific site in the host body. For example, the
composition may have an enteric coating to prevent release of the
active agent(s) in an acidic environment such as the stomach,
allowing release only in the more neutral or basic environment of
the small intestine, colon or rectum. Alternatively or
additionally, the composition may be formulated to provide delayed
release in the mouth, small intestine or large intestine.
[0248] Each of the above-described formulations may contain at
least one pharmaceutically acceptable excipient or carrier,
depending up the intended route of administration, e.g., a solid
for rectal administration or liquid for intravenous or parenteral
administration or administration via cannula. As used herein,
"pharmaceutically acceptable carrier" includes any and all
solvents, dispersion media, coatings, surfactants, antioxidants,
preservatives (e.g., antibacterial agents, antifungal agents),
isotonic agents, absorption delaying agents, salts, preservatives,
drugs, drug stabilizers, gels, binders, excipients, disintegration
agents, lubricants, sweetening agents, flavoring agents, dyes, such
like materials and combinations thereof, as would be known to one
of ordinary skill in the art (see, for example, Remington's
Pharmaceutical Sciences, 18.sup.th Ed. Mack Printing Company, 1990,
pp. 1289-1329, incorporated herein by reference).
[0249] The pharmaceutical compositions for administration can be
present in unit dosage forms to facilitate accurate dosing. Typical
unit dosage forms include prefilled, premeasured ampules or
syringes of the liquid compositions or suppositories, pills,
tablets, capsules or the like in the case of solid compositions. In
some embodiments of such compositions, the active agent, i.e., a
protein as described herein, may be a component (about 0.1 to 50
wt/wt %, 1 to 40 wt/wt %, 0.1 to 1 wt/wt %, or 1 to 10 wt/wt %)
with the remainder being various vehicles or carriers and
processing aids helpful for forming the desired dosing form.
[0250] The actual dosage amount in a unit dosage form of the
present disclosure administered to a patient can be determined by
physical and physiological factors such as body weight, severity of
condition, the type of disease being treated, previous or
concurrent therapeutic interventions, idiopathy of the patient and
on the route of administration. The practitioner responsible for
administration will, in any event, determine the concentration of
active ingredient(s) in a composition and appropriate dose(s) for
the individual subject.
Protein Expression Systems and Protein Production
[0251] Provided herein are compositions and methods for producing
isolated SG proteins of the present disclosure as well as
expression vectors which contain polynucleotide sequence encoding
the SG proteins and host cells which harbor the expression
vectors.
[0252] The SG proteins of the present disclosure can be prepared by
routine recombinant methods, e.g., culturing cells transformed or
transfected with an expression vector containing a nucleic acid
encoding a therapeutic SG protein, variant or fragment thereof.
Host cells comprising any such vector are also provided. Host cells
can be prokaryotic or eukaryotic and examples of host cells include
E. coli, yeast, or mammalian cells. A method for producing any of
the herein described proteins is further provided and comprises
culturing host cells under conditions suitable for expression of
the desired protein and recovering the desired protein from the
cell culture. The recovered protein can then be isolated and/or
purified for use in in vitro and in vivo methods, as well as for
formulation into a pharmaceutically acceptable composition. In some
embodiments, the SG protein is expressed in a prokaryotic cell such
as E. coli and the isolation and purification of the protein
includes step to reduce endotoxin to levels acceptable for
therapeutic use in humans or other animals.
Expression Vectors
[0253] Provided herein are expression vectors which comprise a
polynucleotide sequence which encodes an SG protein of the present
disclosure or a variant and/or fragment thereof. Polynucleotide
sequences encoding the SG proteins of the disclosure can be
obtained using standard recombinant techniques. Desired encoding
polynucleotide sequences may be amplified from the genomic DNA of
the source bacterium, i.e., E. eligens and/or C. bartlettii.
Alternatively, polynucleotides can be synthesized using nucleotide
synthesizer. Once obtained, sequences encoding the polypeptides are
inserted into a recombinant vector capable of replicating and
expressing heterologous (exogenous) polynucleotides in a host cell.
Many vectors that are available and known in the art can be used
for the purpose of the present disclosure. Selection of an
appropriate vector will depend mainly on the size of the nucleic
acids to be inserted into the vector and the particular host cell
to be transformed with the vector. Each vector contains various
components, depending on its function (amplification or expression
of heterologous polynucleotide, or both) and its compatibility with
the particular host cell in which it resides. The vector components
generally include, but are not limited to: an origin of
replication, a selection marker gene, a promoter, a ribosome
binding site (RBS), a signal sequence, the heterologous nucleic
acid insert and a transcription termination sequence.
[0254] In general, plasmid vectors containing replicon and control
sequences which are derived from species compatible with the host
cell are used in connection with these hosts. The vector ordinarily
carries a replication site, as well as marking sequences which are
capable of providing phenotypic selection in transformed cells. For
example, E. coli is typically transformed using a pBR322, pUC, pET
or pGEX vector, a plasmid derived from an E. coli species. Such
vectors contain genes encoding ampicillin (Amp) and tetracycline
(Tet) resistance and thus provides easy means for identifying
transformed cells. These vectors as well as their derivatives or
other microbial plasmids or bacteriophage may also contain, or be
modified to contain, promoters which can be used by the microbial
organism for expression of endogenous proteins.
[0255] An expression vector of the present disclosure may comprise
a promoter, an untranslated regulatory sequence located upstream
(5') and operably linked to a protein-encoding nucleotide sequence
such that the promoter regulated transcription of that coding
sequence. Prokaryotic promoters typically fall into two classes,
inducible and constitutive. An inducible promoter is a promoter
that initiates increased levels of transcription of the encoding
polynucleotide under its control in response to changes in the
culture condition, e.g., the presence or absence of a nutrient or a
change in temperature. A large number of promoters recognized by a
variety of potential host cells are well known and a skilled
artisan can choose the promoter according to desired expression
levels. Promoters suitable for use with prokaryotic hosts include
E. coli promoters such as lac, trp, tac, trc and ara, viral
promoters recognized by E. coli such as lambda and T5 promoters,
and the T7 and T7lac promoters derived from T7 bacteriophage. A
host cell harboring a vector comprising a T7 promoter, e.g., is
engineered to express a T7 polymerase. Such host cells include E.
coli BL21(DE3), Lemo21 (DE3), and NiCo21 (DE3) cells. In some
embodiments, the promoter is an inducible promoter which is under
the control of chemical or environmental factors.
[0256] Further useful plasmid vectors include pIN vectors (Inouye
et al., 1985); and pGEX vectors, for use in generating glutathione
S-transferase (GST) soluble fusion proteins for later purification
and separation or cleavage. Other suitable fusion proteins are
those with .beta.-galactosidase, ubiquitin, and the like.
[0257] Suitable vectors for expression in both prokaryotic and
eukaryotic host cells are known in the art and some are further
described herein.
[0258] Vectors of the present disclosure may further comprise a
signal sequence which allows the translated recombinant protein to
be recognized and processed (i.e., cleaved by a signal peptidase)
by the host cell. For prokaryotic host cells that do not recognize
and process the signal sequences native to the heterologous
polypeptides, the signal sequence is substituted by a prokaryotic
signal sequence selected, for example, from the group consisting of
the alkaline phosphatase, penicillinase, Ipp, or heat-stable
enterotoxin II (STII) leaders, LamB, PhoE, PeIB, OmpA and MBP.
Well-known signal sequences for use in eukaryotic expression
systems include but are not limited to interleukin-2, CDS, the
Immunoglobulin Kappa light chain, trypsinogen, serum albumin, and
prolactin.
[0259] SG proteins or variants or fragments thereof as described
herein can be expressed as a fusion protein or polypeptide.
Commonly used fusion partners include but are not limited to human
serum albumin and the crystallizable fragment, or constant domain
of IgG, Fc. The histidine tag or FLAG tag can also be used to
simplify purification of recombinant protein from the expression
media or recombinant cell lysate. The fusion partners can be fused
to the N- and/or C-terminus of the protein of interest.
Host Cells
[0260] Suitable host cells for cloning or expressing the DNA in the
vectors herein include prokaryote, yeast, or higher eukaryote
cells. Numerous cell lines and cultures are available for use as a
host cell, and they can be obtained for example through the
American Type Culture Collection (ATCC), which is an organization
that serves as an archive for living cultures and genetic
materials. Cell types available for vector replication and/or
expression include, but are not limited to, bacteria, such as E.
coli (e.g., E. coli strain RR1, E. coli LE392, E. coli B, E. coli X
1776 (ATCC No. 31537) as well as E. coli W3110 (F-, lambda-,
prototrophic, ATCC No. 273325), DH5a, JM109, and KCB, bacilli such
as Bacillus subtilis; and other enterobacteriaceae such as
Salmonella typhimurium, Serratia marcescens, various Pseudomonas
species, as well as a number of commercially available bacterial
hosts such as SURE.RTM. Competent Cells and SOLOPACK.TM. Gold Cells
(STRATAGENE.RTM., La Jolla). In certain embodiments, bacterial
cells such as E. coli are particularly contemplated as host
cells.
[0261] Examples of eukaryotic host cells for replication and/or
expression of a vector include, but are not limited to, HeLa,
NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12. Additional
eukaryotic host cells include yeasts (e.g., Pichia pastoris and
Saccharomyces cerevisiae) and cells derived from insects (e.g.,
Spodoptera frugiperda or Trichoplusia ni). Many host cells from
various cell types and organisms are available and would be known
to one of skill in the art. Similarly, a viral vector may be used
in conjunction with either a eukaryotic or prokaryotic host cell,
particularly one that is permissive for replication or expression
of the vector. The selection of the appropriate host cell is deemed
to be within the skill in the art.
[0262] Methods are well known for introducing recombinant DNA,
i.e., an expression vector, into a host cell so that the DNA is
replicable, either as an extrachromosomal element or as a
chromosomal integrant, thereby generating a host cell which harbors
the expression vector of interest. Methods of transfection are
known to the ordinarily skilled artisan, for example, by CaPO.sub.4
and electroporation. Depending on the host cell used,
transformation is performed using standard techniques appropriate
to such cells. The calcium treatment employing calcium chloride, as
described in Sambrook et al. (1989, Cold Spring Harbor Laboratory
Press) or electroporation is generally used for prokaryotes or
other cells that contain substantial cell-wall barriers. General
aspects of mammalian cell host system transformations have been
described in U.S. Pat. No. 4,399,216. Transformations into yeast
are typically carried out according to the method of Van Solingen
et al., J. Bact, 130:946 (1977) and Hsiao et al., Proc. Natl. Acad.
Sci. (USA), 76:3829 (1979). Other methods for introducing DNA into
cells include nuclear microinjection, electroporation, bacterial
protoplast fusion with intact cells, or introduction using
polycations, e.g., polybrene, polyornithine. For various techniques
for transforming mammalian cells, see Keown et al., Methods in
Enzymology. 185:527-537 (1990) and Mansour et al., Nature,
336:348-352 (1988).
[0263] Accordingly, provided herein is a recombinant vector or
expression vector as described above and comprising a
polynucleotide which encodes an SG therapeutic protein sequence of
interest (e.g., SEQ ID NO:2 (SG-15), SEQ ID NO:10 (SG-16), SEQ ID
NO:14 (SG-17) or SEQ ID NO:20 (SG-18), or variant and/or fragment
thereof as described herein). The polynucleotide can be, for
example, any one of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:14 or SEQ
ID NO:20, or a variant or a fragment thereof. Moreover, the present
disclosure teaches a host cell harboring the vector. The host cell
can be a eukaryotic or prokaryotic cell as detailed above. In a
preferred embodiment, the host cell is a prokaryotic cell. In a
further preferred embodiment, the host cell is E. coli. The
recombinant expression vector may be constructed to express an SG
protein with, e.g, an affinity tag at the N-terminus and/or the
C-terminus. The affinity tag can be linked to the SG protein via a
short amino acid sequence which contains a protease cleavage site.
Accordingly, after cleavage of the expressed protein with the
protease, the SG protein may contain exogenous amino acids at the
N- or C-terminus of the therapeutic protein without affecting
functional activity of the protein.
[0264] In some embodiments, the polynucleotide encoding the protein
of interest is codon-optimized. A codon optimization algorithm is
applied to a polynucleotide sequence encoding a protein in order to
choose an appropriate codon for a given amino acid based on the
expression host's codon usage bias. Many codon optimization
algorithms also take into account other factors such as mRNA
structure, host GC content, ribosomal entry sites. Some examples of
codon optimization algorithms and gene synthesis service providers
are: AUTM: www.atum.bio/services/genegps; GenScript:
www.genscript.com/codon-opt.html; ThermoFisher:
www.thermofisher.com/us/en/home/life-science/cloning/gene-synthesis/genea-
rt-gene-synthesis/geneoptimizer.html; and Integrated DNA
Technologies: www.idtdna.com/CodonOpt. The nucleotide sequence is
then synthesized and cloned into an appropriate expression
vector.
Methods to Produce the Protein
[0265] Methods are provided for producing the proteins described
herein but are well known to the ordinarily skilled artisan. Host
cells transformed or transfected with expression or cloning vectors
described herein for protein production are cultured in
conventional nutrient media modified as appropriate for inducing
promoters, selecting and/or maintaining transformants, and/or
expressing the genes encoding the desired protein sequences. The
culture conditions, such as media, temperature, pH and the like,
can be selected by the skilled artisan without undue
experimentation. In general, principles, protocols, and practical
techniques for maximizing the productivity of cell cultures can be
found in Mammalian Cell Biotechnology: A Practical Approach, M.
Butler, ed. (IRL Press, 1991) and Molecular Cloning: A Laboratory
Manual (Sambrook, et al., supra).
[0266] Generally, "purified" will refer to a specific protein
composition that has been subjected to fractionation to remove
non-proteinaceous components and various other proteins,
polypeptides, or peptides, and which composition substantially
retains its activity, as may be assessed, for example, by the
protein assays, as described herein below, or as would be known to
one of ordinary skill in the art for the desired protein,
polypeptide or peptide.
[0267] Where the term "substantially purified" is used, this will
refer to a composition in which the specific protein, polypeptide,
or peptide forms the major component of the composition, such as
constituting about 50% of the proteins in the composition or more.
In preferred embodiments, a substantially purified protein will
constitute more than 60%, 70%, 80%, 90%, 95%, 99% or even more of
the proteins in the composition.
[0268] A peptide, polypeptide or protein that is "purified to
homogeneity," as applied to the present disclosure, means that the
peptide, polypeptide or protein has a level of purity where the
peptide, polypeptide or protein is substantially free from other
proteins and biological components. For example, a purified
peptide, polypeptide or protein will often be sufficiently free of
other protein components so that degradative sequencing may be
performed successfully.
[0269] Although preferred for use in certain embodiments, there is
no general requirement that the protein, polypeptide, or peptide
always be provided in their most purified state. Indeed, it is
contemplated that less substantially purified protein, polypeptide
or peptide, which are nonetheless enriched in the desired protein
compositions, relative to the natural state, will have utility in
certain embodiments.
[0270] Another contemplated is the purification of a specific
fusion protein using a specific binding partner. Such purification
methods are routine in the art. As the present disclosure provides
DNA sequences for the specific proteins, any fusion protein
purification method can now be practiced. This is exemplified by
the generation of a specific protein-glutathione S-transferase
fusion protein, expression in E. coli, and isolation to homogeneity
using affinity chromatography on glutathione-agarose or the
generation of a poly-histidine tag on the N- or C-terminus of the
protein, and subsequent purification using Ni-affinity
chromatography. However, given many DNA and proteins are known, or
may be identified and amplified using the methods described herein,
any purification method can now be employed.
[0271] Recombinantly expressed SG proteins of the present
disclosure can be recovered from culture medium or from host cell
lysates. The suitable purification procedures include, for example,
by fractionation on an ion-exchange (anion or cation) column;
ethanol precipitation; reverse phase HPLC; chromatography on silica
or on a cation-exchange resin such as DEAE; chromatofocusing;
SDS-PAGE; ammonium sulfate precipitation; gel filtration or size
exclusion chromatograph (SEC) using, for example, Sephadex G-75;
and metal chelating columns to bind epitope-tagged forms of a
polypeptide of the present disclosure. Various methods of protein
purification can be employed and such methods are known in the art
and described for example in Deutscher, Methods in Enzymology, 182
(1990); Scopes, Protein Purification: Principles and Practice,
Springer-Verlag, New York (1982). The purification step(s) selected
will depend, for example, on the nature of the production process
used and the particular polypeptide produced.
[0272] Alternative methods, which are well known in the art, can be
employed to prepare an SG protein of the present disclosure. For
example, a sequence encoding a protein or portion thereof, can be
produced by direct peptide synthesis using solid-phase techniques
(see, e.g., Stewart et al., 1969, Solid-Phase Peptide Synthesis,
W.H. Freeman Co., San Francisco, Calif.; Merrifield. J. 1963, Am.
Chem. Soc., 85:2149-2154. Automated synthesis can be accomplished,
for instance, using an Applied Biosystems Peptide Synthesizer
(Foster City, Calif.) using manufacturer's instructions.
[0273] In some embodiments, the disclosure provides chimeric
molecules comprising any of the herein described polypeptides fused
to a heterologous polypeptide or amino acid sequence and the
polynucleotides encoding the chimeric molecules. Examples of such
chimeric molecules include, but are not limited to, any of the
herein described polypeptides fused to an epitope tag sequence, an
Fc region of an immunoglobulin.
Recombinant Bacterial Delivery Systems
[0274] The present disclosure contemplates utilizing delivery
systems outside of the traditional pharmaceutical formulations that
comprise a purified protein. In some embodiments, the disclosure
utilizes recombinant bacterial delivery systems, phage-mediated
delivery systems, chitosan-DNA complexes, or AAV delivery
systems.
[0275] One particular recombinant bacterial delivery system is
based upon Lactococcus lactis. Essentially, one may clone the gene
encoding the therapeutic protein (e.g. SEQ ID NO:1, SEQ ID NO:9,
SEQ ID NO:13 or SEQ ID NO:19) into an expression vector, and then
transform the vector into L. lactis. Subsequently, one may then
administer the L. lactis to a patient. See, e.g. Bratt, et al., "A
phase 1 trial with transgenic bacteria expressing interleukin-10 in
Crohn's disease," Clinical Gastroenterology and Hepatology, 2006,
Vol. 4, pgs. 754-759 ("We treated Crohn's disease patients with
genetically modified Lactococcus lactis (LL-Thyl2) in which the
thymidylate synthase gene was replaced with a synthetic sequence
encoding mature human interleukin-10."); Shigemori, et al., "Oral
delivery of Lactococcus lactis that secretes bioactive heme
oxygenase-1 alleviates development of acute colitis in mice,"
Microbial Cell Factories, 2015, Vol. 14:189 ("Mucosal delivery of
therapeutic proteins using genetically modified strains of lactic
acid bacteria (gmLAB) is being investigated as a new therapeutic
strategy."); Steidler, et al., "Treatment of murine colitis by
Lactococcus lactis secreting interleukin-10," Science, 2000, Vol.
289, pgs. 1352-1355 ("The cytokine interleukin-10 (IL-10) has shown
promise in clinical trials for treatment of inflammatory bowel
disease (IBD). Using two mouse models, we show that the therapeutic
dose of IL-10 can be reduced by localized delivery of a bacterium
genetically engineered to secrete the cytokine. Intragastric
administration of IL-10 secreting Lactococcus lactis caused a 50%
reduction in colitis in mice treated with dextran sulfate sodium
and prevented the onset of colitis in IL-102/2 mice. This approach
may lead to better methods for cost effective and long-term
management of IBD in humans."); Hanniffy, et al., "Mucosal delivery
of a pneumococcal vaccine using Lactococcus lactis affords
protection against respiratory infection," Journal of Infectious
Diseases, 2007, Vol. 195, pgs. 185-193 ("Here, we evaluated
Lactococcus lactis intracellularly producing the pneumococcal
surface protein A (PspA) as a mucosal vaccine in conferring
protection against pneumococcal disease."); and Vandenbroucke, et
al., "Active delivery of trefoil factors by genetically modified
Lactococcus lactis prevents and heals acute colitis in mice,"
Gastroenterology, 2004, Vol. 127, pgs. 502-513 ("We have positively
evaluated a new therapeutic approach for acute and chronic colitis
that involves in situ secretion of murine TFF by orally
administered L. lactis. This novel approach may lead to effective
management of acute and chronic colitis and epithelial damage in
humans.").
[0276] In another embodiment, a "synthetic bacterium" may be used
to deliver an SG protein or variant or fragment thereof wherein a
probiotic bacterium is engineered to express the therapeutic SG
protein (see, e.g., Durrer and Allen, 2017, PLoS One,
12:e0176286).
[0277] Phages have been genetically engineered to deliver specific
DNA payloads or to alter host specificity. Transfer methods, such
as phages, plasmids, and transposons, can be used to deliver and
circulate engineered DNA sequences to microbial communities, via
processes such as transduction, transformation, and conjugation.
For purposes of the present disclosure, it is sufficient to
understand that an engineered phage could be one possible delivery
system for a protein of the disclosure, by incorporating the
nucleic acid encoding said protein into the phage and utilizing the
phage to deliver the nucleic acid to a host microbe that would then
produce the protein after having the phage deliver the nucleic acid
into its genome.
[0278] Similar to the aforementioned engineered phage approach, one
could utilize a transposon delivery system to incorporate nucleic
acids encoding a therapeutic protein into a host microbe that is
resident in a patient's microbiome. See, Sheth, et al.,
"Manipulating bacterial communities by in situ microbiome
engineering," Trends in Genetics, 2016, Vol. 32, Issue 4, pgs.
189-200.
[0279] The following examples are intended to illustrate, but not
limit, the disclosure.
EXAMPLES
[0280] The following experiments utilize a robust mixture of in
vitro experiments combined with in vivo models of IBD to
demonstrate the therapeutic ability of the taught proteins and
methods. Specifically, Examples 1 to 4 below demonstrate the
functional utility of the therapeutic SG proteins to treat a
gastrointestinal inflammatory disease, or disease involving
impaired epithelial barrier integrity/function. Each of Examples 1
to 4 describes in vitro and in vivo experiments to assess
functional activity of proteins SG-15, SG-16, SG-17 and SG-18,
respectively.
Example 1. SG-15
[0281] A. Expression of SG-15
[0282] For experiments described in the examples below, a
polynucleotide comprising a sequence encoding residues 1-400 of SEQ
ID NO:1 (SG-15) was obtained by PCR amplification of genomic DNA
obtained from Eubacterium eligens (C15-B4; DSM 3376 type strain;
See, e.g., Holdeman, L. V., Moore, W.E.C. (1974) New genus,
Coprococcus, twelve new species, and amended descriptions of four
previously described species of bacteria from human feces. Int J
Syst Bacteriol 24, 260-277. The encoding polynucleotide was then
subcloned into an inducible expression vector and used to transform
E. coli BL21(DE3) cells for expression and purification of SG-15 as
detailed below, using culturing and purification methods which are
routine in the art.
[0283] Expression and purification of proteins for use in various
experiments pertaining to the present disclosure and for the
following examples is described here. Expression was achieved using
a pGEX vector system which is designed for inducible, high-level
intracellular expression of genes or gene fragments. Expression in
E. coli yields tagged proteins with the GST moiety at the amino
terminus and the protein of interest at the carboxyl terminus. The
vector has a tac promoter for chemically inducible, high-level
expression and an internal laq1.sup.q gene for use in any E. coli
host.
[0284] The polynucleotide comprising a nucleotide sequence
(PCR-amplified from E. eligens DSM 3376 and encoding residues 1 to
400 of SEQ ID NO:1) was inserted into the BamHI and NotI sties of
the multiple-cloning site of a pGEX-6P-1 vector (GE Healthcare Life
Science, Pittsburgh, Pa.) to express SG-15 as a GST fusion protein
which was then cleaved at the Precision protease site, whereby an
exogenous GPLG sequence is present at the N-terminus and AAS is
present at the C-terminus of the cleaved and purified protein. BL21
(DE) E. coli cells were transformed with the expression construct.
BL21(DE3) transformants were grown in 10 L LB with 50 .mu.g/ml
carbenicillin at 37.degree. C. When cultures reached a density of
0.8 OD.sub.600, they were chilled to 16.degree. C. and expression
was induced with 1 mM IPTG at 16.degree. C. for 16 h. Cells were
harvested and lysed by sonication, and a soluble lysate was applied
to a GSTrap column. Bound protein was washed with HEPES buffer and
then purified tag-free SG-15 was eluted by adding HRV3C protease to
cleave the protein C-terminal to the GST-tag. Eluted fractions
containing protein as determined by SDS-PAGE and Coomasie Brilliant
Blue staining were identified and pooled, then applied to a HiTrap
Q HP anion exchange column then to a HiLoad Superdex 200 26/60
preparative size exclusion column (SEC) to obtain a final
preparation.
[0285] In an alternative method of expression and purification with
the same expression construct, BL21 transformants were grown in LB
and 100 .mu.g/ml carbenicillin and 1 .mu.g/ml chloramphenicol at
30.degree. C. Expression was induced when a culture density of 0.6
OD.sub.600 was reached, with 0.4 mM IPTG for 4 h. Cells were
harvested by centrifugation then lysed by sonication, and a soluble
lysate was applied to a GST-resin column. Bound protein was washed
with PBS and then purified tag-free SG-15 was eluted by adding
PreScission Protease to cleave the protein C-terminal to the
GST-tag.
[0286] Purified proteins were quantified by densitometry using
bovine serum albumin as a reference following SDS-PAGE and
Coomassie Brilliant Blue staining. Endotoxin levels were measured
with Endosafe.RTM. nexgen-MCS.TM. (Charles River, Wilmington,
Mass.) according to the manufacturer's instructions. Endotoxin
levels of proteins used for the assays described herein were lower
than 1 EU/mg.
[0287] B. Effect of SG-15 on Restoration of Epithelial Barrier
Integrity Following Inflammation Induced Disruption
[0288] The following experiment assesses the effects of an SG-15
protein as disclosed herein to restore gastrointestinal epithelial
barrier integrity in vitro.
[0289] Assays were performed as described below in trans-well
plates where co-cultures of multiple cell types were performed
utilizing a permeable membrane to separate cells. In the apical
(top) chamber, human colonic epithelial cells, consisting of a
mixture of enterocytes and goblet cells, were cultured until cells
obtained tight junction formation and barrier function capacity as
assessed by measurement of trans-epithelial electrical resistance
(TEER). In the basolateral chamber, monocytes were cultured
separately. Epithelial cells were primed with inflammatory
cytokines. The assays measured the effect of a therapeutic protein,
i.e., SG-15, on epithelial barrier function, wound healing, and
production of cytokines.
[0290] Cell culture. The HCT8 human enterocyte cell line (ATCC Cat.
No. CCL-244) was maintained in RPMI-1640 medium supplemented with
10% fetal bovine serum, 100 IU/ml penicillin, 100 .mu.g/ml
streptomycin, 10 .mu.g/ml gentamicin and 0.25 .mu.g/ml amphotericin
(cRPMI). HT29-MTX human goblet cells (Sigma-Aldrich (St. Louis,
Mo.; Cat. No. 12040401) were maintained in DMEM medium with 10%
fetal bovine serum, 100 IU/ml penicillin, 100 .mu.g/ml
streptomycin, 10 .mu.g/ml gentamicin and 0.25 .mu.g/ml amphotericin
(cDMEM). Epithelial cells were passaged by trypsinization and were
used between 5 and 15 passages following thawing from liquid
nitrogen stocks. U937 monocytes (ATCC Cat. No. 700928) were
maintained in cRPMI medium as a suspension culture, and split by
dilution as needed to maintain cells between 5.times.10.sup.5 and
2.times.10.sup.6 cells/ml. U937 cells were used up to passage 18
following thawing from liquid nitrogen stocks.
[0291] Epithelial cell culture. A mixture of HCT8 enterocytes and
HT29-MTX goblet cells were plated at a 9:1 ratio, respectively, in
the apical chamber of the transwell plate as described previously
(Berget et al., 2017, Int J Mol Sci, 18:1573; Beduneau et al.,
2014, Eur J Pharm Biopharm, 87:290-298). A total of 10.sup.5 cells
were plated in each well (9.times.10.sup.4 HCT8 cells and
1.times.10.sup.4 HT29-MTX cells per well). Epithelial cells were
trypsinized from culture flasks and viable cells determined by
trypan blue counting. The correct volumes of each cell type were
combined in a single tube and centrifuged. The cell pellet was
resuspended in cRPMI and added to the apical chamber of the
transwell plate. Cells were cultured for 8 to 10 days at 37.degree.
C. +5% CO.sub.2, and media was changed every 2 days.
[0292] Monocyte culture. On day 6 of epithelial cell culture
2.times.10.sup.5 cells/well U937 monocytes were plated into a 96
well receiver plate. Cells were cultured at 37.degree. C. +5%
CO.sub.2 and media was changed every 24 hours for four days.
[0293] Co-culture assay. Following 8-10 days of culture the
transwell plate containing enterocytes were treated with 10 ng/ml
IFN-.gamma. added to the basolateral chamber of the transwell plate
for 24 hours at 37.degree. C. +5% CO.sub.2. After 24 hours fresh
cRPMI was added to the epithelial cell culture plate.
Trans-epithelial electrical resistance (TEER) readings were
measured after the IFN-.gamma. treatment and were used as the
pre-treatment TEER values. SG-15 was then added to the apical
chamber of the transwell plate at a final concentration of 1
.mu.g/ml (40 nM). The myosin light chain kinase (MLCK) inhibitor
peptide 18 (BioTechne, Minneapolis, Minn.) was used at 50 nM as a
positive control to prevent inflammation induced barrier disruption
(Zolotarevskky et al., 202, Gastroenterology, 123:163-172). The
bacterially derived molecule staurosporine was used at 100 nM as a
negative control to induce apoptosis and exacerbate barrier
disruption (Antonsson and Persson, 2009, Anticancer Res,
29:2893-2898). Compounds were incubated on enterocytes for 1 hour
or 6 hours. Following pre-incubation with test compounds the
transwell insert containing the enterocytes was transferred on top
of the receiver plate containing U937 monocytes. Heat killed E.
coli (HK E. coli) (bacteria heated to 80.degree. C. for 40 minutes)
was then added to both the apical and basolateral chambers and a
multiplicity of infection (MOI) of 10. Transwell plates were
incubated at 37.degree. C. +5% CO.sub.2 for 24 hours and a post
treatment TEER measurement was made. The TEER assays were performed
with recombinantly expressed mature (lacking a signal peptide)
SG-15 protein such as that described in Example 1A above.
[0294] Data analysis. Raw electrical resistance values in ohms (Q)
were converted to ohms per square centimeter (.OMEGA.cm.sup.2)
based on the surface area of the transwell insert (0.143 cm.sup.2).
To adjust for differential resistances developing over 10 days of
culture, individual well post treatment .OMEGA.cm.sup.2 readings
were normalized to pre-treatment .OMEGA.cm.sup.2 readings.
Normalized .OMEGA.cm.sup.2 values were then expressed as a percent
change from the mean .OMEGA.cm.sup.2 values of untreated
samples.
[0295] SG-15 protein was added 30 minutes (FIG. 1A) or 6 hours
(FIG. 1B) prior to exposure of both epithelial cells and monocytes
to heat killed Escherichia coli (HK E. coli), inducing monocytes to
produce inflammatory mediators resulting in disruption of the
epithelial monolayer as indicated by a reduction in TEER. A myosin
light chain kinase (MLCK) inhibitor was utilized as a control
compound, which has been shown to prevent barrier disruption and/or
reverse barrier loss triggered by the antibacterial immune
response. Staurosporine was used as a control compound that caused
epithelial cell apoptosis and/or death, thus resulting in a drastic
decrease in TEER, which indicates disruption and/or loss of
epithelial cell barrier integrity/function. In FIG. 1A, TEER of
epithelial cell barrier increased slightly from 69.6% only when
epithelial cells were exposed to heat killed E. coli to 71.4% when
incubating epithelial cells with SG-15 for 30 minutes before
exposing to HK E. coli (p=0.69). In FIG. 1B, epithelial cells
pre-incubated with SG-15 for 6 hours before HK E. coli exposure
maintained 68.5% in TEER and a 68.6% without SG-15 treatment
(p=0.96). The graphs in FIGS. 1A-1B represent data pooled from two
individual experiments (n=6).
[0296] C. Effect of SG-15 on TNF-.alpha., IL-23, and IL-10
Production by Heat Killed Escherichia coli
[0297] The following experiment demonstrates the therapeutic
ability of an SG-15 protein as disclosed herein to reduce immune
activation as measured by cytokine production. The experiment
thereby demonstrates potential functional utility of a therapeutic
SG protein to treat a gastrointestinal inflammatory disease, or
disease involving impaired epithelial barrier integrity/function,
where modulation of cytokine levels would affect the disease state
in a host.
[0298] Production of the cytokines TNF-.alpha., IL-23, and IL-10 by
monocytes was measured in the tissue culture supernatant from the
basolateral chamber of the co-culture TEER assay performed in
Example 1B. Following TEER readings, the supernatants were
centrifuged at 10,000 g for 5 minutes at 4.degree. C. to remove
cell debris. Luminex analysis was performed according to the
manufacturer's instructions (Magpix instrument and xPonent software
version 4.2; Luminex Corporation (Austin, Tex.)). Luminex analysis
was performed to determine the pg/ml concentration of TNF-.alpha.
and IL-23 produced by monocytes. Luminex analysis utilizes a
bead-based system for quantification of multiple cytokines from a
single sample. Like an ELISA, Luminex beads are coated with a
capture antibody, and incubation with samples allows the target to
bind to the capture antibody. Beads are washed and incubated with a
fluorescently labeled detection antibody for quantification of
bound target. Cytometric analysis is used to differentiate bead
populations, which are loaded with differential fluorescent dyes,
and to quantify cytokine levels by measuring detection antibody
signal.
[0299] TNF-.alpha., IL-23, and IL-10 production in untreated cells
and cells pre-incubated with SG-15 for 6 hours prior to HK E. coli
treatment was normalized to pg/ml concentrations elicited by HK E.
coli only, which was set to 1.0. Pre-incubation with SG-15
significantly reduced TNF-.alpha. production to 0.91. Results are
shown in FIG. 2A. Pre-incubation with SG-15 significantly reduced
IL-23 production to 0.57. There was no significant difference
between IL-23 production by control cells treated with media only,
and cells treated with SG-15 and HK E. coli. Results are shown in
FIG. 2B. Pre-incubation with SG-15 significantly reduced IL-10
production to 0.66. Results are shown in FIG. 2C. The graphs in
FIGS. 2A, 2B and 2C each represent data pooled from an individual
experiment (n=3).
[0300] D. Effects of SG-15 on Epithelial Cell Wound Healing
[0301] The following experiment demonstrates the therapeutic
ability of an SG-15 protein as disclosed herein to increase
gastrointestinal epithelial cell wound healing. The experiment is
therefore a demonstration of the functional utility of a
therapeutic SG-15 protein to treat a gastrointestinal inflammatory
disease, or disease involving impaired epithelial barrier
integrity/function, where increased epithelial cell wound healing
would be beneficial.
[0302] HCT8 enterocytes and HT29-MTX goblet cells were used in
wound healing studies. The 96 well Oris Cell Migration assay
containing plugs preventing cell attachment in the center of each
well was used according to the manufacturer's instructions
(Platypus Technologies, Madison, Wis.).
[0303] The migration assay plates were warmed to room temperature
prior to use and plugs were removed from 100% confluence wells
prior to cell addition. The HCT8 enterocyte and HT29-MTX goblet
cell lines were used at a 9:1 ratio with a total of
5.times.10.sup.4 total cells added per well (4.5.times.10.sup.4
HCT8 cells and 0.5.times.10.sup.4 HT29-MTX cells). Cells were
incubated at 37.degree. C. +5% CO.sub.2 for 24 hours. Plugs were
then removed from all control and sample wells. Control wells
included cells treated with the diluent vehicle as the blank, 30
ng/ml epidermal growth factor (EGF) as the positive control, and
100 nM staurosporine as the negative control, all diluted in cRPMI.
Sample wells contained SG-15 protein at a concentration of 1
.mu.g/ml diluted in cRPMI. 100% and 0% wells were cultured in
cRPMI. Treatments were added to cells and incubated at 37.degree.
C. +5% CO.sub.2 for 48 hours. Prior to staining for viable cells,
plugs were removed from the 0% wells. Treatment media was removed
and cells were washed in PBS containing 0.9 mM CaCl.sub.2 and 0.5
mM MgCl.sub.2. The green fluorescent viability dye Calcenin AM was
added to all wells at a concentration of 0.5 .mu.g/ml in PBS
containing 0.9 mM CaCl.sub.2 and 0.5 mM MgCl.sub.2, incubated for
30 min at 37.degree. C. +5% CO.sub.2, the dye was removed and cells
were washed in PBS containing 0.9 mM CaCl.sub.2 and 0.5 mM
MgCl.sub.2 and fluorescence was measured. Relative fluorescent
values from 100% wells where plugs were removed prior to cell
plating were set as the max effect, and 0% wells where plugs
remained in place until immediately before staining were used as
the baseline. Samples were normalized between 100% and 0% samples
and values expressed as a percent growth.
[0304] As shown in FIG. 3, a significant increase in growth was
observed with SG-15. In addition, control compounds modulated wound
healing as expected with EGF increasing proliferation, and
staurosporine suppressing cell proliferation. The graph in FIG. 3
represents data pooled from 4 replicate experiments (n=18).
[0305] E. SG-15 Demonstrates Therapeutic Activity in a DSS Model of
Inflammatory Bowel Disease
[0306] Example 1E demonstrates activity of an SG-15 protein as
disclosed herein for the treatment of inflammatory bowel disease in
an in vivo model. Specifically, the mice in Example 1E were treated
with dextran sodium sulfate (DSS), a chemical known to induce
intestinal epithelial damage and thereby reduce intestinal barrier
integrity and function. DSS mice are well-accepted models of
colitis. In Example 1E, mice were treated with SG-15 protein
approximately concurrent with (6 hours prior to) administration of
DSS. The mice were then assessed for effects of SG-15 on clinically
relevant markers of improved health.
[0307] The graphs presented in Example 1E represent data pooled
from 2 individual experiments, each using 10 mice (n=20). The SG-15
protein used in these experiments was the mature protein (no signal
peptide), expressed as described in Example 1A above.
[0308] Eight-week old C57BL/6 mice were housed 5 animals were cage
and given food and water ad libitum for 7 days. Following the 7-day
acclimation period, treatments were initiated concurrently with
addition of 2.5% DSS to the drinking water. Preliminary tracking
studies with fluorescently labeled bovine serum albumin following
intraperitoneal (i.p.) injection of protein demonstrated proteins
reached the colon at 6 hours after i.p. delivery. Based on these
results, 6 hr prior to addition of 2.5% DSS to the drinking water
mice were treated with 50 nmoles/kg SG-15 i.p. or 0.2 mg/kg
Gly2-GLP2 i.p. Six hours after the initial treatment the drinking
water was changed to water containing 2.5% DSS. The mice were
treated with 2.5% dextran sodium sulfate (DSS) in their drinking
water for 6 days. Treatments were continued with SG-15 or Gly2-GLP2
twice a day (b.i.d.) in the morning and evening (every 8 and 16 hr)
with i.p. injections at 50 nmoles/kg. Fresh 2.5% DSS drinking water
was prepared every 2 days.
[0309] On day six, mice were fasted for four hours and then orally
gavaged with 600 mg/kg 4KDa dextran labeled with fluorescein
isothiocyanate (FITC) [4KDa-FITC]. One hour after the 4KDa-FITC
gavage mice were euthanized, blood was collected and FITC signal
was measured in serum. A significant increase in 4KDa-FITC dextran
translocation across the epithelial barrier was observed in vehicle
treated DSS mice in comparison to untreated mice. Additionally, a
significant reduction in 4KDa-FITC dextran was observed in mice
receiving DSS and treated with SG-15, as compared to DSS mice
treated with vehicle. Results are shown in FIG. 4, and are
presented as mean.+-.SEM. The graph in FIG. 4 represents data
pooled from 2 individual experiments (n=20).
[0310] F. Effects of SG-15 on Inflammation Readouts Responsive to
Impaired Barrier Function in a Concurrent DSS Model of Inflammatory
Bowel Disease
[0311] SG-15 was also assessed for its effects on the levels of LPS
binding protein (LBP) in the blood of the DSS animal with and
without SG-15 administration. LPS binding protein (LBP), which has
been linked to clinical disease activity in subjects with
inflammatory bowel disease, was also measured by ELISA in the serum
of mice tested in the DSS model described in Example 1E. A
significant increase in LBP concentration was observed in
vehicle-treated DSS mice, as compared to untreated mice.
Additionally, a significant reduction in LBP was observed in SG-15
treated mice given DSS as compared to DSS mice treated with
vehicle. Results are shown in FIG. 5, and are presented as
mean.+-.SEM. The graph in FIG. 5 represents data pooled from the 2
individual experiments (n=20).
[0312] G. Effects of SG-15 on Weight Loss in a Concurrent DSS Model
of Inflammatory Bowel Disease
[0313] Also assessed was the therapeutic ability of an SG-15
protein as disclosed herein to ameliorate weight loss in an animal
suffering from an inflammatory intestinal disorder. Weight loss is
a significant and potentially dangerous side effect of inflammatory
bowel disease.
[0314] Body weight was measured daily from mice included in the DSS
model described in Example 1E. Percent change from starting weight
on day 0 was determined for each mouse. SG-15 administration to
DSS-treated mice significantly improved body weight compared to
vehicle-treated DSS mice. Weight loss in mice treated with SG-15 at
day 6 was similar to weight loss observed with Gly2-GLP2. Results
are shown in FIG. 6. The graphs in FIG. 6 represent data pooled
from the 2 individual experiments (n=20).
[0315] H. Effects of SG-15 on Gross Pathology in a DSS Model of
Inflammatory Bowel Disease
[0316] Gross pathology observations were made in mice included in
the concurrent DSS model performed in Example 1E. SG-15
administration to DSS treated mice significantly improved gross
pathology as compared to vehicle treated DSS mice. No differences,
however, were observed between clinical scores in DSS mice treated
with Gly2-GLP2 and DSS mice treated with SG-15. The scoring system
used was: (0)=no gross pathology, (1)=streaks of blood visible in
feces, (2)=completely bloody fecal pellets, (3) bloody fecal
material visible in cecum, (4) bloody fecal material in cecum and
loose stool, (5)=rectal bleeding. Results are shown in FIG. 7, with
the graph representing data pooled from the 2 individual
experiments (n=20).
[0317] I. Effects of SG-15 on the Colon Length in a DSS Model of
Inflammatory Bowel Disease
[0318] The following experiment demonstrates the effects of SG-15
on colon shortening to treat in an in vivo model of inflammatory
bowel disease.
[0319] Colon length was measured in mice included in the DSS model
described in Example 1E. SG-15 administration to DSS treated mice
reduced colon shortening elicited by DSS treatment. An improvement
in colon length was observed with Gly2-GLP2 as a positive control.
Results are shown in FIG. 8. The graph in FIG. 8 represents data
pooled from the 2 individual experiments (n=20).
[0320] J. Effects of SG-15 on Colon Weight to Length Ratio in a DSS
Model of Inflammatory Bowel Disease
[0321] The following experiment demonstrates the effects of SG-15
as disclosed herein on changes in colon weight to length ratio
induced by DSS treatment.
[0322] Colon length and weight were measured in mice included in
the DSS model study described in Example 1E. DSS-treated mice
administered vehicle only resulted in colon shortening (see Example
10, which in combination with increased tissue weight due to edema
results in an increase in the tissue to weight ratio. Accordingly,
the ratio of tissue weight to length can be used as a readout of
DSS induced tissue damage. SG-15 administration to DSS treated mice
(Example 1E) reduced the colon weight to length ratio elicited by
DSS (DSS=3.9 mg/mm, DSS+SG-15=3.5 mg/mm; p=0.13). A reduction in
colon weight to length ratio was also observed with Gly2-GLP2.
However, no difference was observed between treated with SG-15 as
compared to treatment with Gly2GLP2. Results are shown in FIG. 9.
The graph in FIG. 9 represents data pooled from the 2 individual
experiments (n=20).
Example 2. SG-16
[0323] A. Expression of SG-16
[0324] For experiments described in the examples below, a
polynucleotide comprising a sequence encoding residues 1-119 of SEQ
ID NO:9 (SG-16) was obtained by PCR amplification of genomic DNA
obtained from Eubacterium eligens (C15-B4; DSM 3376 type strain),
cloned into the pGEX-6-P1 vectors, expressed in E. coli transformed
with the resultant vector construct, cleaved, and purified as
described above in Example 1A. Purified protein was quantified by
densitometry using bovine serum albumin as a reference following
SDS-PAGE and Coomassie Brilliant Blue staining. Endotoxin levels
were measured with Endosafe.RTM. nexgen-MCS.TM. (Charles River,
Wilmington, Mass.) according to the manufacturer's instructions.
Endotoxin levels of proteins used for the assays described herein
were lower than 1 EU/mg.
[0325] B. Effect of SG-16 on Restoration of Epithelial Barrier
Integrity Following Inflammation Induced Disruption
[0326] The following experiment assesses the effects of an SG-16
protein as disclosed herein to restore gastrointestinal epithelial
barrier integrity in vitro. Assays were performed and data were
analyzed as described in Example 1B above to measure the effect of
SG-16 on epithelial barrier function, muc2 gene expression, wound
healing, and production of cytokines.
[0327] As described in Example 1B, a TEER assay was performed to
study the effects of an SG protein on an in vitro intestinal
epithelial barrier system which was challenged with heat killed E.
coli (HK E. coli). SG-16 protein was added 30 minutes (FIG. 10A) or
6 hours (FIG. 10B) prior to exposure of both epithelial cells and
monocytes to heat killed Escherichia coli (HK E. coli), inducing
monocytes to produce inflammatory mediators resulting in disruption
of the epithelial monolayer as indicated by a reduction in TEER. In
FIG. 10A, TEER of epithelial cell barrier increased from 55.8% only
when epithelial cells were exposed to heat killed E. coli to 60.7%
when incubating epithelial cells with SG-16 for 30 minutes before
exposing to HK E. coli (p=0.49). In FIG. 10B, epithelial cells
pre-incubated with SG-16 for 6 hours before HK E. coli exposure
showed an increase to about 60.0% in TEER from about 53.5% without
SG-16 treatment (p=0.46). The graphs in FIGS. 10A-10B represent
data pooled from 3 individual experiments (n=9).
[0328] C. Effect of SG-16 on TNF-.alpha., IL-23, and IL-10
Production by Heat Killed Escherichia coli
[0329] The following experiment demonstrates the therapeutic
ability of an SG-16 protein as disclosed herein to affect immune
activation as measured by cytokine production. Effects of SG-16 on
cytokine production in a TEER assay were assessed using the
materials and methods detailed in Example 1C above.
[0330] Production of the cytokines TNF-.alpha., IL-23, and IL-10 by
monocytes was measured in the tissue culture supernatant from the
basolateral chamber of the co-culture TEER assay performed in
Example 2B.
[0331] TNF-.alpha., IL-23, and IL-10 production in untreated cells
and cells pre-incubated with SG-16 for 6 hours prior to HK E. coli
treatment was normalized to pg/ml concentrations elicited by HK E.
coli only, which was set to 1.0. Pre-incubation with SG-16
significantly increased TNF-.alpha. production to 1.29 (p=0.01).
Results are shown in FIG. 11A. Pre-incubation with SG-16 increased
IL-23 production slightly to 1.06 (p=0.64). Results are shown in
FIG. 11B. Pre-incubation with SG-16 significantly increased IL-10
production to 1.23 (p=0.04). Results are shown in FIG. 11C. The
graphs in FIGS. 11A, 11B and 11C each represent data pooled from 3
individual experiments (n=9).
[0332] D. Effects of SG-16 on Mucin Expression Following
Stimulation with Heat Killed Escherichia coli
[0333] The following experiment measures effects of an SG-16
protein as disclosed herein to increase mucin expression in
gastrointestinal tissue. The experiment is therefore a
demonstration of the functional utility of the therapeutic protein
SG-16 to treat a gastrointestinal inflammatory disease, or disease
involving impaired epithelial barrier integrity/function, where
increased mucin expression would be beneficial.
[0334] Muc2 gene expression was measured in the epithelial cell
monolayer from the apical chamber of the co-culture TEER assay
described in Example 2B. Total RNA was isolated from the epithelial
cell monolayer, cDNA was synthesized. qRT-PCR was performed on cDNA
generated from the HCT8 & HT29-MTX cells treated with SG-16 (1
.mu.g/ml; 40 nM) for 6 hours prior to addition of HK E. coli for 24
hours. muc2 gene expression is graphed as mean fold change .+-.SEM.
Statistical analysis was performed by a one-way ANOVA compared to
HK E. coli and a Fishers LSD test was used for multiple
comparisons.
[0335] Analysis of muc2 gene expression revealed that no change in
muc2 gene expression was observed in the epithelial cell monolayer
with SG-16 pre-treatment for 6 hours prior to HK E. coli
stimulation, compared to the epithelial cell monolayer stimulated
by HK E. coli without SG-16 pre-treatment (p=0.72). Results are
shown in FIG. 12 with the graph representing data pooled from a
single experiment (n=3).
[0336] E. Effects of SG-16 on Epithelial Cell Wound Healing
[0337] The following experiment demonstrates the therapeutic
ability of SG-16 as disclosed herein to increase gastrointestinal
epithelial cell wound healing. This experiment was performed as
described in Example 1D in which HCT8 enterocytes and HT29-MTX
goblet cells were used for the in vitro wound healing assay. Sample
wells contained SG-16 protein at a concentration of 1 .mu.g/ml
diluted in cRPMI. Treatments were added to cells and incubated at
37.degree. C. +5% CO.sub.2 for 48 hours. Samples were normalized
between 100% and 0% samples and values expressed as a percent
growth.
[0338] As shown in FIG. 13, a significant increase in growth was
observed with SG-16. In addition, control compounds (EGF and
staurosporine) modulated wound healing as expected with EGF
increasing proliferation, and staurosporine suppressing cell
proliferation. Results are shown in FIG. 13, wherein the graph
represents data from a single experiment (n=3).
[0339] F. SG-16 Demonstrates Therapeutic Activity in a DSS Model of
Inflammatory Bowel Disease
[0340] Example 2F demonstrates activity of an SG-16 protein as
disclosed herein for the treatment of inflammatory bowel disease in
an in vivo model. Specifically, the mice in Example 2F were treated
with dextran sodium sulfate (DSS) according to the materials and
methods described in detail in Example 1E above. In Example 2F,
mice were treated with SG-16 protein approximately concurrent with
(6 hours prior to) administration of DSS. In summary, 6 hours after
the initial treatment with SG-16 the drinking water was changed to
water containing 2.5% DSS. The mice were treated with 2.5% dextran
sodium sulfate (DSS) in their drinking water for 6 days. Treatments
were continued with SG-16 or Gly2-GLP2 b.i.d. in the morning and
evening (every 8 and 16 hr) with i.p. injections at 50 nmoles/kg.
Fresh 2.5% DSS drinking water was prepared every 2 days. The mice
were then assessed for effects of SG-16 on clinically relevant
markers of improved health.
[0341] On day 6, mice were fasted for 4 hours and then orally
gavaged with 600 mg/kg 4KDa dextran labeled with fluorescein
isothiocyanate (FITC) [4KDa-FITC]. One hour after the 4KDa-FITC
gavage mice were euthanized, blood was collected and FITC signal
was measured in serum. A significant increase in 4KDa-FITC dextran
translocation across the epithelial barrier was observed in vehicle
treated DSS mice in comparison to untreated mice. Additionally, a
significant reduction in 4KDa-FITC dextran was observed in mice
receiving DSS and treated with SG-16, as compared to DSS mice
treated with vehicle. Results are shown in FIG. 14, and are
presented as mean.+-.SEM. The graph in FIG. 14 represents data from
an individual experiment (n=10).
[0342] G. Effects of SG-16 on Inflammation Readouts Responsive to
Impaired Barrier Function in a Concurrent DSS Model of Inflammatory
Bowel Disease
[0343] SG-16 was also assessed for its effects on the levels of LPS
binding protein (LBP) in the blood of the DSS animals with and
without SG-16 administration, following the materials and methods
detailed in Example 1F above.
[0344] LBP was measured by ELISA in the serum of mice tested in the
DSS model described in Example 2F. A significant increase in LBP
concentration was observed in vehicle-treated DSS mice, as compared
to untreated mice. No change in LBP was observed in SG-16 treated
mice given DSS as compared to DSS mice treated with vehicle.
Results are shown in FIG. 15 and are presented as mean.+-.SEM. The
graph in FIG. 15 represents data from an individual experiment
(n=10).
[0345] H. Effects of SG-16 on Weight Loss in a Concurrent DSS Model
of Inflammatory Bowel Disease
[0346] Also assessed was the therapeutic ability of an SG-16
protein as disclosed herein to ameliorate weight loss in an animal
suffering from an inflammatory intestinal disorder, using materials
and methods detailed in Example 1G above.
[0347] Body weight was measured daily from mice included in the DSS
model described in Example 2F. Percent change from starting weight
on day 0 was determined for each mouse. SG-16 administration to
DSS-treated mice significantly improved body weight compared to
vehicle-treated DSS mice. SG-16 administration to DSS treated mice
did not alter body weight as compared to vehicle treated DSS mice.
Results are shown in FIG. 16, with the graph representing data from
an individual experiment (n=10).
[0348] I. Effects of SG-16 on Gross Pathology in a DSS Model of
Inflammatory Bowel Disease
[0349] Gross pathology observations were made in mice included in
the concurrent DSS model performed in Example 2F, using the scoring
system described in Example 1H above. SG-16 administration to DSS
treated mice did not reduce gross pathology as compared to vehicle
treated DSS mice. Results are shown in FIG. 17, with the graph
representing data pooled from an individual experiment (n=10).
[0350] J. Effects of SG-16 on the Colon Length in a DSS Model of
Inflammatory Bowel Disease
[0351] The following experiment demonstrates the effects of SG-16
on colon shortening to treat in an in vivo model of inflammatory
bowel disease.
[0352] Colon length was measured in mice included in the DSS model
described in Example 2F. SG-16 administration to DSS treated mice
slightly improved colon shortening elicited by DSS treatment. A
significant improvement in colon length was observed with Gly2-GLP2
as a positive control and Gly2-GLP2 treatment had a significant
improvement over SG-16. Results are shown in FIG. 18, with the
graph representing data from an individual experiment (n=10).
[0353] K. Effects of SG-16 on Colon Weight to Length Ratio in a DSS
Model of Inflammatory Bowel Disease
[0354] The following experiment demonstrates the effects of SG-16
as disclosed herein on changes in colon weight to length ratio
induced by DSS treatment.
[0355] Colon length and weight were measured in mice included in
the DSS model study described in Example 2F. SG-16 administration
to DSS treated mice did not alter the colon weight to length ratio
elicited by DSS (DSS+vehicle=4.2 and DSS+SG-16=4.1; p=0.48).
Results are shown in FIG. 19, with the graph representing data from
an individual experiment (n=10).
Example 3. SG-17
[0356] A. Expression of SG-17
[0357] For experiments described in the examples below, a
polynucleotide comprising a sequence encoding residues 1-327 of SEQ
ID NO:13 (SG-17) was obtained by PCR amplification of genomic DNA
obtained from Eubacterium eligens (C15-B4; DSM 3376 type strain),
cloned into the pGEX-6-P1 vectors, expressed in E. coli transformed
with the resultant vector construct, cleaved, and purified as
described above in Example 1A. Purified protein was quantified by
densitometry using bovine serum albumin as a reference following
SDS-PAGE and Coomassie Brilliant Blue staining. Endotoxin levels
were measured with Endosafe.RTM. nexgen-MCS.TM. (Charles River,
Wilmington, Mass.) according to the manufacturer's instructions.
Endotoxin levels of proteins used for the assays described herein
were lower than 1 EU/mg.
[0358] B. Effect of SG-17 on Restoration of Epithelial Barrier
Integrity Following Inflammation Induced Disruption
[0359] The following experiment assesses the effects of an SG-17
protein as disclosed herein to restore gastrointestinal epithelial
barrier integrity in vitro. Assays were performed and data were
analyzed as described in Example 1B above to measure the effect of
SG-17 on epithelial barrier function, muc2 gene expression, wound
healing, and production of cytokines.
[0360] As described in Example 1B, a TEER assay was performed to
study the effects of an SG protein on an in vitro intestinal
epithelial barrier system which was challenged with heat killed E.
coli (HK E. coli). SG-17 protein was added 30 minutes (FIG. 20A) or
6 hours (FIG. 20B) prior to exposure of both epithelial cells and
monocytes to heat killed Escherichia coli (HK E. coli), inducing
monocytes to produce inflammatory mediators resulting in disruption
of the epithelial monolayer as indicated by a reduction in TEER. In
FIG. 20A, TEER of epithelial cell barrier increased from 69.6% only
when epithelial cells were exposed to HK E. coli to 72.0% when
incubating epithelial cells with SG-17 for 30 minutes before
exposing to HK E. coli (p=0.20). In FIG. 20B, epithelial cells
pre-incubated with SG-17 for 6 hours before HK E. coli exposure
showed an increase to about 74.2% in TEER from about 68.6% without
SG-17 treatment (p=0.57). The graphs in FIGS. 20A-20B represent
data pooled from 2 individual experiments (n=6).
[0361] C. Effect of SG-17 on TNF-.alpha., IL-23, and IL-10
Production by Heat Killed Escherichia coli
[0362] The following experiment demonstrates the therapeutic
ability of an SG-17 protein as disclosed herein to affect immune
activation as measured by cytokine production. Effects of SG-17 on
cytokine production in a TEER assay were assessed using the
materials and methods detailed in Example 1C above.
[0363] Production of the cytokines TNF-.alpha., IL-23, and IL-10 by
monocytes was measured in the tissue culture supernatant from the
basolateral chamber of the co-culture TEER assay performed in
Example 3B.
[0364] TNF-.alpha., IL-23, and IL-10 production in untreated cells
and cells pre-incubated with SG-17 for 6 hours prior to HK E. coli
treatment was normalized to pg/ml concentrations elicited by HK E.
coli only, which was set to 1.0. Pre-incubation with SG-17
significantly reduced TNF-.alpha. production to 0.73 (p=0.04).
Results are shown in FIG. 21A. Pre-incubation with SG-17 increased
IL-23 production to 1.10 (p=0.25). Results are shown in FIG. 21B.
Pre-incubation with SG-17 significantly reduced IL-10 production to
0.51 (p=0.005). Results are shown in FIG. 21C. The graphs in FIGS.
21A, 21B and 21C each represent data from an individual experiment
(n=3).
[0365] D. Effects of SG-17 on Mucin Expression Following
Stimulation with Heat Killed Escherichia coli
[0366] The following experiment measures effects of an SG-17
protein as disclosed herein to increase mucin expression in
gastrointestinal tissue. The experiment is therefore a
demonstration of the functional utility of the therapeutic protein
SG-17 to treat a gastrointestinal inflammatory disease, or disease
involving impaired epithelial barrier integrity/function, where
increased mucin expression would be beneficial.
[0367] Muc2 gene expression was measured in the epithelial cell
monolayer from the apical chamber of the co-culture TEER assay
described in Example 3B, following the materials and methods
detailed in Example 2D. Total RNA was isolated from the epithelial
cell monolayer, cDNA was synthesized. qRT-PCR was performed on cDNA
generated from the HCT8 & HT29-MTX cells treated with SG-17 (1
.mu.g/ml; 40 nM) for 6 hours prior to addition of HK E. coli for 24
hours. muc2 gene expression is graphed as mean fold change .+-.SEM.
Statistical analysis was performed by a one-way ANOVA compared to
HK E. coli and a Fishers LSD test was used for multiple
comparisons.
[0368] A decrease in muc2 gene expression was observed in the
epithelial cell monolayer with SG-17 pre-treatment pre-treatment
for 6 hours prior to HK E. coli stimulation, compared to the
epithelial cell monolayer stimulated by HK E. coli without SG-17
pre-treatment (p=0.59). Results are shown in FIG. 22 with the graph
representing data pooled from 2 independent experiments (n=3).
[0369] E. Effects of SG-17 on Epithelial Cell Wound Healing
[0370] The following experiment demonstrates the therapeutic
ability of SG-17 as disclosed herein to increase gastrointestinal
epithelial cell wound healing. This experiment was performed as
described in Example 1D in which HCT8 enterocytes and HT29-MTX
goblet cells were used for the in vitro wound healing assay. Sample
wells contained SG-17 protein at a concentration of 1 .mu.g/ml
diluted in cRPMI. Treatments were added to cells and incubated at
37.degree. C. +5% CO.sub.2 for 48 hours. Samples were normalized
between 100% and 0% samples and values expressed as a percent
growth.
[0371] As shown in FIG. 23, a significant increase in growth was
observed with SG-17. In addition, control compounds (EGF and
staurosporine) modulated wound healing as expected with EGF
increasing proliferation, and staurosporine suppressing cell
proliferation. Results are shown in FIG. 23, with the graph
representing data from 4 replicate experiments (n=18).
[0372] F. Effect of SG-17 on Epithelial Centric Barrier Function
Readouts in a DSS Model of Inflammatory Bowel Disease
[0373] Example 3F demonstrates activity of an SG-17 protein as
disclosed herein for the treatment of inflammatory bowel disease in
an in vivo model. Specifically, the mice in Example 3F were treated
with dextran sodium sulfate (DSS) according to the materials and
methods described in detail in Example 1E above. In Example 3F,
mice were treated with SG-17 protein approximately concurrent with
(6 hours prior to) administration of DSS. In summary, 6 hours after
the initial treatment with SG-17 the drinking water was changed to
water containing 2.5% DSS. The mice were treated with 2.5% dextran
sodium sulfate (DSS) in their drinking water for 6 days. Treatments
were continued with SG-17 or Gly2-GLP2 b.i.d. in the morning and
evening (every 8 and 16 hr) with i.p. injections at 50 nmoles/kg.
Fresh 2.5% DSS drinking water was prepared every 2 days. The mice
were then assessed for effects of SG-17 on clinically relevant
markers of improved health.
[0374] On day 6, mice were fasted for 4 hours and then orally
gavaged with 600 mg/kg 4KDa dextran labeled with fluorescein
isothiocyanate (FITC) [4KDa-FITC]. One hour after the 4KDa-FITC
gavage mice were euthanized, blood was collected and FITC signal
was measured in serum. A significant increase in 4KDa-FITC dextran
translocation across the epithelial barrier was observed in vehicle
treated DSS mice in comparison to untreated mice. 4KDa-FITC dextran
was not altered in mice receiving DSS and treated with SG-17, as
compared to DSS mice treated with vehicle. Results are shown in
FIG. 24, and are presented as mean.+-.SEM. The graph in FIG. 24
represents data from an individual experiment (n=10).
[0375] G. Effects of SG-17 on Inflammation Readouts Responsive to
Impaired Barrier Function in a Concurrent DSS Model of Inflammatory
Bowel Disease
[0376] SG-17 was also assessed for its effects on the levels of LPS
binding protein (LBP) in the blood of the DSS animals with and
without SG-17 administration, following the materials and methods
detailed in Example 1F above.
[0377] LBP was measured by ELISA in the serum of mice tested in the
DSS model described in Example 3F. A significant increase in LBP
concentration was observed in vehicle-treated DSS mice, as compared
to untreated mice. Additionally, a significant reduction in LBP was
observed in SG-17 treated mice given DSS as compared to DSS mice
treated with vehicle. Furthermore, SG-17 had a greater impact on
LBP concentration as compared to the control peptide Gly2-GLP2.
Results are shown in FIG. 25 and are presented as mean.+-.SEM. The
graph in FIG. 25 represents data from an individual experiment
(n=10).
[0378] H. Effects of SG-17 on Weight Loss in a Concurrent DSS Model
of Inflammatory Bowel Disease
[0379] Also assessed was the therapeutic ability of an SG-17
protein as disclosed herein to ameliorate weight loss in an animal
suffering from an inflammatory intestinal disorder, using materials
and methods detailed in Example 1G above.
[0380] Body weight was measured daily from mice included in the DSS
model described in Example 3F. Percent change from starting weight
on day 0 was determined for each mouse. SG-17 administration to
DSS-treated mice did not alter body weight as compared to vehicle
treated DSS mice. Results are shown in FIG. 26, with the graph
representing data from an individual experiment (n=10).
[0381] I. Effects of SG-17 on Gross Pathology in a DSS Model of
Inflammatory Bowel Disease
[0382] Gross pathology observations were made in mice included in
the concurrent DSS model performed in Example 3F, using the scoring
system described in Example 1H above. SG-17 administration to DSS
treated mice did not reduce gross pathology as compared to vehicle
treated DSS mice. Results are shown in FIG. 27, with the graph
representing data pooled from an individual experiment (n=10).
[0383] J. Effects of SG-17 on the Colon Length in a DSS Model of
Inflammatory Bowel Disease
[0384] The following experiment demonstrates the effects of SG-17
on colon shortening to treat in an in vivo model of inflammatory
bowel disease.
[0385] Colon length was measured in mice included in the DSS model
described in Example 3F. SG-17 administration to DSS treated mice
did not reduce colon shortening elicited by DSS treatment. A
significant improvement in colon length was observed with Gly2-GLP2
as a positive control and Gly2-GLP2 treatment had a significant
improvement over SG-17. Results are shown in FIG. 28, with the
graph representing data from an individual experiment (n=10).
[0386] K. Effects of SG-17 on Colon Weight to Length Ratio in a DSS
Model of Inflammatory Bowel Disease
[0387] The following experiment demonstrates the effects of SG-17
as disclosed herein on changes in colon weight to length ratio
induced by DSS treatment.
[0388] Colon length and weight were measured in mice included in
the DSS model study described in Example 3F. SG-17 administration
to DSS treated mice did not alter the colon weight to length ratio
elicited by DSS (DSS+vehicle=3.02 and DSS+SG-17=3.14; p=0.59).
Results are shown in FIG. 29, with the graph representing data from
an individual experiment (n=10).
Example 4. SG-18
[0389] A. Expression of SG-18
[0390] For experiments described in the examples below, a
polynucleotide comprising a sequence encoding residues 1-267 of SEQ
ID NO:19 (SG-18) was obtained by PCR amplification of genomic DNA
obtained from Clostridium bartlettii (ATCC.RTM. BAA-827.TM. Type
Strain; also designated 16795 per DSMZ), cloned into the pGEX-6-P1
vectors, expressed in E. coli transformed with the resultant vector
construct, cleaved, and purified as described above in Example 1A.
Purified protein was quantified by densitometry using bovine serum
albumin as a reference following SDS-PAGE and Coomassie Brilliant
Blue staining. Endotoxin levels were measured with Endosafe.RTM.
nexgen-MCS.TM. (Charles River, Wilmington, Mass.) according to the
manufacturer's instructions. Endotoxin levels of proteins used for
the assays described herein were lower than 1 EU/mg.
[0391] B. Effect of SG-18 on Restoration of Epithelial Barrier
Integrity Following Inflammation Induced Disruption
[0392] The following experiment assesses the effects of an SG-18
protein as disclosed herein to restore gastrointestinal epithelial
barrier integrity in vitro. Assays were performed and data were
analyzed as described in Example 1B above to measure the effect of
SG-18 on epithelial barrier function, wound healing, and production
of cytokines.
[0393] As described in Example 1B, a TEER assay was performed to
study the effects of an SG protein on an in vitro intestinal
epithelial barrier system which was challenged with heat killed E.
coli (HK E. coli). SG-18 protein was added 30 minutes (FIG. 30A) or
6 hours (FIG. 30B) prior to exposure of both epithelial cells and
monocytes to heat killed Escherichia coli (HK E. coli), inducing
monocytes to produce inflammatory mediators resulting in disruption
of the epithelial monolayer as indicated by a reduction in TEER. In
FIG. 30A, TEER of epithelial cell barrier increased from 63.6% only
when epithelial cells were exposed to HK E. coli to 71.0% when
incubating epithelial cells with SG-18 for 30 minutes before
exposing to HK E. coli (p=0.06). In FIG. 30B, epithelial cells
pre-incubated with SG-18 for 6 hours before HK E. coli exposure
showed an increase to about 85.0% in TEER from about 68.6% without
SG-18 treatment (p=0.0002). The graphs in FIGS. 30A-30B represent
data pooled from 2 individual experiments (n=6).
[0394] C. Effect of SG-18 on TNF-.alpha., IL-23, and IL-10
Production by Heat Killed Escherichia coli
[0395] The following experiment demonstrates the therapeutic
ability of an SG-18 protein as disclosed herein to affect immune
activation as measured by cytokine production. Effects of SG-18 on
cytokine production in a TEER assay were assessed using the
materials and methods detailed in Example 1C above.
[0396] Production of the cytokines TNF-.alpha., IL-23, and IL-10 by
monocytes was measured in the tissue culture supernatant from the
basolateral chamber of the co-culture TEER assay performed in
Example 4B.
[0397] TNF-.alpha., IL-23, and IL-10 production in untreated cells
and cells pre-incubated with SG-18 for 6 hours prior to HK E. coli
treatment was normalized to pg/ml concentrations elicited by HK E.
coli only, which was set to 1.0. Pre-incubation with SG-18
increased TNF-.alpha. production to 1.06 (p=0.36). Results are
shown in FIG. 31A. Pre-incubation with SG-18 increased IL-23
production to 1.10 (p=0.34). Results are shown in FIG. 31B.
Pre-incubation with SG-18 reduced IL-10 production slightly to 0.93
(p=0.65). Results are shown in FIG. 31C. The graphs in FIGS. 31A,
31B and 31C each represent data from 2 individual experiments
(n=6).
[0398] D. Effects of SG-18 on Epithelial Cell Wound Healing
[0399] The following experiment demonstrates the therapeutic
ability of SG-18 as disclosed herein to increase gastrointestinal
epithelial cell wound healing. This experiment was performed as
described in Example 1D in which HCT8 enterocytes and HT29-MTX
goblet cells were used for the in vitro wound healing assay. Sample
wells contained SG-18 protein at a concentration of 1 ng/ml diluted
in cRPMI. Treatments were added to cells and incubated at
37.degree. C. +5% CO.sub.2 for 48 hours. Samples were normalized
between 100% and 0% samples and values expressed as a percent
growth.
[0400] As shown in FIG. 32, a slight increase in growth was
observed with SG-18 (p=0.68). In addition, control compounds (EGF
and staurosporine) modulated wound healing as expected with EGF
increasing proliferation, and staurosporine suppressing cell
proliferation. Results shown in FIG. 32 represent data pooled from
4 replicate experiments (n=18).
[0401] E. SG-18 Demonstrates Therapeutic Activity in a DSS Model of
Inflammatory Bowel Disease
[0402] Example 4E demonstrates activity of an SG-18 protein as
disclosed herein for the treatment of inflammatory bowel disease in
an in vivo model. Specifically, the mice in Example 4E were treated
with dextran sodium sulfate (DSS) according to the materials and
methods described in detail in Example 1E above. In Example 4E,
mice were treated with SG-18 protein approximately concurrent with
(6 hours prior to) administration of DSS. In summary, 6 hours after
the initial treatment with SG-18 the drinking water was changed to
water containing 2.5% DSS. The mice were treated with 2.5% dextran
sodium sulfate (DSS) in their drinking water for 6 days. Treatments
were continued with SG-18 or Gly2-GLP2 b.i.d. in the morning and
evening (every 8 and 16 hr) with i.p. injections at 50 nmoles/kg.
Fresh 2.5% DSS drinking water was prepared every 2 days. The mice
were then assessed for effects of SG-18 on clinically relevant
markers of improved health.
[0403] On day 6, mice were fasted for 4 hours and then orally
gavaged with 600 mg/kg 4KDa dextran labeled with fluorescein
isothiocyanate (FITC) [4KDa-FITC]. One hour after the 4KDa-FITC
gavage mice were euthanized, blood was collected and FITC signal
was measured in serum. A significant increase in 4KDa-FITC dextran
translocation across the epithelial barrier was observed in vehicle
treated DSS mice in comparison to untreated mice. Additionally, a
significant reduction in 4KDa-FITC dextran was observed in mice
receiving DSS and treated with SG-18, as compared to DSS mice
treated with vehicle. The magnitude of 4KDa-FITC dextran
translocation observed for SG-18 was even lower than the positive
control, Gly2-GLP2, which is known for enhancing intestinal
epithelial barrier function. Results are shown in FIG. 33, and are
presented as mean.+-.SEM. The graph in FIG. 33 represents data
pooled from 2 individual experiments (n=20).
[0404] F. Effects of SG-18 on Inflammation Readouts Responsive to
Impaired Barrier Function in a Concurrent DSS Model of Inflammatory
Bowel Disease
[0405] SG-18 was also assessed for its effects on the levels of LPS
binding protein (LBP) in the blood of the DSS animals with and
without SG-18 administration, following the materials and methods
detailed in Example 1F above.
[0406] LBP was measured by ELISA in the serum of mice tested in the
DSS model described in Example 4E. A significant increase in LBP
concentration was observed in vehicle-treated DSS mice, as compared
to untreated mice. Similar levels in LBP were observed in SG-18
treated mice given DSS as compared to DSS mice treated with
vehicle. Results are shown in FIG. 34 and are presented as
mean.+-.SEM. The graph in FIG. 34 represents data pooled from 2
individual experiments (n=20).
[0407] G. Effects of SG-18 on Weight Loss in a Concurrent DSS Model
of Inflammatory Bowel Disease
[0408] Also assessed was the therapeutic ability of an SG-18
protein as disclosed herein to ameliorate weight loss in an animal
suffering from an inflammatory intestinal disorder, using materials
and methods detailed in Example 1G above.
[0409] Body weight was measured daily from mice included in the DSS
model described in Example 4E. Percent change from starting weight
on day 0 was determined for each mouse. SG-18 administration to
DSS-treated mice did not alter body weight as compared to vehicle
treated DSS mice. Results are shown in FIG. 35, with the graph
representing data pooled from 2 individual experiments (n=20).
[0410] H. Effects of SG-18 on Gross Pathology in a DSS Model of
Inflammatory Bowel Disease
[0411] Gross pathology observations were made in mice included in
the concurrent DSS model performed in Example 4E, using the scoring
system described in Example 1H above. SG-18 administration to DSS
treated mice did not reduce gross pathology as compared to vehicle
treated DSS mice. Results are shown in FIG. 36, with the graph
representing data pooled from 2 individual experiments (n=20).
[0412] I. Effects of SG-18 on the Colon Length in a DSS Model of
Inflammatory Bowel Disease
[0413] The following experiment demonstrates the effects of SG-18
on colon shortening to treat in an in vivo model of inflammatory
bowel disease.
[0414] Colon length was measured in mice included in the DSS model
described in Example 4E. SG-18 administration to DSS treated mice
did not reduce colon shortening elicited by DSS treatment. A
significant improvement in colon length was observed with Gly2-GLP2
as a positive control and Gly2-GLP2 treatment had a significant
improvement over SG-18. Results are shown in FIG. 37, with the
graph representing data pooled from 2 individual experiments
(n=20).
[0415] J. Effects of SG-18 on Colon Weight to Length Ratio in a DSS
Model of Inflammatory Bowel Disease
[0416] The following experiment demonstrates the effects of SG-18
as disclosed herein on changes in colon weight to length ratio
induced by DSS treatment.
[0417] Colon length and weight were measured in mice included in
the DSS model study described in Example 4E. SG-18 administration
to DSS treated mice reduced the colon weight to length ratio
elicited by DSS (DSS+vehicle=3.9 and DSS+SG-18=3.3; p=0.01). A
significant reduction in colon weight to length ratio was also
observed with Gly2-GLP2 (p=0.007). SG-18 treatment reduced the
colon weight to length ratio to a similar degree as observed for
the positive control Gly2-GLP2 treatment. Results are shown in FIG.
38, with the graph representing data pooled from two individual
experiments (n=20).
[0418] Table 2 describes SEQ ID NOs of the present disclosure with
detailed information.
TABLE-US-00002 TABLE 2 SEQ ID NO Type Description SG-15 1 PRT SG-15
protein sequence 2 DNA coding sequence (cds) for SEQ ID NO: 1 3 PRT
SG-15 protein sequence with "start methionine" 4 DNA cds for SEQ ID
NO: 3 5 PRT GenBank ACR71387 protein sequence 6 DNA cds for SEQ ID
NO: 5 7 PRT GenBank WP_041687898 protein sequence 8 DNA cds for SEQ
ID NO: 7 SG-16 9 PRT SG-16 protein sequence 10 DNA cds for SEQ ID
NO: 9 11 PRT GenBank WP_012738427 protein sequence 12 DNA cds for
SEQ ID NO: 11 SG-17 13 PRT SG-17 protein sequence 14 DNA cds for
SEQ ID NO: 13 15 PRT SG-17 protein sequence with "start methionine"
16 DNA cds for SEQ ID NO: 15 17 PRT GenBank WP_012740767 protein
sequence 18 DNA cds for SEQ ID NO: 17 SG-18 19 PRT SG-18 protein
sequence 20 DNA cds for SEQ ID NO: 19 21 PRT SG-18 protein sequence
with "start methionine" 22 DNA cds for SEQ ID NO: 21 23 PRT GenBank
SKA51491 protein sequence 24 DNA cds for SEQ ID NO: 23 25 PRT
GenBank WP_007286875 protein sequence 26 DNA cds for SEQ ID NO:
25
Numbered Embodiments of the Disclosure
[0419] Notwithstanding the appended claims, the disclosure sets
forth the following numbered embodiments:
Methods of Treatment
[0420] 1. A method of treating a gastrointestinal epithelial cell
barrier function disorder, comprising: [0421] a. administering to a
patient in need thereof a pharmaceutical composition, comprising:
[0422] i. a therapeutic protein comprising an amino acid sequence
having at least about 85% sequence identity to SEQ ID NO: 1, SEQ ID
NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID
NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ
ID NO:23, or SEQ ID NO:25; and [0423] ii. a pharmaceutically
acceptable carrier. [0424] 2. The method of embodiment 1, wherein
the gastrointestinal epithelial cell barrier function disorder is a
disease associated with decreased gastrointestinal wall integrity.
[0425] 3. The method of any one of embodiments 1-2, wherein the
gastrointestinal epithelial cell barrier function disorder is a
disease associated with decreased gastrointestinal mucosal
epithelium integrity. [0426] 4. The method of any one of
embodiments 1-3, wherein the gastrointestinal epithelial cell
barrier function disorder is a disease associated with decreased
intestinal epithelium integrity. [0427] 5. The method of any one of
embodiments 1-4, wherein the gastrointestinal epithelial cell
barrier function disorder is at least one selected from the group
consisting of: inflammatory bowel disease, Crohn's disease,
ulcerative colitis, pouchitis, irritable bowel syndrome, enteric
infections, Clostridium difficile infections, metabolic diseases,
obesity, type 2 diabetes, non-alcoholic steatohepatitis,
non-alcoholic fatty liver disease, liver disorders, alcoholic
steatohepatitis, celiac disease, necrotizing enterocolitis, gastro
intestinal disorders, short bowel syndrome, GI mucositis,
chemotherapy induced mucositis, radiation induced mucositis, oral
mucositis, interstitial cystitis, neurological disorders, cognitive
disorders, Alzheimer's, Parkinson's, multiple sclerosis, autism,
chemotherapy associated steatohepatitis (CASH), and pediatric
versions of the aforementioned diseases. [0428] 6. The method of
any one of embodiments 1-5, wherein the gastrointestinal epithelial
cell barrier function disorder is inflammatory bowel disease.
[0429] 7. The method of any one of embodiments 1-6, wherein the
gastrointestinal epithelial cell barrier function disorder is
Crohn's disease. [0430] 8. The method of any one of embodiments
1-6, wherein the gastrointestinal epithelial cell barrier function
disorder is ulcerative colitis. [0431] 9. The method of any one of
embodiments 1-8, wherein the therapeutic protein comprises an amino
acid sequence having at least about 90% sequence identity to SEQ ID
NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0432] 10. The method of
any one of embodiments 1-9, wherein the therapeutic protein
comprises an amino acid sequence having at least about 95% sequence
identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7,
SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID
NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25.
[0433] 11. The method of any one of embodiments 1-10, wherein the
therapeutic protein comprises an amino acid sequence having at
least about 97% sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ
ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ
ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23,
or SEQ ID NO:25. [0434] 12. The method of any one of embodiments
1-11, wherein the therapeutic protein comprises an amino acid
sequence having at least about 98% sequence identity to SEQ ID NO:
1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0435] 13. The method of
any one of embodiments 1-12, wherein the therapeutic protein
comprises an amino acid sequence having at least about 99% sequence
identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7,
SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID
NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25.
[0436] 14. The method of any one of embodiments 1-13, wherein the
therapeutic protein comprises an amino acid sequence selected from
the group consisting of: SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5,
SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15,
SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID
NO:25. [0437] 15. The method of any one of embodiments 1-14,
wherein the therapeutic protein comprises the amino acid sequence
of SEQ ID NO:1. [0438] 16. The method of any one of embodiments
1-15, wherein administering comprises rectal, parenteral,
intravenous, topical, oral, dermal, transdermal, or subcutaneous
administration. [0439] 17. The method of any one of embodiments
1-16, wherein administering is to the: mouth, gastrointestinal
lumen, and/or intestines of the patient. [0440] 18. The method of
any one of embodiments 1-17, wherein the patient experiences a
reduction in at least one symptom associated with the
gastrointestinal epithelial cell barrier function disorder. [0441]
19. The method of any one of embodiments 1-18, wherein the patient
experiences a reduction in at least one symptom associated with the
gastrointestinal epithelial cell barrier function disorder selected
from the group consisting of: abdominal pain, blood in stool, pus
in stool, fever, weight loss, frequent diarrhea, fatigue, reduced
appetite, tenesmus, and rectal bleeding. [0442] 20. The method of
any one of embodiments 1-19, wherein administering reduces
gastrointestinal inflammation in the patient. [0443] 21. The method
of any one of embodiments 1-19, wherein administering increases the
production of mucin in intestinal tissue in the patient. [0444] 22.
The method of any one of embodiments 1-19, wherein administering
increases intestinal epithelium wound healing in the patient.
[0445] 23. The method of any one of embodiments 1-22, further
comprising: administering at least one second therapeutic agent to
the patient. [0446] 24. The method of any one of embodiments 1-22,
further comprising: administering at least one second therapeutic
agent to the patient, said second therapeutic agent selected from
the group consisting of: an anti-diarrheal, a 5-aminosalicylic acid
compound, an anti-inflammatory agent, an antibiotic, an antibody,
an anti-cytokine agent, an anti-inflammatory cytokine agent, a
steroid, a corticosteroid, and an immunosuppressant.
Expression Vectors
[0446] [0447] 1. An expression vector, comprising: a
polynucleotide, which encodes a protein comprising an amino acid
sequence having at least about 85% sequence identity to SEQ ID NO:
1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0448] 2. The expression
vector of embodiment 1, wherein the encoded protein comprises an
amino acid sequence having at least about 90% sequence identity to
SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9,
SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID
NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0449] 3. The
expression vector of any one of embodiments 1-2, wherein the
encoded protein comprises an amino acid sequence having at least
about 95% sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID
NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or
SEQ ID NO:25. [0450] 4. The expression vector of any one of
embodiments 1-3, wherein the encoded protein comprises an amino
acid sequence having at least about 97% sequence identity to SEQ ID
NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0451] 5. The expression
vector of any one of embodiments 1-4, wherein the encoded protein
comprises an amino acid sequence having at least about 98% sequence
identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7,
SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID
NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25.
[0452] 6. The expression vector of any one of embodiments 1-5,
wherein the encoded protein comprises an amino acid sequence having
at least about 99% sequence identity to SEQ ID NO: 1, SEQ ID NO:3,
SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13,
SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID
NO:23, or SEQ ID NO:25. [0453] 7. The expression vector of any one
of embodiments 1-6, wherein the encoded protein comprises an amino
acid sequence selected from the group consisting of SEQ ID NO: 1,
SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11,
SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID
NO:21, SEQ ID NO:23, and SEQ ID NO:25. [0454] 8. The expression
vector of any one of embodiments 1-7, wherein the encoded protein
comprises the amino acid sequence of SEQ ID NO:1.
Host Cells
[0454] [0455] 1. A host cell, comprising: an exogenous
polynucleotide which encodes a protein comprising an amino acid
sequence having at least about 85% sequence identity to SEQ ID NO:
1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0456] 2. The host cell of
embodiment 1, wherein the encoded protein comprises an amino acid
sequence having at least about 90% sequence identity to SEQ ID NO:
1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0457] 3. The host cell of
any one of embodiments 1-2, wherein the encoded protein comprises
an amino acid sequence having at least about 95% sequence identity
to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID
NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ
ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0458] 4.
The host cell of any one of embodiments 1-3, wherein the encoded
protein comprises an amino acid sequence having at least about 97%
sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID
NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID
NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25.
[0459] 5. The host cell of any one of embodiments 1-4, wherein the
encoded protein comprises an amino acid sequence having at least
about 98% sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID
NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or
SEQ ID NO:25. [0460] 6. The host cell of any one of embodiments
1-5, wherein the encoded protein comprises an amino acid sequence
having at least about 99% sequence identity to SEQ ID NO: 1, SEQ ID
NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID
NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ
ID NO:23, or SEQ ID NO:25. [0461] 7. The host cell of any one of
embodiments 1-6, wherein the encoded protein comprises an amino
acid sequence selected from the group consisting of SEQ ID NO: 1,
SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11,
SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID
NO:21, SEQ ID NO:23, and SEQ ID NO:25. [0462] 8. The host cell of
any one of embodiments 1-7, wherein the encoded protein comprises
the amino acid sequence of SEQ ID NO:1. [0463] 9. The host cell of
any one of embodiments 1-8, wherein the exogenous polynucleotide
further encodes a host cell specific signal sequence. [0464] 10.
The host cell of any one of embodiments 1-9, wherein the exogenous
polynucleotide comprises a nucleic acid sequence having at least
about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, or 100% sequence identity to a nucleic acid sequence
selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ
ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ
ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24,
or SEQ ID NO:26. [0465] 11. The host cell of any one of embodiments
1-10, wherein the host cell is a prokaryotic cell. [0466] 12. The
host cell of any one of embodiments 1-11, wherein the host cell is
an Escherichia coli cell. [0467] 13. The host cell of any one of
embodiments 1-10, wherein the host cell is a eukaryotic cell.
[0468] 14. The host cell of any one of embodiments 1-10 and 13,
wherein the host cell is a Chinese Hamster Ovary cell. [0469] 15. A
method of producing a protein, comprising: culturing the host cell
of any one of embodiments 1-14, under conditions sufficient for
expression of the encoded protein.
Isolated Proteins and Pharmaceutical Compositions Thereof
[0469] [0470] 1. An isolated protein, comprising: an amino acid
sequence having at least about 85% sequence identity to SEQ ID NO:
1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ
ID NO:21, SEQ ID NO:23, or SEQ ID NO:25. [0471] 2. The isolated
protein of embodiment 1, comprising: an amino acid sequence having
at least about 90% sequence identity to SEQ ID NO: 1, SEQ ID NO:3,
SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13,
SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID
NO:23, or SEQ ID NO:25. [0472] 3. The isolated protein of any one
of embodiments 1-2, comprising: an amino acid sequence having at
least about 95% sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ
ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ
ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23,
or SEQ ID NO:25. [0473] 4. The isolated protein of any one of
embodiments 1-3, comprising: an amino acid sequence having at least
about 97% sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID
NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or
SEQ ID NO:25. [0474] 5. The isolated protein of any one of
embodiments 1-4, comprising: an amino acid sequence having at least
about 98% sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID
NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or
SEQ ID NO:25. [0475] 6. The isolated protein of any one of
embodiments 1-5, comprising: an amino acid sequence having at least
about 99% sequence identity to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID
NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or
SEQ ID NO:25. [0476] 7. The isolated protein of any one of
embodiments 1-6, comprising: an amino acid sequence selected from
the group consisting of: SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5,
SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15,
SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID
NO:25. [0477] 8. The isolated protein of any one of embodiments
1-7, comprising: the amino acid sequence of SEQ ID NO:1. [0478] 9.
The isolated protein of any one of embodiments 1-8, wherein the
protein increases electrical resistance in an in vitro
transepithelial electrical resistance assay. [0479] 10. The
isolated protein of any one of embodiments 1-9, wherein the protein
increases electrical resistance in an in vitro transepithelial
electrical resistance assay by at least about 5%, 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99%, as compared to the assay
performed in the absence of the protein. [0480] 11. The isolated
protein of any one of embodiments 1-10, wherein the protein
increases electrical resistance in an in vitro transepithelial
electrical resistance assay, as compared to a control of a kinase
inhibitor. [0481] 12. The isolated protein of any one of
embodiments 1-11, wherein the protein increases electrical
resistance in an in vitro transepithelial electrical resistance
assay, as compared to a control of staurosporine or myosin light
chain kinase. [0482] 13. A pharmaceutical composition, comprising:
[0483] a. the isolated protein of any one of embodiments 1-12; and
[0484] b. a pharmaceutically acceptable carrier. [0485] 14. The
pharmaceutical composition of any one of embodiments 1-13, wherein
the protein comprises the amino acid sequence of SEQ ID NO:1.
[0486] 15. The pharmaceutical composition of any one of embodiments
1-14, formulated for rectal, parenteral, intravenous, topical,
oral, dermal, transdermal, or subcutaneous administration. [0487]
16. The pharmaceutical composition of any one of embodiments 1-15,
formulated such that the protein has activity in the
gastrointestinal lumen and/or intestines of the patient.
INCORPORATION BY REFERENCE
[0488] All references, articles, publications, patents, patent
publications, and patent applications cited herein are incorporated
by reference in their entireties for all purposes.
[0489] However, mention of any reference, article, publication,
patent, patent publication, and patent application cited herein is
not, and should not be taken as, an acknowledgment or any form of
suggestion that they constitute valid prior art or form part of the
common general knowledge in any country in the world.
REFERENCES
[0490] Molodecky et al. 2012, Increasing incidence and prevalence
of the inflammatory bowel diseases with time, based on systematic
review, Gastroenterology 142(1): 46-54. [0491] Aroniadis et al.,
2013, Fecal microbiota transplantation: past, present and future,
Curr. Opin. Gastroenterol. 29(1): 79-84. [0492] Maloy et al., 2011,
Intestinal homeostasis and its breakdown in inflammatory bowel
disease, Nature 474(7351): 298-306. [0493] Needleman et al., 1970,
A general method applicable to the search for similarities in the
amino acid sequence of two proteins J. Mol. Biol., 48(3): 444-453.
[0494] Myers et al., 1988, Optimal alignments in linear space,
CABIOS 4: 11-17. [0495] Altschul, et al., 1990, Basic local
alignment search tool, J. Mol. Biol. 215: 403-410. [0496] Altschul
et al., 1997, Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs, Nucleic Acids Res. 25(17):
3389-3402. [0497] Henikoff et al., 1992, Amino acid substitution
matrices from protein blocks, Proc. Natl. Acad. Sci. 89(22):
10915-10919. [0498] Karlin et al., 1993, Applications and
statistics for multiple high-scoring segments in molecular
sequences, Proc. Natl. Acad. Sci. 90: 5873-5877. [0499] Higgins et
al., 1988, CLUSTAL: a package for performing multiple sequence
alignment on a microcomputer, Gene 73: 237-244. [0500] Person et
al., 1988, Improved tools for biological sequence comparison, Proc.
Natl. Acad. Sci. 85: 2444-2448. [0501] Bowie et al., 1990,
Deciphering the message in protein sequences: tolerance to amino
acid substitutions, Science 247: 1306-1310. [0502] IUPAC Commission
on the Nomenclature of Organic Chemistry (CNOC) and IUPAC-IUB
Commission on Biochemical Nomenclature (CBN), 1975, Nomenclature of
.alpha.-Amino Acids, (Recommendations 1974), Biochemistry 14:
449-462. [0503] Remington's Pharmaceutical Sciences, 17th edition,
Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa.,
USA, 1985. [0504] Encyclopaedia of Pharmaceutical Technology, 3rd
edition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY,
USA, 2007. [0505] Berge et al., 1977, Pharmaceutical salts, J.
Pharm. Sci. 66: 1-19. [0506] Handbook of Pharmaceutical Salts:
Properties, Selection, and Use, Stahl and Wermuth, Wiley-VCH, 2002.
[0507] In re Bergstrom, 427 F.2d 1394, (CCPA 1970) [0508] In re
Bergy, 596 F.2d 952 (CCPA 1979) [0509] Parke-Davis & Co. v. H.
K. Mulford & Co., 189 F. 95 (S.D.N.Y. 1911) aff'd in part,
rev'd in part, 196 F. 496 (2d Cir. 1912) [0510] Merck & Co.,
Inc., v. Olin Mathieson Chemical Corporation, 253 F.2d 156 (4th
Cir. 1958) [0511] Horhota et al., 2006, Glycerol nucleoside
triphosphates: Synthesis and polymerase substrate activities,
Organic Letters 8: 5345-5347. [0512] Botoman et al., 1998,
Management of Inflammatory Bowel Disease, Am. Fam. Physician,
57(1): 57-68. [0513] Neurath, 2014, Cytokines in Inflammatory Bowel
Disease, Nature Reviews Immunology 14: 329-342. [0514] Zhang et
al., 2007, Cytokines, Inflammation and Pain, Int. Anesthesiol.
Clin. 45(2): 27-37. [0515] Strober et al., Proinflammatory
cytokines in the pathogenesis of inflammatory bowel diseases,
Gastroenterology 140 (6): 1756-1767. [0516] Boltin et al., 2013,
Mucin Function in Inflammatory Bowel Disease: An Update, J. Clin.
Gastroenterol. 47(2):106-111. [0517] Kim et al., 2012,
Investigating Intestinal Inflammation in DSS-induced Model of IBD,
Journal of Visualized Experiments, 60: 2-6. [0518] Levesque et al.,
2015 Converging goals of treatment of inflammatory bowel disease
from clinical trials and practice, Gastroenterology 148: 37-51.
[0519] Best et al., 1976, Development of a Crohn's disease activity
index. National Cooperative Crohn's Disease Study, Gastroenterol.
70: 439-444. [0520] Johansson, et al., 2014, Bacteria penetrate the
normally impenetrable inner colon mucus layer in both murine
colitis models and patients with ulcerative colitis, Gut
63:281-291. [0521] Simmonds et al., 2014, Paneth cell metaplasia in
newly diagnosed inflammatory bowel disease in children, BMC
Gastroenterol. 14:93. [0522] Gassier et al., 2001, Inflammatory
bowel disease is associated with changes of enterocytic junctions,
Am. J. Physiol. Gastrointest. Liver Physiol. 281:G216-G228. [0523]
Dewi, et al., 2004, In vitro assessment of human endothelial cell
permeability: effects of inflammatory cytokines and dengue virus
infection. J. Virol. Methods. 121: 171-180. [0524] Mandic, et al.,
2004, Evaluation of head and neck squamous cell carcinoma
invasiveness by the electrical resistance breakdown assay, Clin.
Exp. Metast. 21: 699-704. [0525] Dewi, et al., 2008, Peripheral
blood mononuclear cells increase the permeability of dengue
virus-infected endothelial cells in association with
down-regulation of vascular endothelial cadherin, J. Gen. Virol.
89:642-652. [0526] Sands, 2004, From symptom to diagnosis: clinical
distinctions among various forms of intestinal inflammation,
Gastroenterology 126: 1518-1532. [0527] Danese et al., 2006,
Etiopathogenesis of inflammatory bowel diseases, World J.
Gastroenterol. 12: 4807-4812. [0528] Duncan, S. H., Aminov, R. I.,
Scott, K. P., Louis, P., Stanton, T. B., Flint, H. J. (2006).
Proposal of Roseburia faeces sp. nov., Roseburia hominis sp. nov.
and Roseburia inulinivorans sp. nov., based on isolates from human
faeces. Int. J. Syst. Evol. Microbiol. Vol. 56, pgs. 2437-2441.
[0529] International Human Genome Sequencing Consortium (2004)
Finishing the euchromatic sequence of the human genome. Nature.
431, 931-45. [0530] Jensen 0. N. (2004) Modification-specific
proteomics: Characterization of post-translational modifications by
mass spectrometry. Curr Opin Chem Biol. 8, 33-41. [0531] Ayoubi T.
A. and Van De Ven W. J. (1996) Regulation of gene expression by
alternative promoters. FASEB J. 10, 453-60. [0532] Walsh C. (2006)
Posttranslational modification of proteins: Expanding nature's
inventory. Englewood, Colo.: Roberts and Co. Publishers. xxi, 490
p. p. [0533] Gaston B. M. et al. (2003) S-nitrosylation signaling
in cell biology. Mol Interv. 3, 253-63. [0534] Jaffrey S. R. and
Snyder S. H. (2001) The biotin switch method for the detection of
S-nitrosylated proteins. Sci STKE. 2001, pl1. [0535] Han P. and
Chen C. (2008) Detergent-free biotin switch combined with liquid
chromatography/tandem mass spectrometry in the analysis of
S-nitrosylated proteins. Rapid Commun Mass Spectrom. 22, 1137-45.
[0536] Imai S. et al. (2000) Transcriptional silencing and
longevity protein SIR2 is an NAD-dependent histone deacetylase.
Nature. 403, 795-800. [0537] Glozak M. A. et al. (2005) Acetylation
and deacetylation of non-histone proteins. Gene. 363, 15-23. [0538]
Yang X. J. and Seto E. (2008) Lysine acetylation: Codified
crosstalk with other posttranslational modifications. Mol Cell. 31,
449-61. [0539] Bratt, et al., "A phase 1 trial with transgenic
bacteria expressing interleukin-10 in Crohn's disease," Clinical
Gastroenterology and Hepatology, 2006, Vol. 4, pgs. 754-759. [0540]
Shigemori, et al., "Oral delivery of Lactococcus lactis that
secretes bioactive heme oxygenase-1 alleviates development of acute
colitis in mice," Microbial Cell Factories, 2015, Vol. 14:189.
[0541] Steidler, et al., "Treatment of murine colitis by
Lactococcus lactis secreting interleukin-10," Science, 2000, Vol.
289, pgs. 1352-1355. [0542] Hanniffy, et al., "Mucosal delivery of
a pneumococcal vaccine using Lactococcus lactis affords protection
against respiratory infection," Journal of Infectious Diseases,
2007, Vol. 195, pgs. 185-193. [0543] Vandenbroucke, et al., "Active
delivery of trefoil factors by genetically modified Lactococcus
lactis prevents and heals acute colitis in mice," Gastroenterology,
2004, Vol. 127, pgs. 502-513. [0544] Sheth, et al., "Manipulating
bacterial communities by in situ microbiome engineering," Trends in
Genetics, 2016, Vol. 32, Issue 4, pgs. 189-200. [0545] Lerner et
al., "Dysbiosis may trigger autoimmune diseases via inappropriate
post-translational modification of host proteins," Frontiers in
Microbiology, 2016, Vol. 7, Article 84. [0546] Shawki, A., and D.
F. McCole. 2017. Mechanisms of Intestinal Epithelial Barrier
Dysfunction by Adherent-Invasive Escherichia coli. Cell Mol
Gastroenterol Hepatol 3: 41-50.
Sequence CWU 1
1
261400PRTEubacterium eligens 1Glu Tyr Thr Glu Ile Arg Thr Ala Ser
Glu Leu Val Glu Ala Ala Lys1 5 10 15Ser Ala Ser Gly Asn Tyr Lys Leu
Met Thr Asp Ile Asp Met Thr Gly 20 25 30Val Glu Trp Thr Pro Trp Asp
Phe Ser Gly Thr Phe Asp Gly Asn Gly 35 40 45His Ser Ile Leu Asn Leu
Ser Val Lys Thr Val Ser Lys Lys Thr Met 50 55 60Lys Thr Tyr Asp Gly
Asn Arg Lys Glu Tyr Lys Thr Tyr Gly Ala Gly65 70 75 80Phe Phe Gly
Val Leu Thr Gly Ala Lys Val Thr Gly Leu Asp Ile Tyr 85 90 95Gly Ala
Arg Ile Glu Ile Thr Thr Thr Glu Pro Cys Phe Ala Ala Pro 100 105
110Ile Ala Gly Leu Ala Asp Asp Ser Asp Ile Ser Asp Cys Ile Ile Lys
115 120 125Asp Thr Tyr Val Ser Leu Thr Asp Ser Ala Lys Met Trp Gly
Thr Gly 130 135 140Gly Ile Ala Gly Phe Gly Ser Gly Asn Leu Asp Asn
Ile Thr Thr Asp145 150 155 160Val Thr Leu Val Cys Val Asp Thr Asp
Ala Ala Val Arg Asp Glu Gln 165 170 175Phe Met Gly Gly Ala Tyr Ala
Ala Gly Phe Leu Asn Ile Arg Asn Cys 180 185 190Ser Ile Thr Ile Asp
Gly Tyr Asp Ser Asp His Gly Tyr Val His Asp 195 200 205Gly Gly Leu
Val Gly Met Tyr Met Val Tyr Pro Leu Glu Leu Ser Lys 210 215 220Thr
Tyr Gln Gly Glu Val Leu Asn Asn Lys Val Lys Gly Met Ile Thr225 230
235 240Phe Phe Glu Asp Asn Thr Asp Arg Arg Ala Tyr Cys Gln Ala Asn
Met 245 250 255Gly Glu Val Met Asn Trp Thr Tyr Ala Tyr Ser Gly Phe
Thr Ser Asp 260 265 270Phe Lys Arg Asn Glu Thr Tyr Asp Tyr Ser Val
Thr Leu Leu Pro Glu 275 280 285Met Cys Ser Asn Pro Ser Tyr Thr Asp
Val Val Thr Glu Ala Thr Ala 290 295 300Ser Asp Phe Gly Tyr Thr Thr
His Thr Cys Ser Thr Cys Gly Tyr Thr305 310 315 320Tyr Ser Asp Thr
Tyr Thr Ile His Glu His Lys Val Asp Ser Tyr Ser 325 330 335Val Val
Lys Glu Ala Ala Ser Thr Asp Lys Lys Asp Gly Ile Glu Ala 340 345
350Gly Thr Cys Ser Leu Cys Asn Gln Thr Val Tyr Arg Glu Tyr Ala Ala
355 360 365Asn Val Val Thr Asp Asp Asn Thr Gln Ala Thr Asp Asn Lys
Ala Ser 370 375 380Gly Thr Ala Val Lys Lys Gly Met Lys Glu Ser Thr
Ala Val Phe Ala385 390 395 40021200DNAEubacterium eligens
2gaatacacag aaatccgaac agcgtcagaa cttgtggaag cagctaagag tgcgtcagga
60aattataaac tgatgacaga tatagatatg acaggagttg agtggacgcc atgggatttt
120tcgggaacat ttgacggtaa cggacacagc atacttaacc tgtcagtaaa
gacagtaagc 180aagaagacaa tgaagaccta tgacggcaac agaaaagagt
acaaaacata cggcgcaggc 240ttctttgggg tgcttacagg tgcgaaagta
acaggactgg atatatatgg agcaagaatt 300gagattacta caacggaacc
atgttttgcg gcaccaatag cagggcttgc agacgacagc 360gacatatcag
actgtataat taaggataca tatgtgtcac tcacagattc agctaaaatg
420tggggaacag gcggaatcgc tggatttgga agcggcaatc ttgataatat
tactacagat 480gtgacacttg tatgtgtaga tacagacgca gcggtcaggg
acgagcagtt catgggaggc 540gcgtatgcag caggtttcct taatataagg
aattgttcta taacaataga tggatatgat 600tcagaccacg gatatgtgca
tgatggcgga cttgtcggca tgtatatggt atatccattg 660gaactgtcaa
agacatatca gggcgaagtg cttaacaaca aagttaaggg aatgataaca
720tttttcgaag acaatacaga ccgccgtgca tactgtcagg caaatatggg
tgaggtcatg 780aactggacat atgcatattc aggcttcaca tcagatttta
agagaaatga gacatatgat 840tattcagtga cactgcttcc ggaaatgtgc
agcaatcctt catacacaga tgtagtgaca 900gaagcaacag catcagactt
tggatacaca acacacacct gcagtacatg tggctacaca 960tattcagaca
cttacacaat acatgagcat aaggtcgaca gttacagcgt ggtaaaggaa
1020gcagccagca cagacaagaa agacggaata gaggcaggaa catgcagcct
gtgcaatcag 1080acagtttaca gggaatatgc tgcaaatgta gtaacagacg
ataatacaca ggcaacagac 1140aataaagcat caggcacggc tgtcaaaaaa
ggaatgaaag aaagtacagc agtatttgca 12003401PRTEubacterium eligens
3Met Glu Tyr Thr Glu Ile Arg Thr Ala Ser Glu Leu Val Glu Ala Ala1 5
10 15Lys Ser Ala Ser Gly Asn Tyr Lys Leu Met Thr Asp Ile Asp Met
Thr 20 25 30Gly Val Glu Trp Thr Pro Trp Asp Phe Ser Gly Thr Phe Asp
Gly Asn 35 40 45Gly His Ser Ile Leu Asn Leu Ser Val Lys Thr Val Ser
Lys Lys Thr 50 55 60Met Lys Thr Tyr Asp Gly Asn Arg Lys Glu Tyr Lys
Thr Tyr Gly Ala65 70 75 80Gly Phe Phe Gly Val Leu Thr Gly Ala Lys
Val Thr Gly Leu Asp Ile 85 90 95Tyr Gly Ala Arg Ile Glu Ile Thr Thr
Thr Glu Pro Cys Phe Ala Ala 100 105 110Pro Ile Ala Gly Leu Ala Asp
Asp Ser Asp Ile Ser Asp Cys Ile Ile 115 120 125Lys Asp Thr Tyr Val
Ser Leu Thr Asp Ser Ala Lys Met Trp Gly Thr 130 135 140Gly Gly Ile
Ala Gly Phe Gly Ser Gly Asn Leu Asp Asn Ile Thr Thr145 150 155
160Asp Val Thr Leu Val Cys Val Asp Thr Asp Ala Ala Val Arg Asp Glu
165 170 175Gln Phe Met Gly Gly Ala Tyr Ala Ala Gly Phe Leu Asn Ile
Arg Asn 180 185 190Cys Ser Ile Thr Ile Asp Gly Tyr Asp Ser Asp His
Gly Tyr Val His 195 200 205Asp Gly Gly Leu Val Gly Met Tyr Met Val
Tyr Pro Leu Glu Leu Ser 210 215 220Lys Thr Tyr Gln Gly Glu Val Leu
Asn Asn Lys Val Lys Gly Met Ile225 230 235 240Thr Phe Phe Glu Asp
Asn Thr Asp Arg Arg Ala Tyr Cys Gln Ala Asn 245 250 255Met Gly Glu
Val Met Asn Trp Thr Tyr Ala Tyr Ser Gly Phe Thr Ser 260 265 270Asp
Phe Lys Arg Asn Glu Thr Tyr Asp Tyr Ser Val Thr Leu Leu Pro 275 280
285Glu Met Cys Ser Asn Pro Ser Tyr Thr Asp Val Val Thr Glu Ala Thr
290 295 300Ala Ser Asp Phe Gly Tyr Thr Thr His Thr Cys Ser Thr Cys
Gly Tyr305 310 315 320Thr Tyr Ser Asp Thr Tyr Thr Ile His Glu His
Lys Val Asp Ser Tyr 325 330 335Ser Val Val Lys Glu Ala Ala Ser Thr
Asp Lys Lys Asp Gly Ile Glu 340 345 350Ala Gly Thr Cys Ser Leu Cys
Asn Gln Thr Val Tyr Arg Glu Tyr Ala 355 360 365Ala Asn Val Val Thr
Asp Asp Asn Thr Gln Ala Thr Asp Asn Lys Ala 370 375 380Ser Gly Thr
Ala Val Lys Lys Gly Met Lys Glu Ser Thr Ala Val Phe385 390 395
400Ala41203DNAEubacterium eligens 4atggaataca cagaaatccg aacagcgtca
gaacttgtgg aagcagctaa gagtgcgtca 60ggaaattata aactgatgac agatatagat
atgacaggag ttgagtggac gccatgggat 120ttttcgggaa catttgacgg
taacggacac agcatactta acctgtcagt aaagacagta 180agcaagaaga
caatgaagac ctatgacggc aacagaaaag agtacaaaac atacggcgca
240ggcttctttg gggtgcttac aggtgcgaaa gtaacaggac tggatatata
tggagcaaga 300attgagatta ctacaacgga accatgtttt gcggcaccaa
tagcagggct tgcagacgac 360agcgacatat cagactgtat aattaaggat
acatatgtgt cactcacaga ttcagctaaa 420atgtggggaa caggcggaat
cgctggattt ggaagcggca atcttgataa tattactaca 480gatgtgacac
ttgtatgtgt agatacagac gcagcggtca gggacgagca gttcatggga
540ggcgcgtatg cagcaggttt ccttaatata aggaattgtt ctataacaat
agatggatat 600gattcagacc acggatatgt gcatgatggc ggacttgtcg
gcatgtatat ggtatatcca 660ttggaactgt caaagacata tcagggcgaa
gtgcttaaca acaaagttaa gggaatgata 720acatttttcg aagacaatac
agaccgccgt gcatactgtc aggcaaatat gggtgaggtc 780atgaactgga
catatgcata ttcaggcttc acatcagatt ttaagagaaa tgagacatat
840gattattcag tgacactgct tccggaaatg tgcagcaatc cttcatacac
agatgtagtg 900acagaagcaa cagcatcaga ctttggatac acaacacaca
cctgcagtac atgtggctac 960acatattcag acacttacac aatacatgag
cataaggtcg acagttacag cgtggtaaag 1020gaagcagcca gcacagacaa
gaaagacgga atagaggcag gaacatgcag cctgtgcaat 1080cagacagttt
acagggaata tgctgcaaat gtagtaacag acgataatac acaggcaaca
1140gacaataaag catcaggcac ggctgtcaaa aaaggaatga aagaaagtac
agcagtattt 1200gca 12035494PRTEubacterium eligens 5Met Arg Tyr Asn
Gln Thr Ala Lys Asp Ala Asn Ile Ser Glu Glu Arg1 5 10 15Gly Ile Lys
Met Phe Asn Lys Ser Ile Ile Lys Lys Ala Ala Ala Ile 20 25 30Ala Ala
Val Ile Leu Ala Val Thr Ala Leu Pro Thr Asn Met Thr Lys 35 40 45Ala
Asp Thr Gln Thr Ser Gly Ser Thr Val Ser Gln Thr Thr Ser Glu 50 55
60Tyr Thr Glu Ile Arg Thr Ala Ser Glu Leu Val Glu Ala Ala Lys Ser65
70 75 80Ala Ser Gly Asn Tyr Lys Leu Met Thr Asp Ile Asp Met Thr Gly
Val 85 90 95Glu Trp Thr Pro Trp Asp Phe Ser Gly Thr Phe Asp Gly Asn
Gly His 100 105 110Ser Ile Leu Asn Leu Ser Val Lys Thr Val Ser Lys
Lys Thr Met Lys 115 120 125Thr Tyr Asp Gly Asn Arg Lys Glu Tyr Lys
Thr Tyr Gly Ala Gly Phe 130 135 140Phe Gly Val Leu Thr Gly Ala Lys
Val Thr Gly Leu Asp Ile Tyr Gly145 150 155 160Ala Arg Ile Glu Ile
Thr Thr Thr Glu Pro Cys Phe Ala Ala Pro Ile 165 170 175Ala Gly Leu
Ala Asp Asp Ser Asp Ile Ser Asp Cys Ile Ile Lys Asp 180 185 190Thr
Tyr Val Ser Leu Thr Asp Ser Ala Lys Met Trp Gly Thr Gly Gly 195 200
205Ile Ala Gly Phe Gly Ser Gly Asn Leu Asp Asn Ile Thr Thr Asp Val
210 215 220Thr Leu Val Cys Val Asp Thr Asp Ala Ala Val Arg Asp Glu
Gln Phe225 230 235 240Met Gly Gly Ala Tyr Ala Ala Gly Phe Leu Asn
Ile Arg Asn Cys Ser 245 250 255Ile Thr Ile Asp Gly Tyr Asp Ser Asp
His Gly Tyr Val His Asp Gly 260 265 270Gly Leu Val Gly Met Tyr Met
Val Tyr Pro Leu Glu Leu Ser Lys Thr 275 280 285Tyr Gln Gly Glu Val
Leu Asn Asn Lys Val Lys Gly Met Ile Thr Phe 290 295 300Phe Glu Asp
Asn Thr Asp Arg Arg Ala Tyr Cys Gln Ala Asn Met Gly305 310 315
320Glu Val Met Asn Trp Thr Tyr Ala Tyr Ser Gly Phe Thr Ser Asp Phe
325 330 335Lys Arg Asn Glu Thr Tyr Asp Tyr Ser Val Thr Leu Leu Pro
Glu Met 340 345 350Cys Ser Asn Pro Ser Tyr Thr Asp Val Val Thr Glu
Ala Thr Ala Ser 355 360 365Asp Phe Gly Tyr Thr Thr His Thr Cys Ser
Thr Cys Gly Tyr Thr Tyr 370 375 380Ser Asp Thr Tyr Thr Ile His Glu
His Lys Val Asp Ser Tyr Ser Val385 390 395 400Val Lys Glu Ala Ala
Ser Thr Asp Lys Lys Asp Gly Ile Glu Ala Gly 405 410 415Thr Cys Ser
Leu Cys Asn Gln Thr Val Tyr Arg Glu Tyr Ala Ala Asn 420 425 430Val
Val Thr Asp Asp Asn Thr Gln Ala Thr Asp Asn Lys Ala Ser Gly 435 440
445Thr Ala Val Lys Lys Gly Met Lys Glu Ser Thr Ala Val Phe Ala Val
450 455 460Ile Leu Val Val Ile Val Ile Val Ile Ile Ile Thr Val Val
Met Met465 470 475 480Val Gln Asn Asn Lys Arg Lys Arg Arg Tyr Asn
Arg Arg Arg 485 49061482DNAEubacterium eligens 6ttgcgttata
atcagacagc gaaagatgca aatatatcag aagaaagagg cataaaaatg 60tttaataaat
caattataaa aaaggcagcg gcgatagcag cagtaatact tgcagtgaca
120gcacttccga ctaatatgac gaaggcagat acacaaacat caggaagtac
cgtaagccag 180acaacatcag aatacacaga aatccgaaca gcgtcagaac
ttgtggaagc agctaagagt 240gcgtcaggaa attataaact gatgacagat
atagatatga caggagttga gtggacgcca 300tgggattttt cgggaacatt
tgacggtaac ggacacagca tacttaacct gtcagtaaag 360acagtaagca
agaagacaat gaagacctat gacggcaaca gaaaagagta caaaacatac
420ggcgcaggct tctttggggt gcttacaggt gcgaaagtaa caggactgga
tatatatgga 480gcaagaattg agattactac aacggaacca tgttttgcgg
caccaatagc agggcttgca 540gacgacagcg acatatcaga ctgtataatt
aaggatacat atgtgtcact cacagattca 600gctaaaatgt ggggaacagg
cggaatcgct ggatttggaa gcggcaatct tgataatatt 660actacagatg
tgacacttgt atgtgtagat acagacgcag cggtcaggga cgagcagttc
720atgggaggcg cgtatgcagc aggtttcctt aatataagga attgttctat
aacaatagat 780ggatatgatt cagaccacgg atatgtgcat gatggcggac
ttgtcggcat gtatatggta 840tatccattgg aactgtcaaa gacatatcag
ggcgaagtgc ttaacaacaa agttaaggga 900atgataacat ttttcgaaga
caatacagac cgccgtgcat actgtcaggc aaatatgggt 960gaggtcatga
actggacata tgcatattca ggcttcacat cagattttaa gagaaatgag
1020acatatgatt attcagtgac actgcttccg gaaatgtgca gcaatccttc
atacacagat 1080gtagtgacag aagcaacagc atcagacttt ggatacacaa
cacacacctg cagtacatgt 1140ggctacacat attcagacac ttacacaata
catgagcata aggtcgacag ttacagcgtg 1200gtaaaggaag cagccagcac
agacaagaaa gacggaatag aggcaggaac atgcagcctg 1260tgcaatcaga
cagtttacag ggaatatgct gcaaatgtag taacagacga taatacacag
1320gcaacagaca ataaagcatc aggcacggct gtcaaaaaag gaatgaaaga
aagtacagca 1380gtatttgcag taatattggt ggtaatagtt attgtaataa
ttataacagt agtcatgatg 1440gtacagaata ataaaagaaa aagaagatat
aacagacgca ga 14827475PRTEubacterium eligens 7Met Phe Asn Lys Ser
Ile Ile Lys Lys Ala Ala Ala Ile Ala Ala Val1 5 10 15Ile Leu Ala Val
Thr Ala Leu Pro Thr Asn Met Thr Lys Ala Asp Thr 20 25 30Gln Thr Ser
Gly Ser Thr Val Ser Gln Thr Thr Ser Glu Tyr Thr Glu 35 40 45Ile Arg
Thr Ala Ser Glu Leu Val Glu Ala Ala Lys Ser Ala Ser Gly 50 55 60Asn
Tyr Lys Leu Met Thr Asp Ile Asp Met Thr Gly Val Glu Trp Thr65 70 75
80Pro Trp Asp Phe Ser Gly Thr Phe Asp Gly Asn Gly His Ser Ile Leu
85 90 95Asn Leu Ser Val Lys Thr Val Ser Lys Lys Thr Met Lys Thr Tyr
Asp 100 105 110Gly Asn Arg Lys Glu Tyr Lys Thr Tyr Gly Ala Gly Phe
Phe Gly Val 115 120 125Leu Thr Gly Ala Lys Val Thr Gly Leu Asp Ile
Tyr Gly Ala Arg Ile 130 135 140Glu Ile Thr Thr Thr Glu Pro Cys Phe
Ala Ala Pro Ile Ala Gly Leu145 150 155 160Ala Asp Asp Ser Asp Ile
Ser Asp Cys Ile Ile Lys Asp Thr Tyr Val 165 170 175Ser Leu Thr Asp
Ser Ala Lys Met Trp Gly Thr Gly Gly Ile Ala Gly 180 185 190Phe Gly
Ser Gly Asn Leu Asp Asn Ile Thr Thr Asp Val Thr Leu Val 195 200
205Cys Val Asp Thr Asp Ala Ala Val Arg Asp Glu Gln Phe Met Gly Gly
210 215 220Ala Tyr Ala Ala Gly Phe Leu Asn Ile Arg Asn Cys Ser Ile
Thr Ile225 230 235 240Asp Gly Tyr Asp Ser Asp His Gly Tyr Val His
Asp Gly Gly Leu Val 245 250 255Gly Met Tyr Met Val Tyr Pro Leu Glu
Leu Ser Lys Thr Tyr Gln Gly 260 265 270Glu Val Leu Asn Asn Lys Val
Lys Gly Met Ile Thr Phe Phe Glu Asp 275 280 285Asn Thr Asp Arg Arg
Ala Tyr Cys Gln Ala Asn Met Gly Glu Val Met 290 295 300Asn Trp Thr
Tyr Ala Tyr Ser Gly Phe Thr Ser Asp Phe Lys Arg Asn305 310 315
320Glu Thr Tyr Asp Tyr Ser Val Thr Leu Leu Pro Glu Met Cys Ser Asn
325 330 335Pro Ser Tyr Thr Asp Val Val Thr Glu Ala Thr Ala Ser Asp
Phe Gly 340 345 350Tyr Thr Thr His Thr Cys Ser Thr Cys Gly Tyr Thr
Tyr Ser Asp Thr 355 360 365Tyr Thr Ile His Glu His Lys Val Asp Ser
Tyr Ser Val Val Lys Glu 370 375 380Ala Ala Ser Thr Asp Lys Lys Asp
Gly Ile Glu Ala Gly Thr Cys Ser385 390 395 400Leu Cys Asn Gln Thr
Val Tyr Arg Glu Tyr Ala Ala Asn Val Val Thr 405 410 415Asp Asp Asn
Thr Gln Ala Thr Asp Asn Lys Ala Ser Gly Thr Ala Val 420 425 430Lys
Lys Gly Met Lys Glu Ser Thr Ala Val Phe Ala Val Ile Leu Val 435 440
445Val Ile Val Ile Val Ile Ile Ile Thr Val Val Met Met Val Gln Asn
450 455 460Asn Lys Arg Lys Arg Arg Tyr Asn Arg Arg Arg465 470
47581425DNAEubacterium eligens 8atgtttaata aatcaattat aaaaaaggca
gcggcgatag cagcagtaat acttgcagtg 60acagcacttc cgactaatat gacgaaggca
gatacacaaa catcaggaag taccgtaagc
120cagacaacat cagaatacac agaaatccga acagcgtcag aacttgtgga
agcagctaag 180agtgcgtcag gaaattataa actgatgaca gatatagata
tgacaggagt tgagtggacg 240ccatgggatt tttcgggaac atttgacggt
aacggacaca gcatacttaa cctgtcagta 300aagacagtaa gcaagaagac
aatgaagacc tatgacggca acagaaaaga gtacaaaaca 360tacggcgcag
gcttctttgg ggtgcttaca ggtgcgaaag taacaggact ggatatatat
420ggagcaagaa ttgagattac tacaacggaa ccatgttttg cggcaccaat
agcagggctt 480gcagacgaca gcgacatatc agactgtata attaaggata
catatgtgtc actcacagat 540tcagctaaaa tgtggggaac aggcggaatc
gctggatttg gaagcggcaa tcttgataat 600attactacag atgtgacact
tgtatgtgta gatacagacg cagcggtcag ggacgagcag 660ttcatgggag
gcgcgtatgc agcaggtttc cttaatataa ggaattgttc tataacaata
720gatggatatg attcagacca cggatatgtg catgatggcg gacttgtcgg
catgtatatg 780gtatatccat tggaactgtc aaagacatat cagggcgaag
tgcttaacaa caaagttaag 840ggaatgataa catttttcga agacaataca
gaccgccgtg catactgtca ggcaaatatg 900ggtgaggtca tgaactggac
atatgcatat tcaggcttca catcagattt taagagaaat 960gagacatatg
attattcagt gacactgctt ccggaaatgt gcagcaatcc ttcatacaca
1020gatgtagtga cagaagcaac agcatcagac tttggataca caacacacac
ctgcagtaca 1080tgtggctaca catattcaga cacttacaca atacatgagc
ataaggtcga cagttacagc 1140gtggtaaagg aagcagccag cacagacaag
aaagacggaa tagaggcagg aacatgcagc 1200ctgtgcaatc agacagttta
cagggaatat gctgcaaatg tagtaacaga cgataataca 1260caggcaacag
acaataaagc atcaggcacg gctgtcaaaa aaggaatgaa agaaagtaca
1320gcagtatttg cagtaatatt ggtggtaata gttattgtaa taattataac
agtagtcatg 1380atggtacaga ataataaaag aaaaagaaga tataacagac gcaga
14259119PRTEubacterium eligens 9Met Thr Gly Cys Ser Gly Ser Lys Glu
Pro Asp Asn Lys Thr Ser Val1 5 10 15Asp Tyr Thr Val Val Glu Asn Ala
Asp Leu Pro Glu Glu Leu Lys Lys 20 25 30Leu Ile Glu Ser Lys Lys Asp
Lys Val Met Arg Leu Thr Tyr Thr Thr 35 40 45Lys Asp Tyr Thr Tyr Val
Val Ala Gly Tyr Gly Thr Arg Glu Thr Ser 50 55 60Gly Tyr Ser Ile Lys
Val Asn Asp Val Tyr Thr Gly Asp Asn Ala Leu65 70 75 80Tyr Ile Asp
Leu Asn Leu Ile Gly Pro Ala Ala Gly Glu Ala Val Asn 85 90 95Glu Val
Glu Thr Tyr Pro Val Ile Val Leu Lys Met Glu Arg Arg Glu 100 105
110Glu Ser Val Val Phe Lys Met 11510357DNAEubacterium eligens
10atgacagggt gttctggcag caaagagcca gataataaga ccagtgttga ttatacagtg
60gttgaaaatg cagacctgcc ggaagagctt aagaagctta ttgaaagcaa aaaagataaa
120gtgatgaggc ttacatacac gactaaggat tatacatatg ttgtggccgg
ttatggaaca 180agggaaacaa gtggatattc aattaaggta aatgatgtat
acacaggaga taatgcacta 240tacattgatc ttaatctgat aggtccggca
gcgggggaag ctgtaaatga ggttgagaca 300tatccggtaa tagtgcttaa
gatggaaaga cgtgaagaaa gcgttgtttt taaaatg 35711143PRTEubacterium
eligens 11Met Cys Gly Lys Leu Trp Gly Lys Val Val Thr Val Val Leu
Ala Leu1 5 10 15Leu Ile Ile Met Pro Ala Cys Ala Met Thr Gly Cys Ser
Gly Ser Lys 20 25 30Glu Pro Asp Asn Lys Thr Ser Val Asp Tyr Thr Val
Val Glu Asn Ala 35 40 45Asp Leu Pro Glu Glu Leu Lys Lys Leu Ile Glu
Ser Lys Lys Asp Lys 50 55 60Val Met Arg Leu Thr Tyr Thr Thr Lys Asp
Tyr Thr Tyr Val Val Ala65 70 75 80Gly Tyr Gly Thr Arg Glu Thr Ser
Gly Tyr Ser Ile Lys Val Asn Asp 85 90 95Val Tyr Thr Gly Asp Asn Ala
Leu Tyr Ile Asp Leu Asn Leu Ile Gly 100 105 110Pro Ala Ala Gly Glu
Ala Val Asn Glu Val Glu Thr Tyr Pro Val Ile 115 120 125Val Leu Lys
Met Glu Arg Arg Glu Glu Ser Val Val Phe Lys Met 130 135
14012429DNAEubacterium eligens 12atgtgtggga aattatgggg aaaagttgtg
actgttgtgt tggcattgct gataattatg 60cctgcgtgtg caatgacagg gtgttctggc
agcaaagagc cagataataa gaccagtgtt 120gattatacag tggttgaaaa
tgcagacctg ccggaagagc ttaagaagct tattgaaagc 180aaaaaagata
aagtgatgag gcttacatac acgactaagg attatacata tgttgtggcc
240ggttatggaa caagggaaac aagtggatat tcaattaagg taaatgatgt
atacacagga 300gataatgcac tatacattga tcttaatctg ataggtccgg
cagcggggga agctgtaaat 360gaggttgaga catatccggt aatagtgctt
aagatggaaa gacgtgaaga aagcgttgtt 420tttaaaatg
42913327PRTEubacterium eligens 13Cys Asn Ser Lys Ile Asp Val Lys
Tyr Asp Tyr Asn Val Glu Asp Tyr1 5 10 15Val Gln Leu Gly Gln Tyr Glu
Asn Ile Ser Val Gln Val Asp Lys Thr 20 25 30Ser Ile Glu Asn Glu Leu
Ile Glu Ser Lys Ile Lys Gln Asp Val Glu 35 40 45Asp Asn Thr Thr Tyr
Thr Glu Val Asp Arg Gly Ala Ile Ala Ser Asp 50 55 60Gln Ile Leu Val
Thr Tyr Thr Ala Thr Ser Ser Gly Ala Ser Leu Ser65 70 75 80Gly Leu
Thr Asn Thr Asp Gly Lys Thr Met Ile Leu Gly Thr Asp Thr 85 90 95Leu
Gly Leu Glu Leu Asp Glu Leu Asp Gln Ala Leu Tyr Gly Met Thr 100 105
110Pro Gly Gln Thr Lys Ile Leu Ile Val Asp Ile Pro Glu Asp Tyr Ser
115 120 125Ser Asp Leu Tyr Lys Gly Thr Arg Val Val Phe Glu Leu Thr
Met Gln 130 135 140Thr Val Ala Gln Ala Asn Val Pro Met Ile Thr Asn
Ala Tyr Val Lys145 150 155 160Glu Ala Phe Gly Tyr Asp Thr Val Glu
Glu Tyr Arg Gln Ser Ile Lys 165 170 175Glu Ser Leu Glu Thr Asp Ile
Asn Ser Lys Val Glu Asn Lys Ile Gln 180 185 190Glu Asp Val Leu Ser
Ser Leu Gln Asp Thr Phe Lys Ile Ser Ser Tyr 195 200 205Pro Asp Ser
Leu Met Glu Glu Thr Arg Ser Arg Leu Glu Thr Ser Ile 210 215 220Gly
Phe Tyr Ala Asp Phe Ser Asn Leu Ser Lys Asp Glu Tyr Cys Gln225 230
235 240Lys Gln Tyr Gly Leu Ser Phe Asp Asp Phe Val Lys Lys Ser Val
Val 245 250 255Gln Gln Leu Ile Met Glu Ala Ile Val Lys Asp Arg Asn
Met Thr Met 260 265 270Arg Glu Tyr Asp Tyr Lys Gly Ser Leu Asp Asp
Phe Ala Ala Asp Asn 275 280 285Gly Tyr Ser Asn Ala Asp Thr Phe Val
Glu Lys Phe Gly Lys Asp Lys 290 295 300Ile Val Lys Ala Met Leu Val
Gln Lys Ala Gln Asp Tyr Val Ile Glu305 310 315 320His Ala Asn Ile
Ser Tyr Lys 32514981DNAEubacterium eligens 14tgtaatagta agattgatgt
taagtatgat tataatgttg aagattatgt tcagcttgga 60cagtatgaaa acatatcagt
ccaggtagat aaaacttcaa tagagaatga acttatagag 120agtaaaatta
aacaggatgt agaagataat actacttata cagaagttga cagaggtgcg
180atagcttctg atcagattct tgttacatat actgctacat cttcaggcgc
atctcttagc 240ggacttacta atacagatgg taaaacaatg attcttggaa
cggatactct cggacttgaa 300cttgatgagt tagatcaggc tttatatggt
atgaccccag gtcagacaaa gatacttatt 360gttgatatac ctgaggatta
tagttcggat ttatataagg gcacgagggt tgtatttgaa 420cttacaatgc
agacagttgc acaggcaaat gttccaatga taactaatgc atatgttaag
480gaagcgtttg gatatgatac cgttgaagaa tatagacagt caataaagga
atctcttgaa 540actgatatta attcaaaggt tgagaacaag atacaggaag
atgtattatc ttctttacag 600gatacattca agataagcag ttatcctgat
tcacttatgg aagaaacaag atccagactt 660gaaacatcta ttggtttcta
tgcggatttt tcaaatcttt caaaggatga atactgtcag 720aagcagtatg
gactttcttt tgatgacttt gttaagaaat ctgttgtaca gcagcttatc
780atggaggcta tagttaaaga ccgcaatatg acaatgagag aatacgatta
taaaggttct 840cttgatgatt ttgcggcaga taatggatat tctaatgcgg
atacatttgt tgaaaaattc 900ggaaaagata agattgtaaa ggctatgctt
gtgcagaagg cacaggatta tgttattgag 960catgccaata tttcttataa g
98115328PRTEubacterium eligens 15Met Cys Asn Ser Lys Ile Asp Val
Lys Tyr Asp Tyr Asn Val Glu Asp1 5 10 15Tyr Val Gln Leu Gly Gln Tyr
Glu Asn Ile Ser Val Gln Val Asp Lys 20 25 30Thr Ser Ile Glu Asn Glu
Leu Ile Glu Ser Lys Ile Lys Gln Asp Val 35 40 45Glu Asp Asn Thr Thr
Tyr Thr Glu Val Asp Arg Gly Ala Ile Ala Ser 50 55 60Asp Gln Ile Leu
Val Thr Tyr Thr Ala Thr Ser Ser Gly Ala Ser Leu65 70 75 80Ser Gly
Leu Thr Asn Thr Asp Gly Lys Thr Met Ile Leu Gly Thr Asp 85 90 95Thr
Leu Gly Leu Glu Leu Asp Glu Leu Asp Gln Ala Leu Tyr Gly Met 100 105
110Thr Pro Gly Gln Thr Lys Ile Leu Ile Val Asp Ile Pro Glu Asp Tyr
115 120 125Ser Ser Asp Leu Tyr Lys Gly Thr Arg Val Val Phe Glu Leu
Thr Met 130 135 140Gln Thr Val Ala Gln Ala Asn Val Pro Met Ile Thr
Asn Ala Tyr Val145 150 155 160Lys Glu Ala Phe Gly Tyr Asp Thr Val
Glu Glu Tyr Arg Gln Ser Ile 165 170 175Lys Glu Ser Leu Glu Thr Asp
Ile Asn Ser Lys Val Glu Asn Lys Ile 180 185 190Gln Glu Asp Val Leu
Ser Ser Leu Gln Asp Thr Phe Lys Ile Ser Ser 195 200 205Tyr Pro Asp
Ser Leu Met Glu Glu Thr Arg Ser Arg Leu Glu Thr Ser 210 215 220Ile
Gly Phe Tyr Ala Asp Phe Ser Asn Leu Ser Lys Asp Glu Tyr Cys225 230
235 240Gln Lys Gln Tyr Gly Leu Ser Phe Asp Asp Phe Val Lys Lys Ser
Val 245 250 255Val Gln Gln Leu Ile Met Glu Ala Ile Val Lys Asp Arg
Asn Met Thr 260 265 270Met Arg Glu Tyr Asp Tyr Lys Gly Ser Leu Asp
Asp Phe Ala Ala Asp 275 280 285Asn Gly Tyr Ser Asn Ala Asp Thr Phe
Val Glu Lys Phe Gly Lys Asp 290 295 300Lys Ile Val Lys Ala Met Leu
Val Gln Lys Ala Gln Asp Tyr Val Ile305 310 315 320Glu His Ala Asn
Ile Ser Tyr Lys 32516984DNAEubacterium eligens 16atgtgtaata
gtaagattga tgttaagtat gattataatg ttgaagatta tgttcagctt 60ggacagtatg
aaaacatatc agtccaggta gataaaactt caatagagaa tgaacttata
120gagagtaaaa ttaaacagga tgtagaagat aatactactt atacagaagt
tgacagaggt 180gcgatagctt ctgatcagat tcttgttaca tatactgcta
catcttcagg cgcatctctt 240agcggactta ctaatacaga tggtaaaaca
atgattcttg gaacggatac tctcggactt 300gaacttgatg agttagatca
ggctttatat ggtatgaccc caggtcagac aaagatactt 360attgttgata
tacctgagga ttatagttcg gatttatata agggcacgag ggttgtattt
420gaacttacaa tgcagacagt tgcacaggca aatgttccaa tgataactaa
tgcatatgtt 480aaggaagcgt ttggatatga taccgttgaa gaatatagac
agtcaataaa ggaatctctt 540gaaactgata ttaattcaaa ggttgagaac
aagatacagg aagatgtatt atcttcttta 600caggatacat tcaagataag
cagttatcct gattcactta tggaagaaac aagatccaga 660cttgaaacat
ctattggttt ctatgcggat ttttcaaatc tttcaaagga tgaatactgt
720cagaagcagt atggactttc ttttgatgac tttgttaaga aatctgttgt
acagcagctt 780atcatggagg ctatagttaa agaccgcaat atgacaatga
gagaatacga ttataaaggt 840tctcttgatg attttgcggc agataatgga
tattctaatg cggatacatt tgttgaaaaa 900ttcggaaaag ataagattgt
aaaggctatg cttgtgcaga aggcacagga ttatgttatt 960gagcatgcca
atatttctta taag 98417345PRTEubacterium eligens 17Met Lys Lys Thr
Ala Val Ala Leu Leu Ser Val Ser Met Leu Met Val1 5 10 15Thr Ala Cys
Asn Ser Lys Ile Asp Val Lys Tyr Asp Tyr Asn Val Glu 20 25 30Asp Tyr
Val Gln Leu Gly Gln Tyr Glu Asn Ile Ser Val Gln Val Asp 35 40 45Lys
Thr Ser Ile Glu Asn Glu Leu Ile Glu Ser Lys Ile Lys Gln Asp 50 55
60Val Glu Asp Asn Thr Thr Tyr Thr Glu Val Asp Arg Gly Ala Ile Ala65
70 75 80Ser Asp Gln Ile Leu Val Thr Tyr Thr Ala Thr Ser Ser Gly Ala
Ser 85 90 95Leu Ser Gly Leu Thr Asn Thr Asp Gly Lys Thr Met Ile Leu
Gly Thr 100 105 110Asp Thr Leu Gly Leu Glu Leu Asp Glu Leu Asp Gln
Ala Leu Tyr Gly 115 120 125Met Thr Pro Gly Gln Thr Lys Ile Leu Ile
Val Asp Ile Pro Glu Asp 130 135 140Tyr Ser Ser Asp Leu Tyr Lys Gly
Thr Arg Val Val Phe Glu Leu Thr145 150 155 160Met Gln Thr Val Ala
Gln Ala Asn Val Pro Met Ile Thr Asn Ala Tyr 165 170 175Val Lys Glu
Ala Phe Gly Tyr Asp Thr Val Glu Glu Tyr Arg Gln Ser 180 185 190Ile
Lys Glu Ser Leu Glu Thr Asp Ile Asn Ser Lys Val Glu Asn Lys 195 200
205Ile Gln Glu Asp Val Leu Ser Ser Leu Gln Asp Thr Phe Lys Ile Ser
210 215 220Ser Tyr Pro Asp Ser Leu Met Glu Glu Thr Arg Ser Arg Leu
Glu Thr225 230 235 240Ser Ile Gly Phe Tyr Ala Asp Phe Ser Asn Leu
Ser Lys Asp Glu Tyr 245 250 255Cys Gln Lys Gln Tyr Gly Leu Ser Phe
Asp Asp Phe Val Lys Lys Ser 260 265 270Val Val Gln Gln Leu Ile Met
Glu Ala Ile Val Lys Asp Arg Asn Met 275 280 285Thr Met Arg Glu Tyr
Asp Tyr Lys Gly Ser Leu Asp Asp Phe Ala Ala 290 295 300Asp Asn Gly
Tyr Ser Asn Ala Asp Thr Phe Val Glu Lys Phe Gly Lys305 310 315
320Asp Lys Ile Val Lys Ala Met Leu Val Gln Lys Ala Gln Asp Tyr Val
325 330 335Ile Glu His Ala Asn Ile Ser Tyr Lys 340
345181035DNAEubacterium eligens 18atgaagaaga cagcagttgc tttattatca
gtttctatgc ttatggtaac ggcatgtaat 60agtaagattg atgttaagta tgattataat
gttgaagatt atgttcagct tggacagtat 120gaaaacatat cagtccaggt
agataaaact tcaatagaga atgaacttat agagagtaaa 180attaaacagg
atgtagaaga taatactact tatacagaag ttgacagagg tgcgatagct
240tctgatcaga ttcttgttac atatactgct acatcttcag gcgcatctct
tagcggactt 300actaatacag atggtaaaac aatgattctt ggaacggata
ctctcggact tgaacttgat 360gagttagatc aggctttata tggtatgacc
ccaggtcaga caaagatact tattgttgat 420atacctgagg attatagttc
ggatttatat aagggcacga gggttgtatt tgaacttaca 480atgcagacag
ttgcacaggc aaatgttcca atgataacta atgcatatgt taaggaagcg
540tttggatatg ataccgttga agaatataga cagtcaataa aggaatctct
tgaaactgat 600attaattcaa aggttgagaa caagatacag gaagatgtat
tatcttcttt acaggataca 660ttcaagataa gcagttatcc tgattcactt
atggaagaaa caagatccag acttgaaaca 720tctattggtt tctatgcgga
tttttcaaat ctttcaaagg atgaatactg tcagaagcag 780tatggacttt
cttttgatga ctttgttaag aaatctgttg tacagcagct tatcatggag
840gctatagtta aagaccgcaa tatgacaatg agagaatacg attataaagg
ttctcttgat 900gattttgcgg cagataatgg atattctaat gcggatacat
ttgttgaaaa attcggaaaa 960gataagattg taaaggctat gcttgtgcag
aaggcacagg attatgttat tgagcatgcc 1020aatatttctt ataag
103519267PRTClostridium bartlettii 19Glu Val Asp Ser Ser Lys Glu
Gln Ala Thr Ser Lys Asp Glu Lys Gln1 5 10 15Val Val Val Ala Thr Ser
Val Ala Ile Thr Glu Ile Leu Asp Arg Leu 20 25 30Gly Val Glu Val Ser
Gly Val Pro Gln Thr Ser Tyr Glu Leu Pro Glu 35 40 45Ser Ala Lys Gly
Ala Thr Glu Ile Gly Ser Pro Met Asn Pro Asp Met 50 55 60Glu Ile Ile
Lys Ser Leu Asn Pro Thr Asp Val Ile Cys Val Asp Thr65 70 75 80Leu
Gly Ser Asp Phe Glu Lys Gln Phe Glu Glu Asn Asn Ile Asn Ala 85 90
95Asp Phe Tyr Asn Leu Ser Asn Val Asp Gly Leu Lys Glu Thr Ile Ala
100 105 110Ala Leu Gly Glu Lys Phe Asn Lys Gln Asp Lys Ala Asn Glu
Ile Leu 115 120 125Asp Glu Ile Lys Glu Val Glu Asn Lys Val Asn Ser
Asn Lys Lys Ser 130 135 140Asp Asp Lys Ile Leu Val Leu Phe Gly Ala
Pro Gly Ser Val Met Val145 150 155 160Ala Thr Asp Lys Ser Tyr Ile
Gly Asn Leu Val Glu Leu Ala Gly Gly 165 170 175Asn Asn Ile Phe Ser
Asn Ala Thr Ser Ser Phe Thr Gln Ile Asn Leu 180 185 190Glu Glu Ile
Ile Lys Leu Asn Pro Asp Lys Ile Leu Val Met Thr His 195 200 205Ala
Val Pro Glu Ala Ala Lys Lys Ser Val Glu Glu Glu Leu Ser Lys 210 215
220Asp Leu Trp Lys Asn Val Asn Ala Val Lys Asn Asn Asp Ile Thr
Tyr225 230 235 240Leu Glu Asn Gly Tyr Phe Gly Met Ser Ala Asn Leu
Gln Ile Val Glu 245 250 255Ala Val Glu Lys Leu Gly Asp Ile Leu Tyr
Glu 260 26520801DNAClostridium bartlettii 20gaggtagata gttctaaaga
acaagctaca tcaaaagatg aaaaacaagt agtagtagct 60acatcagttg caattactga
aatattagat aggttaggtg tagaagttag tggtgtacca 120caaactagct
atgaacttcc agaaagtgca aaaggtgcta cggaaattgg aagtccaatg
180aatccagata tggaaataat aaaatcacta aatccaacag acgtaatatg
tgttgatact 240ttaggaagtg attttgaaaa acaatttgaa gaaaacaata
taaatgctga tttttataat 300ctaagcaatg tagacggatt aaaagaaaca
atagctgctt taggagaaaa attcaataaa 360caagataaag caaatgaaat
attagatgaa ataaaagaag tagaaaataa agttaattct 420aataaaaaat
ctgatgataa gatcttagta ttatttggag caccaggaag tgtaatggta
480gctacggaca aaagttatat aggaaactta gtcgagttag ctggaggaaa
taatatattc 540tcaaatgcaa ctagctcatt tactcaaata aacttagaag
aaataataaa gttaaatcca 600gataaaatat tagttatgac tcatgccgtt
ccagaggctg caaaaaaatc tgtagaagaa 660gaattaagta aagacctttg
gaaaaatgta aatgcagtta aaaataacga tataacttat 720ttagaaaatg
gttatttcgg aatgagtgca aacttacaaa tagttgaggc agtagaaaaa
780ttaggagata tattatatga g 80121268PRTClostridium bartlettii 21Met
Glu Val Asp Ser Ser Lys Glu Gln Ala Thr Ser Lys Asp Glu Lys1 5 10
15Gln Val Val Val Ala Thr Ser Val Ala Ile Thr Glu Ile Leu Asp Arg
20 25 30Leu Gly Val Glu Val Ser Gly Val Pro Gln Thr Ser Tyr Glu Leu
Pro 35 40 45Glu Ser Ala Lys Gly Ala Thr Glu Ile Gly Ser Pro Met Asn
Pro Asp 50 55 60Met Glu Ile Ile Lys Ser Leu Asn Pro Thr Asp Val Ile
Cys Val Asp65 70 75 80Thr Leu Gly Ser Asp Phe Glu Lys Gln Phe Glu
Glu Asn Asn Ile Asn 85 90 95Ala Asp Phe Tyr Asn Leu Ser Asn Val Asp
Gly Leu Lys Glu Thr Ile 100 105 110Ala Ala Leu Gly Glu Lys Phe Asn
Lys Gln Asp Lys Ala Asn Glu Ile 115 120 125Leu Asp Glu Ile Lys Glu
Val Glu Asn Lys Val Asn Ser Asn Lys Lys 130 135 140Ser Asp Asp Lys
Ile Leu Val Leu Phe Gly Ala Pro Gly Ser Val Met145 150 155 160Val
Ala Thr Asp Lys Ser Tyr Ile Gly Asn Leu Val Glu Leu Ala Gly 165 170
175Gly Asn Asn Ile Phe Ser Asn Ala Thr Ser Ser Phe Thr Gln Ile Asn
180 185 190Leu Glu Glu Ile Ile Lys Leu Asn Pro Asp Lys Ile Leu Val
Met Thr 195 200 205His Ala Val Pro Glu Ala Ala Lys Lys Ser Val Glu
Glu Glu Leu Ser 210 215 220Lys Asp Leu Trp Lys Asn Val Asn Ala Val
Lys Asn Asn Asp Ile Thr225 230 235 240Tyr Leu Glu Asn Gly Tyr Phe
Gly Met Ser Ala Asn Leu Gln Ile Val 245 250 255Glu Ala Val Glu Lys
Leu Gly Asp Ile Leu Tyr Glu 260 26522804DNAClostridium bartlettii
22atggaggtag atagttctaa agaacaagct acatcaaaag atgaaaaaca agtagtagta
60gctacatcag ttgcaattac tgaaatatta gataggttag gtgtagaagt tagtggtgta
120ccacaaacta gctatgaact tccagaaagt gcaaaaggtg ctacggaaat
tggaagtcca 180atgaatccag atatggaaat aataaaatca ctaaatccaa
cagacgtaat atgtgttgat 240actttaggaa gtgattttga aaaacaattt
gaagaaaaca atataaatgc tgatttttat 300aatctaagca atgtagacgg
attaaaagaa acaatagctg ctttaggaga aaaattcaat 360aaacaagata
aagcaaatga aatattagat gaaataaaag aagtagaaaa taaagttaat
420tctaataaaa aatctgatga taagatctta gtattatttg gagcaccagg
aagtgtaatg 480gtagctacgg acaaaagtta tataggaaac ttagtcgagt
tagctggagg aaataatata 540ttctcaaatg caactagctc atttactcaa
ataaacttag aagaaataat aaagttaaat 600ccagataaaa tattagttat
gactcatgcc gttccagagg ctgcaaaaaa atctgtagaa 660gaagaattaa
gtaaagacct ttggaaaaat gtaaatgcag ttaaaaataa cgatataact
720tatttagaaa atggttattt cggaatgagt gcaaacttac aaatagttga
ggcagtagaa 780aaattaggag atatattata tgag 80423290PRTClostridium
bartlettii 23Met Lys Lys Ile Leu Cys Leu Ile Ser Ile Leu Met Val
Thr Phe Ser1 5 10 15Val Ile Gly Cys Ser Ser Ser Glu Val Asp Ser Ser
Lys Glu Gln Ala 20 25 30Thr Ser Lys Asp Glu Lys Gln Val Val Val Ala
Thr Ser Val Ala Ile 35 40 45Thr Glu Ile Leu Asp Arg Leu Gly Val Glu
Val Ser Gly Val Pro Gln 50 55 60Thr Ser Tyr Glu Leu Pro Glu Ser Ala
Lys Gly Ala Thr Glu Ile Gly65 70 75 80Ser Pro Met Asn Pro Asp Met
Glu Ile Ile Lys Ser Leu Asn Pro Thr 85 90 95Asp Val Ile Cys Val Asp
Thr Leu Gly Ser Asp Phe Glu Lys Gln Phe 100 105 110Glu Glu Asn Asn
Ile Asn Ala Asp Phe Tyr Asn Leu Ser Asn Val Asp 115 120 125Gly Leu
Lys Glu Thr Ile Ala Ala Leu Gly Glu Lys Phe Asn Lys Gln 130 135
140Asp Lys Ala Asn Glu Ile Leu Asp Glu Ile Lys Glu Val Glu Asn
Lys145 150 155 160Val Asn Ser Asn Lys Lys Ser Asp Asp Lys Ile Leu
Val Leu Phe Gly 165 170 175Ala Pro Gly Ser Val Met Val Ala Thr Asp
Lys Ser Tyr Ile Gly Asn 180 185 190Leu Val Glu Leu Ala Gly Gly Asn
Asn Ile Phe Ser Asn Ala Thr Ser 195 200 205Ser Phe Thr Gln Ile Asn
Leu Glu Glu Ile Ile Lys Leu Asn Pro Asp 210 215 220Lys Ile Leu Val
Met Thr His Ala Val Pro Glu Ala Ala Lys Lys Ser225 230 235 240Val
Glu Glu Glu Leu Ser Lys Asp Leu Trp Lys Asn Val Asn Ala Val 245 250
255Lys Asn Asn Asp Ile Thr Tyr Leu Glu Asn Gly Tyr Phe Gly Met Ser
260 265 270Ala Asn Leu Gln Ile Val Glu Ala Val Glu Lys Leu Gly Asp
Ile Leu 275 280 285Tyr Glu 29024870DNAClostridium bartlettii
24ttgaaaaaga ttttatgttt aatatcgatt ttgatggtta ctttttcagt aattggatgc
60tcatctagcg aggtagatag ttctaaagaa caagctacat caaaagatga aaaacaagta
120gtagtagcta catcagttgc aattactgaa atattagata ggttaggtgt
agaagttagt 180ggtgtaccac aaactagcta tgaacttcca gaaagtgcaa
aaggtgctac ggaaattgga 240agtccaatga atccagatat ggaaataata
aaatcactaa atccaacaga cgtaatatgt 300gttgatactt taggaagtga
ttttgaaaaa caatttgaag aaaacaatat aaatgctgat 360ttttataatc
taagcaatgt agacggatta aaagaaacaa tagctgcttt aggagaaaaa
420ttcaataaac aagataaagc aaatgaaata ttagatgaaa taaaagaagt
agaaaataaa 480gttaattcta ataaaaaatc tgatgataag atcttagtat
tatttggagc accaggaagt 540gtaatggtag ctacggacaa aagttatata
ggaaacttag tcgagttagc tggaggaaat 600aatatattct caaatgcaac
tagctcattt actcaaataa acttagaaga aataataaag 660ttaaatccag
ataaaatatt agttatgact catgccgttc cagaggctgc aaaaaaatct
720gtagaagaag aattaagtaa agacctttgg aaaaatgtaa atgcagttaa
aaataacgat 780ataacttatt tagaaaatgg ttatttcgga atgagtgcaa
acttacaaat agttgaggca 840gtagaaaaat taggagatat attatatgag
87025279PRTClostridium bartlettii 25Met Val Thr Phe Ser Val Ile Gly
Cys Ser Ser Ser Glu Val Asp Ser1 5 10 15Ser Lys Glu Gln Ala Thr Ser
Lys Asp Glu Lys Gln Val Val Val Ala 20 25 30Thr Ser Val Ala Ile Thr
Glu Ile Leu Asp Arg Leu Gly Val Glu Val 35 40 45Ser Gly Val Pro Gln
Thr Ser Tyr Glu Leu Pro Glu Ser Ala Lys Gly 50 55 60Ala Thr Glu Ile
Gly Ser Pro Met Asn Pro Asp Met Glu Ile Ile Lys65 70 75 80Ser Leu
Asn Pro Thr Asp Val Ile Cys Val Asp Thr Leu Gly Ser Asp 85 90 95Phe
Glu Lys Gln Phe Glu Glu Asn Asn Ile Asn Ala Asp Phe Tyr Asn 100 105
110Leu Ser Asn Val Asp Gly Leu Lys Glu Thr Ile Ala Ala Leu Gly Glu
115 120 125Lys Phe Asn Lys Gln Asp Lys Ala Asn Glu Ile Leu Asp Glu
Ile Lys 130 135 140Glu Val Glu Asn Lys Val Asn Ser Asn Lys Lys Ser
Asp Asp Lys Ile145 150 155 160Leu Val Leu Phe Gly Ala Pro Gly Ser
Val Met Val Ala Thr Asp Lys 165 170 175Ser Tyr Ile Gly Asn Leu Val
Glu Leu Ala Gly Gly Asn Asn Ile Phe 180 185 190Ser Asn Ala Thr Ser
Ser Phe Thr Gln Ile Asn Leu Glu Glu Ile Ile 195 200 205Lys Leu Asn
Pro Asp Lys Ile Leu Val Met Thr His Ala Val Pro Glu 210 215 220Ala
Ala Lys Lys Ser Val Glu Glu Glu Leu Ser Lys Asp Leu Trp Lys225 230
235 240Asn Val Asn Ala Val Lys Asn Asn Asp Ile Thr Tyr Leu Glu Asn
Gly 245 250 255Tyr Phe Gly Met Ser Ala Asn Leu Gln Ile Val Glu Ala
Val Glu Lys 260 265 270Leu Gly Asp Ile Leu Tyr Glu
27526837DNAClostridium bartlettii 26atggttactt tttcagtaat
tggatgctca tctagcgagg tagatagttc taaagaacaa 60gctacatcaa aagatgaaaa
acaagtagta gtagctacat cagttgcaat tactgaaata 120ttagataggt
taggtgtaga agttagtggt gtaccacaaa ctagctatga acttccagaa
180agtgcaaaag gtgctacgga aattggaagt ccaatgaatc cagatatgga
aataataaaa 240tcactaaatc caacagacgt aatatgtgtt gatactttag
gaagtgattt tgaaaaacaa 300tttgaagaaa acaatataaa tgctgatttt
tataatctaa gcaatgtaga cggattaaaa 360gaaacaatag ctgctttagg
agaaaaattc aataaacaag ataaagcaaa tgaaatatta 420gatgaaataa
aagaagtaga aaataaagtt aattctaata aaaaatctga tgataagatc
480ttagtattat ttggagcacc aggaagtgta atggtagcta cggacaaaag
ttatatagga 540aacttagtcg agttagctgg aggaaataat atattctcaa
atgcaactag ctcatttact 600caaataaact tagaagaaat aataaagtta
aatccagata aaatattagt tatgactcat 660gccgttccag aggctgcaaa
aaaatctgta gaagaagaat taagtaaaga cctttggaaa 720aatgtaaatg
cagttaaaaa taacgatata acttatttag aaaatggtta tttcggaatg
780agtgcaaact tacaaatagt tgaggcagta gaaaaattag gagatatatt atatgag
837
* * * * *
References